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ABSTRACT 
Nina DiPrimio 
Surface Loop Dynamics of a Parvovirus 
“Under the direction of Dr. Richard Jude Samulski” 
 
  
 
 
 
In order to understand Adeno-associated virus and its potential as a gene delivery 
vehicle, we are obligated to characterize virus structure-function relationships and their 
ability to be manipulated for efficient gene delivery.  In this dissertation, multiple capsid 
surface loops were characterized in order to understand their roles in the virus life cycle and 
the potential for advancement of viral gene therapy. 
Primarily, the HI loop, surrounding the five-fold pore on the capsid surface was 
characterized. Via domain swapping between serotypes, mutagenesis and biochemical 
analyses, it was determined that the HI loop is crucial for VP assembly.  Specifically, a 
phenylalanine-proline interaction between subunits is necessary for maintaining full length 
VP1 incorporation into the intact particle during capsid assembly.  From these studies, it was 
determined that the HI loop is highly plastic and certain amino acids are amenable to 
alteration.  Therefore, the HI loop was substituted with alternative motifs including hexa-
histidine.  Not only did we generate vectors capable of metal ion affinity purification, but 
also conjugation to Ni-NTA nanogold beads for EM applications.  Additionally, the hexa-
histidine viruses display unique profiles in vivo, with tissue detargeting capabilities, 
modulated by altering the number of hexa-histidine tags on the surface.  This alteration in 
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targeting may be due to capsid stability but the exact mechanism remains to be determined, 
however, this finding may add to the development of liver detargeting vectors for the 
treatment of specific genetic disorders. 
Post characterization of the five-fold surface loop, interests expanded to amino acid 
position 265 within surface loop I between the five-fold and two-fold axes, deemed important 
in an alternative stage of the virus life cycle, infectivity.  Upon AAV2 and AAV1 265 
insertion and substitution, vectors display remarkable enhancements in liver and muscle 
transduction.  Additionally, amino acid 265 substitution rescues infectivity of AAV2i8, a 
vector incapable of transducing the liver. Based on further characterization, mutation of 
position 265 enhances the ability of viral particles to enter cells, gaining tropism in multiple 
tissue types for potential use as gene therapy vectors.  Therefore, the aforementioned data 
transcend virus biology to vectorology. 
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Viruses are intelligent nanoparticles completely reliant on a host for persistence but 
can undergo evolutionary change to outsmart obstacles in their path.  Our interest in viruses 
spans many genres.  We study them to defeat them in the case of those causing disease, 
utilize them for vaccinations, or exploit their endogenous properties as genome containing 
particles to deliver payloads.  In our laboratory we perform the latter, by utilizing an already 
known non-pathogenic virus, adeno-associated virus (AAV), as a vehicle to deliver genes of 
interest to a specific tissue target. In the process we aim to understand the virus life cycle in 
order to generate the best possible medium to accomplish the task.  The following 
introduction will give an in depth background on AAV as a virus and a vector.  
 
1. T=1 Isocahedral Viruses 
 An icosahedral virus is composed of identical protein subunits ordered in a 2-3-5 
symmetry rotation pattern. The two-fold, three-fold and five-fold symmetries are located 
through the center of each edge, face and corner, respectively. T=1 icosahedral symmetry is 
generated from 60 identical viral protein subunits, T being the triangulation number or the 
square of the distance between two adjacent five-fold vertices.  Generally, viruses are 
classified into four groups: helical, icosahedral, enveloped or complex.  Helical viruses, like 
tobacco mosaic virus (21), are viruses comprised of a single protein repeatedly stacked to 
form a hollow tube around a central axis and are identifiable by their rod like structures.  
Enveloped viruses, such as influenza (129), utilize the cell lipid bilayer post budding from 
the infected cell as an outer shell protecting the capsid protein layer.  As the virus assembles 
inside the host cell, matrix proteins attach themselves to the lipid bilayer and bud off the cell 
surface containing glycoproteins and transport channels.  These viruses use their outer lipid 
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bilayer consisting of specific glycoproteins. When the virus enters another cell, the lipid 
envelope fuses with the host cell surface to deliver the capsid, making viral entry an easier 
process.  Complex viruses (95), like bacteriophages, structurally appear to be a combination 
of helical and icosahedral viruses with additional features to the icosahedral head and helical 
tail such as protein tail fibers.  These unique fibers are structures necessary for the docking of 
bacteriophages to a host bacterial cell and ejecting the viral genome.  There are obviously a 
vast range of viruses with different structures, however, our focus is on a parvovirus, AAV, a 
T=1 icosahedral virus, which has many homologous partners, some of which have been 
researched for potential utilization in gene therapy.  
 
2. Subfamily Parvovirinae genus Dependovirus  
Parvoviruses are of the smallest non-enveloped viruses known, whose members 
include, canine parvovirus (CPV) (111, 161), minute virus of mice (MVM) (15, 78), porcine 
parvovirus (PPV) (109, 122), adeno-associated virus (AAV) (114, 163), feline parvovirus 
(FPV) (1, 99), B19 (63, 167) and many more.  These viruses have a single-stranded DNA 
(ssDNA) genome averaging 5kb in length, which is flanked by short palindromic sequences, 
generating inverted terminal repeats (ITRs).  Part of the Parvorinae subfamily, is the genus 
dependovirus, comprised only of AAV serotypes, being dependent on other viruses for 
genome replication.  AAV2, being the main player in this family, will be discussed in more 
detail below. 
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3. Adeno-associated Virus Life Cycle 
 The AAV life cycle is similar to all parvovirus cell infection mechanisms, beginning 
with host cell recognition. AAVs interacts with the host cell via primary receptor recognition 
(heparan sulfate proteoglycan for AAV2) and internalizes via co-receptor interactions 
(integrin, FGFR and C-Met for AAV2) (5, 62, 105).  The interactions between different 
serotypes and their specific host cell receptor accounts for the variances in tissue tropism.  
From what has been determined to date, AAV serotypes bind initially to a carbohydrate on 
the cell surface, which adds to the tropism variability since there are a wide array of 
carbohydrate variants on multiple tissue types.  For instance, AAV1, 4, 5 and 6 have been 
shown to bind sialic acid (142), and receptors such as FGFR (105), PDGFR (20) and laminin 
(3) have been shown to play a role in the attachment of various serotypes. Primarily amino 
acids present at the three-fold axis of symmetry are responsible for receptor recognition (75, 
94, 96, 157), which will be discussed in more detail when describing capsid structure-
function relationships.   
 Post cellular attachment and virus internalization, are the intracellular trafficking 
steps (23, 25).  It has been shown that AAV2 enters cells via clathrin-coated pits and 
blocking the endosome or changing endosomal pH inhibits AAV2 infection.  Specifically for 
AAV2, once cell surface binding occurs, the Rac1 PI3 Kinase cascade is activated (115), 
which could aid in the translocation of AAV2 to the nucleus.  It is not known whether the 
virus releases the viral genome perinuclearly, in the nucleus or the nucleolus.  But recent data 
from our lab (59) has shown that the AAV capsid remains intact upon entry and can 
translocate to the nucleus and the nucleolus, and has been determined that the viral genome is 
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released in both of these locations, the importance of which is yet to be determined.  
However, this may not be the case for other serotypes, since they interact with different 
receptors and cell lines, which could dictate the pathway of viral infection.  Our knowledge 
of AAV trafficking comes from studies on AAV2 and AAV5.  AAV5 follows a similar 
infectious life cycle utilizing receptor-mediated endocytosis for cellular entry (6) and 
endosomal escape for nuclear translocation.  There is also evidence that both AAV2 and 
AAV5 traffic to the trans-Golgi network (6, 98). 
 AAV only replicates in the presence of a helper such as adenovirus or herpesvirus as 
previously mentioned (33).  Post infection, the Rep proteins are located in the nucleus along 
with the viral genome (52), then the Cap proteins are generated and detected near Rep 
proteins in the nucleoplasm.  Replication centers have been shown to form where adenovirus 
helper proteins are present (147), such as E1a which activates the AAV promoters and then 
E1b and E4 which aid in AAV messenger RNA accumulation.  When there are no factors 
driving AAV replication, AAV2 can persist as a latent infection (8), where it can integrate 
into chromosome 19 with help from the Rep protein or remain episomally (45, 103).    Once 
replication is induced, the viral genome is packaged into the capsid in the nucleoplasm (151).  
However, empty capsids can assemble intracellularly in the nucleolus without the presence of 
viral DNA (152).  It is important to note that the viral proteins cannot self assemble and are 
reliant on the presence of cellular factors for assembly (126).   
 
4. AAV Genome Replication and Site-specific Integration 
AAV does not contain its own replication machinery, and can only replicate in the 
presence of a helper virus.  Being a ssDNA genome, second strand synthesis has to occur for 
6 
 
viral DNA replication (28).  The genome is flanked by inverted terminal repeats that are 
145bp in length and form T shaped hairpin structures (143).  During replication a 3’ duplex is 
formed and Rep 68 or 78 nick the hairpin, which is then unwound and extended, and refolded 
to form the hairpin.  Generated is a duplex and a ssDNA genome both of which can serve as 
templates for further replication (90).  The genome has the option of maintaining persistence 
via episomal formations or integrating into host chromosome 19 (34, 104).  However, the 
viral genome most often remains in an episomal conformation post infection.  
 
5. Adeno-associated Virus rep Gene and Proteins 
 Directly following the left hand ITR is the rep gene driven by the p5 and p19 
promoters generating two transcripts that are differentially spliced at the 3’ end leading to 
four different messages.  The messages are translated to Rep78, Rep68, Rep52 and Rep40 
named according to kilodalton size.  Each Rep protein has a different function in the virus 
life cycle.  Rep78 and 68 are endonucleases (49), which can cleave the AAV ITR at the 
designated terminal resolution site at nucleotide 124 and aid in replication and site specific 
integration into chromosome 19 of the human genome.  Rep52 and 40 are necessary for the 
generation of ssDNA genomes during replication (66, 133). All Rep proteins have the ability 
to bind ATP and act as helicases to unwind the viral genome during packaging, additionally, 
they have been shown to upregulate the p40 promoter which drives cap gene expression and 
downregulate or inhibit p5 and p19 driven expression of the Rep proteins (93, 146). 
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6. Adeno-associated Virus capsid Gene and Proteins  
 The capsid gene is to the left of the right ITR driven by p40 promoter.  The gene 
encodes three viral proteins from a single transcript.  VP1 is the full-length transcript with its 
own start site, VP2 is a splice variant of VP1 with a threonine start site, and VP3 has a 
methionine start site internal to the VP2 start.  Therefore, VP1 has a unique N-terminal 
extension, and VP1 and VP2 contain the VP3 amino acid sequence within them.  These three 
viral proteins come together to assemble the intact capsid particle. 
The AAV icosahedral capsid is 26nm in diameter (163), being one of the smallest 
viruses in nature.  The capsid surrounding the viral genome is made up of three viral proteins, 
VP1, VP2 and VP3 in a 1:1:10 ratio.  VP1 and VP2 unique N-terminal extensions remain 
internal to the intact capsid until triggered by a stage in the virus life cycle for externalization 
(71, 125).  Based on the crystal structure, the viral proteins come together to form the 2-fold, 
3-fold and 5-fold axes of symmetry. The 2-fold axes is the weakest part of the capsid with the 
lowest contact energies, and the 3-fold is the most highly interdigitated region of the capsid 
with the largest contact energies.  Since the symmetry axes go through the capsid, from point 
to point, there are twenty-eight 2-fold, twenty 3-fold and twelve 5-fold axes (163). 
 The capsid proteins of the multiple serotypes dictate the variances in serotype 
functionality.  Each serotype is known for its ability to transduce different tissue types based 
on their amino acid sequence.  AAV1 infects the lung and muscle (46), AAV2 liver and 
neurons (51), AAV3 nothing, AAV4 heart, lung eye and astrocytes (77), AAV5 eye (80) and 
brain, AAV6 muscle and lung, AAV7 muscle and liver, AAV8 systemically but abundantly 
liver, and AAV9 systemically (169).  This is all based on the fact that the amino acids in each 
capsid protein for each serotype recognize different receptors on various tissue types.  Now 
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that we know that each individual serotype has unique qualities affecting their phenotypes, 
we can use our knowledge of the crystal structure combined with mutagenesis studies in 
order to discern which capsid domains on each serotype are responsible for different 
functionalities. 
   
7. AAV Crystal Structures 
 Knowing the crystal structure for AAV2 has been extremely beneficial to the field of 
AAV gene therapy (163).  For it has allowed us to understand the capsid topology and amino 
acid composition and their implications in the virus life cycle.  Additionally, with the 
resolution of crystal structures from multiple AAV serotypes we have been able to 
characterize and understand specific functions of other AAV variants (McKenna 
unpublished, Asokan unpublished).  
There are key structural elements present within the AAV capsid that all parvoviral 
capsids contain based on the crystal structures.  One consistency is that the VP1 unique N-
terminus has not been crystallized since it is present in low copy number and potentially 
incorporated in different amounts within each capsid or in a heterogeneous fashion.  Also, the 
genome has not been crystallized with the capsid since it does not seem to be ordered 
symmetrically.  Assembly of the viral protein subunits, is primarily based on hydrophobic 
interactions between the amino acids at the interfaces.  However, it is not known how the 
viral protein subunits come together, whether they form trimers or pentamers first. When the 
VPs do assemble, a 5-fold pore is formed, twelve of which are present on the capsid and the 
3-fold peaks are formed, twenty of which are present. 
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 From the AAV2 crystal structure alone, surface loops and beta sheets have been 
named and assigned, and with the resolution of other serotypes and autonomous parvoviruses 
are seemingly conserved structural regions. In the AAV monomer, a jelly-roll beta barrel is 
conserved connected by long loops.  The most variable parts of the monomers are the loops 
connecting beta strands, making up many of the unique variable surface topologies.  
Protruding off of the AAV capsid are the three-fold peaks, which are formed from 
neighboring interdigitated VP subunits.  A subloop resides in the center of each loop, 
forming the GH loop, named from the beta strands in which the loop begins and ends.   At 
the five-fold axis resides the HI loop, comprising amino acids 655-667, interacting with a 
neighboring underlying subunit at the BC and EF loops (163). 
 Crystal structures for AAV1 (84), 4 (38), 5 (22, 140), 6 (162) and 8 (92) have been 
solved and others are on the way (Dr. Mavis Agbandje-McKenna personal communication).  
From these structures, differences in topology have been noted.  AAV1 x-ray 
crystallographic studies are preliminary but do show that this particle is topologically similar 
to AAV2.  AAV4 and 5 differ the most structurally.  The variation between the AAV 
serotypes is most likely due to the differences in amino acid sequence and structure between 
the surface loops.  The loops are responsible for host cell interactions, receptor recognition 
and antigenicity (137), which will be discussed in the next section in further detail.  AAV4 
and 5 based on the crystal structure are missing the basic regions that are necessary for 
AAV2 heparan recognition, and they also differ significantly topologically in this region, 
resulting in blunted three-fold protrusions.  Therefore, the surface loop amino acid sequence 
and structure differences observed in AAV4 and 5 may account for their disparate receptor 
recognition, and in conjunction it has been determined that these two serotypes bind sialic 
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acid and not heparan sulfate (117, 141, 142).  Recently, co-crystals of AAV5 with sialic acid 
have been resolved determining that amino acids at the three-fold on the capsid surface 
interact with this receptor (McKenna unpublished), and similar studies have been executed 
for AAV2 and its primary receptor heparan sulfate proteoglycan (75, 94).  However, in order 
to confirm that the surface loops are potentiating variances in receptor recognition between 
the serotypes, further co-crystallization and mutagenesis studies must be performed. 
 Not only are AAV4 and 5 the most variant in overall amino acid sequence and 
surface loop topology, but they are also extremely different from AAV2 antigenically.  The 
known A20 antibody used to detect intact AAV2 particles via a conformational epitope does 
not recognize (153) AAV4 and 5 which is confirmed by the crystal structure since the 
variable loops that A20 recognizes in AAV2 are different structurally and sequentially than 
in AAV4 and 5. 
 The AAV8 crystal structure (92) has revealed many similarities to AAV2 in topology 
unlike AAV4 and 5.  There are only three variable region differences in structure as 
compared to AAV2, whereas AAV4 and 5 had differences in all nine designated variable 
regions.   One of which is variable region I, a surface loop spanning amino acids 263-271 
(AAV8 numbering), present at the between two-fold and five-fold axes of symmetry.  
Variable region II, another area of disparity between AAV8 and AAV2, is the loop that 
generates the channel for the five-fold pore.  And the last variable region between the two 
serotypes is the GH loop, responsible for heparan sulfate binding of the AAV2 capsid.  It is 
known that AAV8 does not bind heparan sulfate, but it is not know which receptor it does 
bind, therefore there are strong implications based on the structure and sequence information 
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that the inability of this serotype to bind heparan leads to its ability to transduce systemically 
(Asokan unpublished). 
 
8. Adeno-associated Virus Structure-function 
8.1 Two-fold axis of symmetry including proximal dead zone 
 This axis of the capsid is the weakest based on amino acid interactions determined by 
the crystal structure (160) but has recently gained attention in multiple research studies due to 
a region in close proximity. The region between this axis and the five-fold has been termed 
the dead zone (79, 96), for it has fallen victim to multiple mutagenesis studies not affecting 
heparan sulfate binding, or primary receptor interactions, but virus transduction.  This region 
covers 15% of the capsid surface and was proposed to play a role in receptor binding based 
on its proximity to the heparan binding site and lack of mutational toleration (79), for many 
of these mutants were unable to infect cells but still bound heparin. Recent cryo-EM analysis 
has further substantiated this fact via capsid-heparin footprint analysis, however, it is does 
not rule out the possibility of this region interacting with co-receptors on the cell surface 
(94). 
 One mutagenesis study demonstrated that mutation of the surface loop I within the 
dead zone on this axis led to increased viral transduction (79).  Specifically, mutation of 
S267 to A or T increased transduction four-fold to nine-fold, respectively.  Other mutations 
to the dead zone decreased virus transduction without affecting heparan binding (79).   
Additionally, another mutagenesis study on this surface loop on the capsid, led to non-
infectious particles, or particles that were partially defective in infectivity and lacking A20 
antibody recognition (156). 
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 A recent study named this region a hot spot on the capsid (168).  The authors mutated 
all surface tyrosine residues to phenylalanines, due to the possibility of capsid tyrosine 
phosphorylation leading to capsid degradation.  Specifically tyrosine 730 in close proximity 
to the 265 surface loop (168), played a role in virus transduction upon mutagenesis.  
Alteration of this single amino acid led to increased virus transduction in specific tissue types 
and further research is being performed to determine the mechanism causing this phenotype.    
Additionally, research from our lab by Dawn Bowles (unpublished) determined that 5 
residues in the AAV1 capsid along this region were necessary for the increased muscle 
transduction as compared to AAV2. The amino acids from AAV1 were put into the AAV2 
backbone, increasing AAV2 muscle transduction in vivo and decreasing AAV2 neutralizing 
antibody recognition.  This mutant was deemed AAV2.5 and is currently in clinical trial for 
muscular dystrophy.  One of the five amino acids is located at position 265 in surface loop I 
of the AAV1 capsid, in the dead zone, and was shown alone to potentiate an increase in viral 
transduction when inserted into the AAV2 capsid at the corresponding position (Bowles 
unpublished).  Due to the research mentioned above and the research that will be 
presented in Chapter IV of this dissertation, this region of the capsid is no longer the 
“dead zone,” but a proposed hot zone that upon mutagenesis results in remarkable 
levels of increased virus transduction in multiple AAV backgrounds. 
 
8.2 Three-fold axis of symmetry 
Over the past decade advances in resolving the crystal structures of multiple AAV 
serotypes has allowed (92, 97, 140, 160) the AAV community to gain further insight in AAV 
structural elements and their functional correlates. AAV2 being the first cloned AAV 
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serotype, has been the most characterized and was therefore the first AAV serotype to be 
crystallized.  Instead of visualizing the capsid protein linearly, we are able to place 
approximately 530 of the amino acids three dimensionally, and begin to assess key functions 
of structural domains.  Mutagenesis studies took place prior to understanding the capsid 
protein structure (156), which shed some light on amino acids that are crucial for stages in 
the AAV life cycle.  From these experiments residues necessary for primary receptor binding 
were resolved and later located to the three-fold axis of symmetry (64, 96).    The three-fold 
axis of symmetry receives a significant amount of attention in the AAV community due to 
the topology of this region of the capsid and its implications in AAV biology.  Since the 
AAV2 crystal structure has been solved, it has easily been the most characterized serotype, 
specifically with regards to receptor recognition (3, 5, 64, 96).   
At the three-fold axis of symmetry, three viral protein subunits assemble and two VPs 
form each protrusion, being the most interdigitated region of the capsid and completely 
accessible to cell surface receptors of target tissues.  These three-fold peaks are located at 
every three-fold axis of symmetry, totaling 60 peaks on the capsid surface. Each peak 
contains a subloop at its center stemming from the GH loop of a single VP subunit and is 
located between two subloops from the neighboring VP GH loop.   
Interestingly, as mentioned previously prior to resolution of the AAV2 crystal 
structure, it was determined that heparan sulfate proteoglycan is the primary receptor for 
AAV2 (128).  Further mutagenesis to the capsid  revealed that mutations at the three-fold 
axis of symmetry, specifically an alanine substitution at 585-RGNR-588 and an epitope 
insertion at position 591 disrupted heparin binding affinity (156). Once data aligned this 
region of the capsid with dictating virus tissue tropism, it was determined that the exact 
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heparin binding motif is comprised of positively charged amino acids at the three-fold R585-
R588, R484-R487 and K532 (64). These residues form a basic patch on the surface of the 
three-fold, however, they lie in the valleys between the peaks, creating a perfect location for 
the negatively charged heparin molecule to dock itself on the AAV2 surface.   
Once the AAV2 capsid docks to the cell surface utilizing the heparan sulfate binding 
motif, it then internalizes using co-receptors (3, 5, 62, 105).  At amino acid positions 511-513 
on the AAV2 capsid near the three-fold axis resides an NGR domain, which recognizes 
alpha5beta1 integrin coreceptor for virus internalization (5).  Integrin is not the only 
proposed coreceptor for AAV2 but also the laminin receptor (3), thought to bind at the three-
fold axis, and FGFR (105).  The laminin receptor is also reported to be utilized by serotypes 
AAV3, 8 and 9 (3). 
Not all AAV serotypes bind to the same receptors. For instance, AAV1, 5 and 6 and 
AAV4 bind N-linked and O-linked sialic acid, respectively (61, 142) and  AAV5 PDGFR as 
a coreceptor (20).  However, it is still not known which residues these receptors interact with 
on the AAV4 capsid surface, but due to the compelling amount of data on AAV2 and 
receptor binding and recent data on AAV5 (unpublished), it is assumed that most serotypes 
use the three-fold as the site for receptor binding.  Interestingly, knowing that this region of 
the capsid is a hotspot for receptor binding, the tissue tropism of the capsid could potentially 
be altered by mutating this region. 
For instance, Asokan et al. replaced the heparin binding residues in AAV2 with the 
corresponding residues from AAV8 as determined by the amino acid sequence and crystal 
structure, which does not bind heparan sulfate. In doing so, the AAV2 capsid with AAV8 
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amino acids (AAV2i8) detargeted the liver and transduced all tissues including the skeletal 
and heart muscle (Asokan unpublished).   
With regards to AAV1 and 6 (84, 162), they are homologous in amino acid sequence, 
but it has been shown that AAV6 can bind heparin, even though it does not contain the basic 
patch seen in the AAV2 crystal structure responsible for heparin binding recognition.  What 
AAV6 does have in this region that AAV1 does not, is a lysine at position 531 (157), where 
upon mutation, heparin binding capabilities are ablated.  This residue lies within its own 
basic patch of lysines and an arginine, contributing to receptor recognition and further 
demonstrating this region of the capsid plays an enormous role in receptor recognition of 
other AAV serotypes. Interestingly, a study attempted to uncover the amino responsible for 
AAV1 tissue tropism and the amino acid stretch was narrowed down to approximately 100 
(aa350-430) within VP3 (46)  at the three-fold peaks.   
In addition to receptor interaction, the AAV2 heparan binding site at the three-fold 
has been named as an antigenic site on the capsid based on the ability of the RXXR motif to 
induce T cell activation (137).  Therefore, the three-fold axis and its involvement in receptor 
recognition and host immunity activation has been extremely important for gene therapy 
applications due to our ability to alter the capsid and affect tissue tropism for disease 
specificity.  With the addition of the crystal structures from AAV1, 4, 5, 6 and 8, it has 
increased capsid rational mutagenesis and characterization of tropic and antigenic 
determinants or has shed light on previous mutagenesis studies (46, 118). 
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8.3 Five-fold axis of symmetry 
 The five-fold axis of symmetry has yet to be implicated in receptor recognition like 
the three-fold axis, but partakes in many other stages of the virus life cycle.   The five-fold 
axis of symmetry is formed when five viral protein subunits assemble generating the 
pentamer. In the center of the pentamer is the five-fold pore, twelve of which are on the 
capsid surface. Surrounding the five-fold pore is the HI loop, extending from one viral 
protein subunit to the next, being the primary contacts at the five-fold axis. Both the pore and 
the HI loop have been implicated as key players in the AAV life cycle (10, 24, 75). 
 In 2000, Muzyczka’s group performed gross mutagenesis on the AAV2 capsid in 
hopes of determining multiple regions of importance (156). In doing so, it was determined 
that inserting an HA tag at amino acid position 328 in the five-fold pore, ablated virus 
particle infectivity and vector genome packaging.  However, HA tag insertion into the HI 
loop surrounding the five-fold pore at position 664 did not affect viral infectivity or vector 
genome packaging. From this study, it was not understood why the five-fold mutations 
affected the capsid properties, but was determined that specific changes to certain regions of 
the capsid can have a huge impact on stages in the life cycle. 
 Following this study, a more in depth investigation was performed on the role of the 
five-fold pore (10).  Mutation of residues in conserved regions led to packaging and 
infectivity defects, and interestingly, the decrease in infectivity was due to an inability to 
expose the VP1 unique N terminal phospholipase activity.  This led to the conclusion that the 
five-fold pore is not only important for DNA packaging, as implied by the previous study, 
but also in VP1 N –terminal extrusion for infectivity.  Additional research from 
Kleinschmidt’s lab, following the work on the five-fold pore, further corroborated the 
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importance of the five-fold pore in DNA packaging.   In 2006 Bleker et al. (9) demonstrated 
that a specific amino acid at the pentamer interface R432, previously shown to have ablated 
viral packaging capabilities when mutated to an alanine (156), had increased Rep protein 
binding to the capsid.  This further suggested the role of the five-fold axis in viral genome 
packaging and potential Rep protein interactions.  In the case of VP1 N-terminal 
externalization, Kronenberg et al. has suggested the five-fold pore as the potential site for 
VP1 extrusion based on electron microscopy density analysis (71).  Therefore the five-fold 
pore is an important capsid structure in viral genome packaging and infectivity. 
 As for the HI loop surrounding the five-fold pore, it has the potential to participate in 
all of the functions mentioned above.  Up until this point there has been little 
characterization of this region of the capsid, however, based on studies explored in this 
dissertation, it has been determined that this loop plays a crucial role in viral capsid 
assembly also affecting viral genome packaging and infectivity.  This region of the 
capsid will be discussed further in Chapter II. 
  
9. AAV Gene Therapy 
Advancements in the past 25years have led to the development of vectors for gene 
therapy, however where we are today would be impossible without the work accomplished in 
1982 (114).  With the cloning of AAV2, researchers have been able to utilize this virus for 
efficient gene delivery taken from bench top to bedside (145).  AAV2, was initially cloned 
with the intention of understanding the viral life cycle.  In turn, it was determined that this 
unique virus is dependent upon helper viruses such as adenovirus or herpes virus for lytic 
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infection.  Additionally the genome of this virus can integrate into chromosome 19 site 
specifically, and/or remain episomally post host cell infection.   
 The dependency on a helper virus for viral genome replication and completion of the 
lytic cycle made AAV an obvious reagent for gene delivery, being able to treat patients 
without the fear of viral replication post delivery.  In addition, AAV is a non-pathogenic 
virus with the capability of packaging a transgene of choice, further validating its 
attractiveness as a vector. The TRs flanking the ssDNA genome allows for the packaging of a 
desired transgene, as long as it meets the size requirements and is flanked by TRs.   The 
ability to package a transgene is one of the utilization limitations since the virus cannot 
package a gene over a certain size (41).  One other limitation is post viral genome entry into 
a cell, the ssDNA genome has to convert to a double strand in order to express the transgene.  
Both of these issues are currently being tackled in AAV gene therapy with the development 
of vectors with increased packaging size, size optimized transgenes (73), and double stranded 
(ds) DNA vector genomes to circumvent genome conversion (4, 57).   
 AAV gene therapy is in preclinical or clinical trial primarily for genetic diseases like 
cystic fibrosis, duchenne muscular dystrophy, hemophilia, alpha-1 antitrypsin deficiency and 
rheumatoid arthritis, and also for tumors, neurological disorders, ocular and cardiovascular 
diseases (145). These trials began due to compelling evidence that the virus could be used 
safely.  Two large areas of interest were and are cystic fibrosis and hemophilia, both genetic 
disorders resulting in the inability to incorporate the cystic fibrosis transmembrane 
conductance regulator or produce blood clotting factors, respectively.  In the case of CFTR, 
the CFTR DNA was packaged into an AAV2 capsid and delivered intranasally and 
endobronchially to patients (29).  Gene transfer was accomplished with minimal side effects, 
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however, the duration of correction was limited and the patient immune response was 
stimulated, generating antibodies against the AAV2 capsid (87, 139).   For Hemophilia B, the 
studies were also promising, displaying gene transfer post hepatic delivery, however, there 
seemed to be an elimination of AAV2 capsids due to a correlative decrease in vector 
expression (14, 89). Due to these findings, there was a research focus on the ability to 
generate vectors that would not be recognized by the immune system (53, 67, 76, 79, 164), 
understand the immunity observed in patients (Li et al. 2009 submitted) and or transduce 
specific cell types in vivo necessary for specific transgene expression.  
 Recently, retinal gene therapy has succeeded via supplementation of the RPE65 gene, 
which is mutated in congenital amaurosis leading to blindness.   AAV2 carrying the RPE 
transgene was injected into three patients.  Two to three weeks post injection the patients’ 
vision improved significantly (81). 
 Along with the promising ocular studies, there have been equally promising results 
with neurodegenerative diseases such as Canavan’s (55, 82), Parkinson’s  (130) and 
Alzheimer’s (30).  In the case of Canavan’s disease, a neurodegenerative disease caused by a 
defective aspartoacyclase enzyme necessary for breaking down building blocks for myelin, 
much progress has been made.   In 1996 the first Canavan’s patient was treated and since 
then not only has this patient’s degeneration halted, but also all patients have shown clinical 
improvement.     
 The first Parkinson’s study was funded and started by Neurologix in 2005, supplying 
the glutamic acid decarboxylase gene, which is responsible for synthesizing gamma 
aminobutyric acid, an inhibitory neurotransmitter in the brain.  Post treatment, patients 
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displayed improvement in motor function and a decrease in Parkinson’s severity and brain 
abnormalities.    
 Even though there have been great advances in gene therapy there are still some 
reservations as to the safety and efficacy of the vector.  Currently, there is a research effort to 
characterize the immune response to the virus capsid and/or delivered transgene.  Recent 
reports have indicated a potential immune response to AAV2 transduced hepatocytes during 
Factor IX delivery for hemophilia (89).  However, this response may be due to the transgene 
products from multiple open reading frames (Li et al. unpublished).  Recently, a commentary 
published in Gene Therapy (44) demonstrates that it is not the capsid or transgene alone that 
elicits an immune response.  It may be the combination of the transgene supplied and what its 
impact is on the immune system for it to trigger a response against capsid proteins.  For 
instance, when targeting the TNF receptor in baboon hearts, using AAV TNFRII-Fc, 
myocarditis developed (83).  Through multiple studies it was determined that blocking TNF 
prevented the development of T cells that tolerate the AAV capsid which subsequently 
triggered the immune response again the AAV capsid leading to myocarditis. In order to 
determine the cause of the immune response generated post AAV gene therapy, more work 
has to be done, but it is promising and researchers are getting a better feel for which 
transgenes and capsids to utilize for specific therapies to minimize the response, and are also 
considering treatments such as immunosuppressants (58).  
There has been an effort to understand the amino acids responsible for T cell or 
antibody recognition in the host post administration.  Currently, we and others are working 
on generating capsid mutants that will not be recognized by the immune system.  Besides 
controlling the immune response there is a strong effort to modulate the capsid in order to 
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generate increased vectors for gene deliver to specific tissue types.  This has been 
accomplished via capsid mutagenesis to find the determinants of tissue tropism (Asokan et al. 
unpublished) and enhanced vector transduction (Bowles et al. unpublished) and also through 
insertion of targeting peptides onto the capsid surface to redirect the virus to specific tissue 
types (35, 101, 119, 120, 154).  
To date 22 clinical trials have been completed, are currently active or recruiting.  Not 
all of the AAV serotypes are approved for clinical trial, only AAV1, AAV2, AAV6 and 
AAV8. Currently, AAV1 packaging the SERCA2a transgene is being used to treat heart 
failure and is also being used to treat Limb Girdle Muscular dystrophy (NIAMS). In this case 
AAV1 is used because it transduces the myocardium and the skeletal muscle more efficiently 
than AAV2.  AAV2 and variants of AAV2 are being used in multiple clinical trials 
specifically involving AAV-RPE65 for Leber Congenital Amaurosis (OHSU, UMASS), 
AAV-CFTR for Cystic Fibrosis (UFl), AAV-NGF for Alzheimers (Ceregene) and AAV2-
hFIX16 for Hemophilia (CHOP).  Additional to the AAV1 heart failure trial, researchers at 
Imperial College London are using AAV6-SERCA2a for heart failure 
(http://www.clinicaltrials.gov).   
 
10. Vector Purity for Clinical Use 
 As mentioned above, multiple serotypes are utilized for various clinical trials.  In 
order to use these AAV vectors, they have to be produced in large amounts and purified 
properly for optimal prep cleanliness and infectivity.  Currently there is no universal method 
for purification of all AAV serotypes, however, there are many techniques that are being 
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utilized for multiple serotypes and are necessary for the development of clinical vectors, 
which will be discussed in further detail. 
 The triple transfection method (159) is most commonly used while producing virus. 
This technique involves the triple transfection of 293 cells with a helper plasmid carrying the 
cap and rep genes, a TR plasmid containing the transgene (i.e. TR-CMV/CBA-luciferase) 
and a plasmid carrying the adenovirus helper genes for viral production as mentioned 
previously, pXX6-80.  In addition to 293 cells transfection, insect cells are being optimized 
for AAV production using the baculovirus system (124, 135).  Post virus harvesting from the 
cells there are multiple paths one can take in order to purify the vector preparation.  In the 
case of AAV2 the preferred purification method is separating empty particles from genome 
containing particles via iodixanol gradient and then purification on a heparin column to 
remove cellular protein post gradient centrifugation (39).  AAV2 can be purified on a heparin 
column since it binds heparan sulfate as a primary receptor however, the other AAV 
serotypes do not bind heparin sulfate as a primary receptor, or their primary receptors are not 
yet known.  
 Currently, most techniques for purification involve a gradient to separate empty 
particles from genome containing particles followed by a column for cleanup. There have 
been many advances in AAV purification post-production in recent years.  A few researchers 
have put tags on the virus surface, specifically a six-histidine tag at the VP3 N-terminus 
(165) and also at the 3-fold loops at amino acid position 585 (68). These techniques will be 
expounded upon in chapter 2. 
 Additional to the metal affinity column purification, there have been advances in 
chromatography.  Recently Smith et al 2008 (123) described a technique involving 
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polyethylene-glycol purification, anion-exchange chromatography and gel filtration.  
Additionally, authors report using a POROS 50HS for cation-exchange followed by anion 
exchange resin Q-sepharose XL (106) in order to separate empty from genome containing 
capsids.  All techniques have their advantages and disadvantages but have yet to be expanded 
and applied to all serotypes and their variants.  However, without these advances in 
purification, clinical grade vectors would not be producible. 
 In Chapter III of this dissertation, I will discuss my findings on the utilization of 
the HI loop as a potential domain for placing a hexa-histidine tag for purification of all 
AAV serotypes.  Additionally, this tag not only aids in the universal purification of 
virus particles, but also a domain for nanogold particle conjugation for EM 
applications.  Furthermore, the hexa-histidine motif can be utilized as a domain to 
modulate muscle and liver targeting.   
In the following dissertation multiple topics will be discussed including the HI 
loop at the five-fold axis and its role in viral assembly, the utilization of this loop as a 
novel site for hexa-histidine tag incorporation and its implications, and the analysis of 
surface loop I in the dead zone between the two-fold and five-fold axes and its role in 
virus infectivity. 
 
CHAPTER II 
Surface Loop Dynamics in AAV Capsid Assembly 
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Abstract 
 
The HI loop is a prominent domain on the AAV capsid surface that extends from 
each VP subunit overlapping the neighboring five-fold VP.  Despite the highly conserved 
nature of the residues at the five-fold pore, the HI loops surrounding this critical region vary 
significantly in amino acid sequence between the AAV serotypes.  In order to understand the 
role of this unique capsid domain, we ablated side chain interactions between the HI loop and 
the underlying EF loop in the neighboring VP subunit by generating a collection of deletion, 
insertion and substitution mutants. A mutant lacking the HI loop was unable to assemble 
particles while a substitution mutant (ten glycine residues) assembled particles but was 
unable to package viral genomes.  Substitution mutants carrying corresponding regions from 
AAV1, AAV4, AAV5 and AAV8 yielded; a) particles with titers and infectivity identical to 
AAV2 (AAV2 HI1 & HI8), b) particles with decreased virus titer (one log), but normal 
infectivity (HI4), and c) particles that synthesized VPs but were unable to assemble into 
intact capsids (HI5).  AAV5 HI is shorter than all other HI loops by one amino acid.  
Replacing the missing residue (threonine) in AAV2 HI5 resulted in a moderate particle 
assembly rescue.  In addition, we substituted the HI loop with peptides varying in length and 
amino acid sequence.  This region tolerated seven-amino acid peptide substitutions, unless 
spanning a conserved phenylalanine at amino acid position 661.  Mutation of this highly 
conserved phenylalanine to a glycine resulted in a modest decrease in virus titer, but a 
substantial decrease (one log order) in infectivity.   Subsequently, confocal studies revealed 
that AAV2 F661G is incapable of efficiently completing a key step in the infectious pathway, 
nuclear entry, hinting at a possible perturbation of VP1 phospholipase activity.  Molecular 
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modeling studies with the F661G mutant suggest that disruption of interactions between 
F661 and an underlying P373 residue in the EF loop of the neighboring subunit might 
adversely affect incorporation of the VP1 subunit at the five-fold axis. Western blot analysis 
confirmed inefficient incorporation of full length VP1 as well as a proteolytically processed 
VP1 subunit that could account for the markedly reduced infectivity.  This phenomenon is 
most likely caused by the unstable interaction between the HI loop and the neighboring 
subunit upon mutation of F661, leading to an exposed VP1 unique N-terminus amenable to 
protease digestion post viral capsid assembly.  In summary, our studies show that the HI 
loop, while flexible in amino acid sequence, is critical for AAV capsid assembly, proper VP1 
subunit incorporation, and viral genome packaging all of which implicate a potential role for 
this unique surface domain in viral infectivity.   
 
Introduction 
 
Adeno-associated virus (AAV), a 26nm nonpathogenic human parvovirus, is distinct 
from most viruses due to the dependence on a helper virus for productive infection (Ad or 
HSV) (8).  In light of the rapidly growing applications of AAV as a gene therapy vector (145, 
158), several efforts to understand events in the infectious pathway including host cell 
recognition (3, 20, 64, 105, 142), intracellular trafficking (7, 23) and uncoating (131) in the 
absence of helper are currently underway.  Within this context, a thorough understanding of 
the structural correlates of the AAV capsid and how they contribute to steps during viral 
transduction is necessary (156).   The determination of crystal structures of several AAV 
29 
 
serotypes (97, 140, 163) and related parvoviruses (2, 63) over the past few years has been 
critical in this regard. 
With respect to AAV, the capsid is encoded by three overlapping viral proteins (VPs) 
VP1, VP2 and VP3 (112), which are incorporated into a 60 subunit capsid in a 1:1:10 ratio.  
VP1 has a unique N-terminus containing a phospholipase (PLA2) domain (36) and nuclear 
localization sequences (42, 125) thought to be necessary for endosomal escape (27) and 
possibly nuclear entry (138).  VP2 also has an extended N-terminus (compared to VP3) that 
remains internal to the capsid similar to VP1 until exposed to experimental conditions 
involving low pH or heat (71).  Although this protein has been suggested to be nonessential 
for viral assembly and infectivity (144) the exact role remains unknown (42).  VP3 is the 
primary capsid protein (contained within VP1 and VP2) that constitutes the surface topology 
of the AAV capsid, which in turn dictates antigenicity (48, 79) and tropism (3, 5, 96).  Based 
on crystal structures of AAV, the VP amino acids involved in forming the icosahedral five-
fold (Figure 1B), three-fold (5) and two-fold symmetry interfaces have been visualized.  The 
three-fold axis has the largest amount of buried surface area and the highest contact energy, 
being the most interdigitated region of the capsid (163).  The surface loops at the three-fold 
axis of symmetry are thought to be involved in host cell receptor binding (5, 64) and has been 
the target of several mutagenesis studies (79, 96, 121, 156, 157). In addition, recent data has 
shown that a single amino acid change K531E located at the base of the three-fold loops has 
the ability to alter the phenotypes of multiple AAV serotypes (157) suggesting an incomplete 
understanding of this critical region.  The two-fold axis of symmetry has the weakest amino 
acid interactions and the lowest contact energy, while the five-fold symmetry axis is thought 
to have intermediate interactions (163).   As mentioned above there have been many studies 
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on the three-fold axis of symmetry, however, the role of surface loops that form the 
interactions at the five-fold and two-fold symmetry axes remains to be determined.  
The pentameric assembly of VP3 subunits results in the formation of twelve pores at 
the five-fold axis of symmetry (Figure 1B), which have been the focus of several recent 
investigations.  Mutagenesis of residues that constitute the pore has suggested a critical role 
in assembly and packaging (10, 40, 156).  Therefore, it is likely that the five-fold pore is 
necessary for DNA packaging including Rep protein binding, capsid assembly, and VP1 N-
terminus exposure.  Surrounding this pore at the five-fold axis of symmetry is a prominent 
region of the AAV capsid - the HI loop located between the β strands βH and βI, which 
spans residues 653 to 669 (VP1 numbering) and extends to overlap each adjacent subunit 
(Figure 1).  Recent data has shown that the HI loop conformationally changes upon capsid 
interaction with the primary receptor heparan sulfate proteoglycan (75) eluding to an 
important capsid conformational change for subsequent stages in the AAV life cycle.  In this 
study, we have carried out a thorough characterization of the HI loop through deletion and 
substitution mutagenesis as well as a battery of biochemical assays to assess the role of this 
surface feature in the AAV life cycle.  Our results help demonstrate the plasticity of the HI 
loop and implicate a potential role in viral genome packaging.  Simultaneously, we identified 
a critical residue within the HI loop that dictates proper incorporation of VP1 in the viral 
capsid.  
 
Materials and Methods 
 
Generation of mutants 
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All constructs were generated in the pXR2 (108) backbone using primers and 
restriction sites for PCR or oligo insertion, respectively.  PCR was used to generate AAV2 
poly-glycine and AAV2 HI-/- mutants.  PCR was performed using the Expand Long 
Template PCR kit from Roche.  All other mutants generated were the result of enzyme 
digests and oligo insert ligations. Restriction sites were placed downstream and upstream of 
the HI loop, Sbf1 and Afe1 (pXSA), respectively.  The HI loops from AAV4 and AAV5 
were amplified with these restriction sites on the 5’ and 3’ ends, digested and inserted into 
the digested pXSA backbone.  pXR1 and pXR8 were digested with Sbf1 and Afe1, removing 
the HI loop, which was then ligated into pXSA.  Restriction enzyme sites were generated at 
amino acid position 648 (Age1) and 666 (Nhe1) surrounding the HI loop in order to insert 
oligos into this region.  Oligos were ordered with corresponding restriction sites at the 5’ and 
3’ ends, digested, and ligated into the digested backbone. All oligos were synthesized by 
Integrated DNA Technologies (www.idtdna.com).  Site directed mutagenesis was also used 
in order to generate point mutations within the pXR2 backbone within the HI loop using the 
Stratagene QuikChange Site-Directed Mutagenesis kit.  Primers generated are listed in Table 
1. 
Virus production 
Virus was produced using the triple transfection method developed in our lab as 
described in Xiao et al. 1998 (159).  Cells were transfected with pXR2 containing the capsid 
mutations, pXX6-80 helper plasmid, and pTR-CMV-Luciferase containing the luciferase 
reporter transgene flanked by terminal repeats.  Cells were harvested 60hrs post transfection 
and purified using cesium chloride gradient density centrifugation for 5hrs at 65,000 rpm or 
overnight at 55,000rpm.  Gradients were fractionated and virus dialyzed against 1X PBS 
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supplemented with calcium and magnesium.  Viral titers were determined in triplicate by 
treating 2µl of the virus fractions with DNase, digesting the capsid with proteinase-K and 
loading the viral genomic DNA on to a Hybond-XL membrane (Amersham).  The viral DNA 
was detected using a 32P-labeled probe complementary to the luciferase transgene.  To carry 
out experiments in the paper we generated over 35 capsid mutants, a subset of which were 
generated multiple times.  For example: AAV2 HI-/- > five times; AAV2 HI4, two times; 
AAV2 HI5, > five times; and AAV2 F661G two times.  Each mutant virus preparation was 
made in conjunction with control AAV2 for a transfection control and titer comparison.  
Representative titers and phenotypes were documented in the results. 
 
Western dot blot, heat treatment, and western blot  
Production of empty and full capsids was determined post transfection by loading 2ul 
of the virus fractions onto a nitrocellulose membrane in a dot blot apparatus.  Membranes 
were blocked in 10% milk in PBS for 30mins at RT and incubated with A20 primary 
antibody (dilution 1:20) (153) in 2% milk for 1 hour at RT.  Membranes were washed 5 times 
with 1X PBS and incubated with goat anti-mouse horseradish peroxidase-conjugated 
secondary antibody (Pierce dilution 1:5000) for 30mins.  The membranes were washed as 
described above, and capsid production was visualized using the SuperSignal West Femto 
Maximum Sensitivity Substrate chemiluminescence kit from Pierce.  To examine VP1 
exposure, capsids were heat treated at a range of temperatures (Results) and blotted onto a 
nitrocellulose membrane through a dot blot apparatus.  The membrane was incubated as 
described above except A1 (1:20) and B1 (1:20) (153) primary antibodies were used to detect 
VP1 exposure and capsid viral protein dissociation upon heat treatment, respectively.  For 
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western blotting approximately 1E10 dialyzed vg containing particles were mixed with 
NuPAGE LDS sample buffer  (Invitrogen), run on a NuPAGE gel (Invitrogen), transferred to 
a nitrocellulose membrane (Invitrogen) and blotted as described above.  Other antibodies 
used to analyze the VP1 unique region during western blotting were anti-aa15-29 (1:1000) 
and anti-aa60-74 (1:1000)  (Pacific Immunology: Grieger, Samulski unpublished).  All films 
were exposed anywhere from 10 seconds to 1 minute.   
 
Viral transduction assay 
Viral transduction was analyzed by quantifying the luciferase transgene expression in 
293-cell lysate no more than 24hrs post infection.  2E5 293 cells were transduced with 3000 
vector genomes (vg) /cell and lysed using 1X Passive Lysis Buffer provided by Promega.  
Relative light units were analyzed post addition of the D-luciferin substrate (NanoLight) to 
the cell lysates using a Victor2 Luminometer (PerkinElmer).   
 
Electron microscopy 
10µl of purified and dialyzed full and empty virus particles in 1X PBS with Ca++ and 
Mg++ were pipetted onto a glow-discharged copper grid. The grid was washed twice with 
water and then stained with 2% uranyl acetate.  EM images were taken with a LEO EM 910 
TEM at varying magnifications at the UNC Microscopy Labs. 
 
Heparin binding assay 
1E10 vector genome containing particles of virus were incubated with pre-
equilibrated heparin type III-S agarose beads (Sigma).  The flowthrough was collected and 
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the beads washed two times with 1X PBS.  The washes were collected, and the beads were 
washed with increasing salt concentrations from 0.2M to 0.6M PBS.  A load control, the 
flowthrough, washes and elutions were blotted onto a nitrocellulose membrane using a dot 
blot apparatus.  The membrane was blocked, incubated with antibody as described earlier in 
the methods.  In this case, A20 was used as the primary antibody in order to detect intact 
capsids, and determine the affinity of virus mutants to heparin beads. 
 
Confocal microscopy 
Coverslips were plated with 50,000 Helas/slip in a 24 well plate.  Each well was 
infected with 30,000vg/cell.  12hrs post infection cells were fixed with 2% paraformaldehyde 
and washed with 1X PBS.  Cells were permeabilized with 0.1% Triton X-100 at room temp 
for 5mins and washed with 1X PBS and 1X Immunofluorescence wash buffer (IFWB: dH2O, 
20mM Tris pH 7.5, 137mM NaCl, 3mM KCl, 1.5mM MgCl2, 5mg/ml BSA, 0.05% Tween).  
Cells incubated in A20 primary (1:10) in IFWB for 1hr at 37°C.  Cells were washed with 1X 
PBS and incubated with 488nm fluorophore-conjugated secondary antibody (1:1250) in 
IFWB for 1 hr at 37°C (Abcam).  Coverslips were mounted onto slides using Prolong 
antifade gold with DAPI mounting media.  Slides were viewed on a Leica microscope in the 
Michael Hooker Microscopy Facility at UNC-Chapel Hill. 
 
Molecular modeling studies 
Homologous models of HI loop mutants were generated using VIPER (110) and/or 
Swiss-Model  (http://swissmodel.expasy.org) in order to visualize the effects of mutagenesis 
on the virus capsid.  The available structure of AAV2 (PDB accession No. 1LP3) was 
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supplied as a template for the mutant models generated in the AAV2 background.  Once the 
Swiss-model pdbs were generated, the program O (Jones et al., 1991) was used to generate 
symmetry related models of the monomer subunits using icosahedral matrix multiplication. 
Structure visualization of mutant models and the structures of other AAV serotypes whose 
HI loops were substituted into AAV2 (e.g. AAV4, PDB accession No. 2G8G (38); AAV8, 
PDB accession No. 2qa0) AAV1 (84) and AAV5 (140) were performed using winCOOT® 
(http://www.chem.gla.ac.uk/~bernhard/coot/wincoot.html) and images were rendered with 
MacPyMOL® (http://pymol.sourceforge.net). 
 
Results 
 
With respect to structure and topology, the HI loop is highly conserved between the AAV 
serotypes and autonomous parvoviruses (Figure 1C); however the amino acid (aa) sequence 
varies significantly.  In order to determine the role of the HI loop as it pertains to the AAV 
capsid structure and life cycle, the AAV2 HI loop sequence was mutated, swapped between 
serotypes or substituted, and the resulting viruses assayed for viral assembly, encapsidation 
of the viral DNA, binding to heparan sulfate, and the ability to successfully infect target cells.  
Mutagenesis was performed on the ten varying amino acids of the HI loop, starting with 
serine 658 and ending with alanine 667 in the AAV2 capsid (Figure 1A).   
 
Deletion and glycine substitution mutants  
First, mutations were generated in which the AAV2 HI loop amino acids were either 
deleted (AAV2 HI-/-) or substituted with a poly-glycine peptide (AAV2 poly-glycine).   In 
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the substitution mutant the ten most variable HI loop amino acids were replaced with a chain 
of glycine residues in order to generate a flexible loop structure devoid of all amino acid side 
chain contacts between this loop and the EF loop (located between the β-strands βE and βF) 
in the underlying subunit (Figure 2A).  Upon removal of the HI loop, AAV2 HI-/- capsid 
viral proteins were expressed (data not shown) but unable to assemble into particles as 
determined by A20 western dot blot analysis (Figure 2B) and DNA dot blot (Table 2).  
Interestingly, as shown in Figure 2B, the AAV2 poly-glycine mutant formed AAV particles 
based on western dot blot analysis (see fractions 10 and 11 of the cesium chloride gradient), 
however, these particles were devoid of DNA (Table 2).  The AAV2 poly-glycine empty 
particles appear to be similar to AAV2 empty particles when analyzed under EM (Figure 
2C), with the exception of a ring-like staining pattern more apparent with AAV2 poly-
glycine particles.  Although no other gross structural changes were evident by EM, potential 
conformational changes to the capsid were suggested by the ring-like staining therefore, 
further biochemical analyses were carried out such as heparin binding affinity 
chromatography.  The AAV2 poly-glycine mutant had a comparable affinity for heparin 
sulfate as wt AAV2 particles as determined through a heparin binding assay, eluting from the 
heparin column mostly at 0.4M salt (Table 2).  From these data, three important conclusions 
can be drawn; the presence of the HI loop is necessary for capsid assembly, and specific 
amino acid side-chain interactions within this loop appear to be necessary for packaging the 
viral genomic DNA.  In addition, residues forming the HI loop and adjacent capsid regions 
do not play a role in heparan sulfate receptor attachment. 
 
HI loop domain swapping 
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Based on the observations from the glycine residue replacement studies, we carried 
out HI loop swaps from representative serotypes in hopes of obtaining more information on 
critical amino acids that have evolved for the HI loops of specific serotypes.  The serotypes 
chosen for this study were AAV1, AAV4, AAV5 and AAV8 which are 83%, 61%, 59% and 
83% identical to the overall amino acid sequence of the AAV2 capsid, respectively (Figure 
1A) and represent the range of sequence homology between AAV2 and the other serotypes 
characterized to date (32).  The AAV1 and 8 HI loops are similar in conformation (Figure 
3B) but vary significantly in amino acid sequence (Figure 3A).  AAV2 with the loops from 
AAV1 (AAV2 HI1) or AAV8 (AAV2 HI8) generated titers only two-fold lower than wt 
AAV2 at 3E9vg/µl, 3E9vg/µl and 6E9vg/µl, respectively (Figure 3D) and display similar to 
wt AAV2 heparan sulfate elution profiles (e.g. mostly at 0.4M PBS Figure 3E).  As 
determined through EM analysis, the full particles obtained for the mutant seem to be similar 
to wt AAV2 full particles in gross conformation (Figure 3C).  In addition, as seen in Figure 
3D AAV2 HI1, AAV2 HI8 and AAV2 all transduced 293 cells (infected with 3000vg/cell) 
with similar efficiency as determined through a luciferase assay.   
At the other end of the phenotype spectrum, swapping of the HI loops from the less 
homologous serotypes AAV4 and AAV5 did not produce mutant viruses that were similar to 
wt AAV2.  As shown in Figure 4A, AAV2 HI4 based on dot blot analysis, produced a virus 
titer one log lower than wt AAV2, 1.05E9vg/µl and 1.13E8vg/µl, respectively.  However, 
when 293 cells were infected with the same number of vector genomes per cell, AAV2 HI4 
and wt AAV2 infected cells with similar efficiency (Figure 4A).  Interestingly, when wt 
AAV2 and AAV2 HI4 full particles were heat treated at one-degree increments ranging from 
55°C to 65°C, AAV2 capsid dissociation was initiated at temperatures as low as 55°C, with 
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complete dissociation at 63°C, whereas, AAV2 HI4 did not dissociate and expose VP1 until 
63°C (Figure 4B).  This observation suggests that the, AAV2 HI4 mutant capsid is more 
stable than that of wt AAV2, although we are still unsure if there is a correlation between 
capsid stability and titer. 
The AAV5 capsid VP subunit, with 59% homology in amino acid sequence to AAV2, 
contains an HI loop that is one amino acid shorter than those observed in AAV2 and the 
other AAV serotypes characterized to date.  The AAV5 HI loop is structurally lacking a 
threonine at the amino acid position equivalent to residue 659 in AAV2.  Substitution of this 
HI loop into AAV2 (AAV2 HI5) resulted in a change in amino acid sequence beginning at 
position 655 instead of 658 due to the low homology (Figure 5A).  Although, AAV2 HI5 can 
express VP1, 2 and 3 when the cell lysate is subjected to western blot analysis (data not 
shown) the subunit proteins are unable to assemble into intact capsid particles as determined 
by A20 western dot blot (Figure 5B).  In order to determine if the length of the HI loop is 
contributing to the inability of AAV2 HI5 to assemble particles, a threonine was inserted into 
AAV2 HI5 at position 659 (AAV2 HI5 TTSF).  The threonine insertion does minimally 
restore capsid assembly but not packaging based on western dot blot (Figure 5B) and DNA 
dot blot analyses (Table 2), respectively.   
The HI loop swap phenotypes show that specific amino acid side chain interactions of 
the HI loop can affect particle stability as seen with the AAV2 HI4 mutant, and the length of 
the HI loop appears to be crucial for maintaining proper capsid assembly as in AAV2 HI5; 
however DNA packaging ability seems to be more stringently controlled by loop sequence as 
concluded from the AAV2 poly-glycine mutant.  In addition, the data shows that this capsid 
VP region can tolerate amino acid differences in assembling an AAV capsid seen in AAV2 
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HI1 and HI8, consistent with the observation of the HI loop in all the parvovirus structures 
determined to date (Figure 1A) despite the lack of sequence similarity.   
 
Site-directed mutagenesis 
To determine which amino acids within the HI loop are critical for viral genome 
packaging into the assembled capsids, a series of site-directed mutants were generated in this 
region based on sequence conservation between the AAV serotypes and observed 
interactions with the underlying amino acids, since replacing the AAV2 HI loop with 
glycines appears to ablate DNA packaging capabilities.  As shown in the serotype sequence 
alignment in Figure 1A, a phenylalanine at position 661 within the HI loop is conserved in 
the AAV serotypes aligned.  In the crystal structure of AAV2 the side chain of F661 interacts 
with a conserved proline at position 373 in the EF loop within the underlying subunit 
possibly through hydrophobic interactions (Figure 7B).  Such interactions have been shown 
to play key roles in protein stability and folding (18).  Also seen in the sequence alignment, 
residue K665 is present in most serotypes (Figure 1A), which based on the crystal structure 
forms a salt bridge with an aspartic acid at position 368 of the underlying subunit.  Another 
amino acid of interest is F666, which resides in a hydrophobic pocket of the underlying 
subunit.  As seen in the sequence and structure alignment (Figure 1), there is a hydrophobic 
residue such as valine or isoleucine at this position in all serotypes compared.  In order to 
determine which of these three conserved residues are critical for the AAV2 capsid to fully 
assemble and package the viral genome, the glycine residues at position 661, 665 and 666 in 
the AAV2 poly-glycine mutant were individually changed back to the amino acids present in 
the wt AAV2 HI loop, F661, K665 and F666, respectively.  Mutating the residues one at a 
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time did not restore the ability of the AAV2 poly-glycine mutant to package the viral DNA 
(Table 2).  This suggests that cooperative interactions facilitated by individual residues are 
critical for maintaining viral genome packaging capabilities, as seen in the AAV2 HI loop 
swap mutants (Table 2).  This conclusion is further substantiated by the experiments 
mentioned below.   
 
Peptide substitution studies 
In order to determine the plasticity of the HI loop, gross mutagenesis of amino acid 
residues within this region was carried out on the capsid.  Since data mentioned previously 
suggests a cooperative effect between amino acids is necessary for viral genome packaging, 
semi-conserved residues K665 and F666 were left unchanged.  The AAV2 HI loop was 
substituted with a range of peptide sequences varying in length and beginning at different 
amino acid positions.  First, short RGD peptides were substituted, in an effort to “walk 
through” the HI loop and characterize the effects of disparate non-AAV sequences on viral 
assembly and packaging.  Amino acid positions 658-660, 660-662, 662-664, and 663-665 
were substituted with an RGD peptide (120) (AAV2 RGD 658, AAV2 RGD 660, AAV2 
RGD 662 and AAV2 RGD 663, respectively) (Figure 6A).  Most mutants were obtained at 
virus titers within two-fold of wt AAV2 with the exception of mutant AAV2 RGD 660, 
which was obtained at a six-fold lower titer than wt AAV2 at 1.48E8vg/µl compared to 
8.81E8vg/µl (Figure 6B).  AAV2 RGD 658 and AAV2 RGD 662, after adjusting for vector 
genome number, resulted in similar infectivity to wt based on a luciferase assay (Table 2).  
However, when 293 cells were infected with AAV2 RGD 660, it was five-fold less infectious 
than wt AAV2 (Figure 6B).  RGD 660 was lower in titer and infectivity than wildtype, and 
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results in the substitution of the conserved F661 (see Site-directed mutagenesis) with a 
glycine residue, suggesting a potential role of F661 in the virus life cycle.  In light of this 
single amino acid and its phenotypic effects, we introduced longer peptides into the AAV2 
HI loop for increased amino acid variability, and to gain more insight into structure-function 
constraints in manipulating this region. 
Seven amino acid peptides, successfully used as insertions in previous capsid 
mutagenesis studies, were chosen in order to determine if the variable region of the HI loop 
could tolerate these peptides as substitutions.  Starting at position 658 in the AAV2 HI loop, 
we substituted with peptides QPEHSST, VNTANST, SIGYPLP (154)  and SGRGDS (70) 
(Figure 6A).  All mutants generated virus.  AAV2 QPEHSST was able to make virus in titers 
similar to that of wt (within 2-fold) followed by AAV2 VNTANST (3.5-fold lower than 
AAV2), and AAV2 SIGYPLP and AAV2 SGRGDS (4.5-fold lower than AAV2).  However, 
AAV2 VNTANST was 27-fold less infectious than wt AAV2 while, AAV2 SIGYPLP was 
reduced by approximately 10-fold in infectivity (Table 1).   AAV2 SGRGDS and AAV2 
QPEHSST were 4.5 and 2-fold less infectious than wt AAV2, respectively (Figure 6B).  The 
aforementioned changes in titer and infectivity upon gross mutagenesis of the AAV2 HI 
loops suggest that the amino acid interactions between the HI loop and underlying subunit 
are crucial for maintaining AAV viability.  Previous data in the literature suggests that the 
five-fold axis is necessary for viral genome packaging and VP1 externalization (10, 71, 156).  
We do see a viral genome packaging defect in some of the mutants mentioned above, 
correlating with a decrease in infectivity.  To further understand the phenotypic changes 
observed, we carried out a battery of biochemical analyses. 
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Biochemical analysis   
A series of biochemical analyses such as heparin binding, heat treatment and western 
blotting were performed in order to understand why the titer and infectivity of AAV2 RGD 
660, AAV2 VNTANST, AAV2 SIGYPLP and AAV2 SGRGDS were consistently lower 
than wt AAV2, from such studies, western blot analysis revealed an interesting capsid 
phenotype as shown in Figure 6C.  We used monoclonal antibodies B1 and A1 (153) that 
recognize the VP3 C-terminus and VP1 unique N-terminus, respectively, to characterize the 
peptide substitution variants described above. Based on B1 staining, AAV2 VNTANST had 
decreased VP1 incorporation and an extra protein band between VP2 and VP3.  In addition, 
AAV2 SIGYPLP had decreased VP1 incorporation.   Interestingly, when blotted with A1 
antibody against the VP1 unique region of AAV2, AAV2 QPEHSST, AAV2 RGD 660, and 
AAV2 SGRGDS revealed a second band at 77kDa.  Notably, AAV2 RGD 660 and the 
longer peptide substitutions that were detrimental to virus titer and infectivity all changed the 
amino acid type at the conserved phenylalanine at position 661 (Figure 1C).  Therefore the 
role of this residue in the AAV2 HI loop functionality was further investigated. 
 
Analysis of the conserved F661 residue   
F661, which is completely conserved throughout all AAV serotypes (Figure 7A) and 
interacts with a proline in the underlying VP subunit, was mutated to a glycine residue in 
AAV2 (AAV2 F661G).  AAV2 F661G produced virus five-fold lower in titer than wt AAV2 
based on dot blot analysis, 8.2E7vg/µl and 4.1E8 vg/µl respectively (Figure 7C).   AAV2 
F661G also binds heparin with a similar affinity as wt AAV2 based on heparin column 
binding and elution with increasing concentrations of salt (Table 2).  Interestingly, AAV2 
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F661G is one log less infectious than AAV2 based on a luciferase assay (Figure 7D).  In 
addition to these data, AAV2 F661G and wt AAV2 capsids were heat treated at 37°C, 50°C, 
60°C, 65°C and 75°C.  While, AAV2 was able to expose the VP1 N-terminus based on A1 
antibody staining at 60°C, AAV2 F661G is unable to do so at this temperature, and can only 
expose the VP1 N-terminus when heated to 75°C upon capsid dissociation (Figure 8A).  To 
further corroborate the data showing decreased incorporation of VP1 and reduced infectivity 
of AAV2 F661G, we carried out intracellular trafficking studies using confocal fluorescence 
microscopy.  Briefly, Hela cells were infected with 30,000vg/cell of wt AAV2 and AAV2 
F661G particles.  The cells were fixed 12hrs post infection and stained with primary A20 
antibody for intact capsid detection and then secondary goat-anti mouse 488nm-fluorophore 
conjugated antibody.  In addition, the nuclei were stained with DAPI.  Based on this analysis, 
AAV2 F661G was unable to enter the nucleus efficiently and appeared to remain perinuclear, 
unlike wt AAV2, which trafficked into the nucleus more efficiently (Figure 8B).   
In addition, when 1E9vg dialyzed full particles were run on a western blot and stained 
with monoclonal B1 and A1 antibodies, AAV2 F661G revealed a fourth molecular weight 
capsid species between VP1 and VP2 consistently running at 77kDa.  Using antibodies that 
specifically detect amino acids 15-29 and 60-74 in the VP1 unique region (Figure 9A), the 
capsid band at 77kDa was not detected on the western blot, further confirming an N-terminal 
truncation of this capsid subunit (Figure 9B). This molecular weight species is identical to 
the novel protein band seen in the western blot with AAV2 QPEHSST, AAV2 RGD 660 and 
AAV2 SGRGDS capsid subunit proteins.  The novel capsid subunit is approximately 100 
amino acid residues shorter than VP1 (Figure 6B), implicating potential proteolytic 
processing of the exposed VP1 N-terminus in these HI loop variants.  
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 Therefore, the aforementioned data demonstrates that the HI loop can tolerate most 
amino acid changes, and specific cooperative amino acid interactions are necessary for 
proper viral genome packaging.  Additionally, the F661/P373 hydrophobic interaction 
appears crucial for proper incorporation of the VP1 subunit into the AAV2 capsid.  Without 
the proper interactions a distinct VP1 subunit lacking its N-terminus containing the 
phospholipase activity is incorporated into the capsid, directly impacting virus infectivity. 
 
Discussion 
 
With the availability of the AAV2 crystal structure (160), many aspects of the adeno-
associated virus life cycle including host cell recognition (3, 20, 64, 105, 142), intracellular 
trafficking (7, 23) and uncoating (131) are now possible to correlate to structure.  The first of 
such studies have centered around the three-fold loops and the determination that they are 
key topological features in host cell recognition (5, 64).  Similar structure-function studies 
have extended from the three-fold loops to the five-fold axis and the location of the virion 
pore and its potential role in viral genome packaging, capsid assembly and VP1 unique N-
terminal exposure (10, 71, 156).  Interestingly, the HI loop surrounds the five-fold pore, and 
has an essential structural role in viral assembly by overlapping the neighboring VP3 subunit 
forming amino acid interactions with the underlying EF loop (see Figure 1).  Recently Dr. 
Mavis Agbandje-McKenna has observed the HI loop flipping up 90° upon AAV2-heparan 
sulfate proteoglycan binding suggesting a dynamic role of this structure in the viral infectious 
pathway (75).  To better understand the role of this capsid structure, we chose to characterize 
in detail the HI loop as it may contribute to specific stages in the virus life cycle such as viral 
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genome packaging, assembly, and subsequent stages during the infectious pathway.  The 
results of this study demonstrate that the AAV2 HI loop is essential for proper capsid 
assembly, packaging of the viral DNA, and viral infectivity when the conserved 
phenylalanine at amino acid position 661 is altered. 
We carried out a comprehensive amino acid deletion and substitution study to 
uncover the role of the HI loop in the AAV life cycle.  From these efforts we determined that 
removal of the HI loop (AAV2 HI-/-) leads to capsids that cannot assemble (Figure 2).  We 
assayed viral assembly primarily using the monoclonal A20 antibody (153) that detects 
tertiary structure of properly assembled AAV capsids.  Viruses that were unable to form 
virions were further studied using gradients and western blot analyses that confirmed the 
ability to synthesize viral protein subunits (data not shown).  Although we relied primarily on 
A20 recognition to confirm the ability to form proper virion structures, additional studies 
such as iodixanol gradient purified AAV2 HI-/- cell lysate followed by EM analysis further 
determined that this mutant only appears to generate monomer subunits (data not shown).  In 
contrast, substitution of the loop with glycines (AAV2 poly-glycine) generated A20 
recognizable assembled capsids, however these capsids were deficient in the ability to 
package the viral DNA.  Even though this mutant provided sufficient structure to assemble 
intact AAV particles, the glycine substitutions specifically ablate amino acid side-chain 
interactions with the EF loop of the underlying subunit, suggesting that the HI loop structure 
and the backbone interactions of the HI loop with the underlying subunit are sufficient 
enough to facilitate capsid formation. However, the specific amino acid interactions are 
required for efficient packaging of the viral DNA.  Although we can not draw from our 
studies the exact mechanism for the viral genome packaging deficiencies of the glycine 
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substitution mutant, it is interesting to speculate that this phenotype can possibly be attributed 
to gross conformational changes in the structure of the five-fold pore since the five-fold pore 
has been implicated as the site of Rep protein binding, a necessary step for efficient DNA 
encapsidation (9, 10). As a result, it will be of interest to determine ability of HI loop mutants 
to bind Rep protein in pull down experiments as previously described (9). 
In addition to the deletion and substitution studies above, we decided to swap the 
AAV2 HI loop with those from representative serotypes.  Domain swapping, specifically 
between virus serotypes allows for determination of the role of that specific region of the 
capsid in the virus life cycle.  For example, in adenovirus, the fiber necessary for host cell 
recognition (155), was swapped between adenovirus subgroups resulting in alteration of 
intracellular trafficking of the adenovirus vectors (85).  Alternatively, in the case of AAV, 
domains were swapped between AAV1 and 2 in order to characterize determinants necessary 
for AAV1 muscle tropism (46).  In a similar study regarding AAV, domains from AAV2 
were swapped with those from AAV8, demonstrating that Loop IV of AAV8 at the three-fold 
axis of symmetry is responsibly for dictating liver tropism (118).  Interestingly in our studies, 
swapping the HI loop with that of AAV1 and AAV8 did not affect titer, transduction, heparin 
binding or gross conformation.  However, this can be expected due to the relatively higher 
sequence homology between AAV2 and these serotypes.  More importantly, these results 
suggest that the HI loop most likely does not contain determinants of tissue tropism or 
receptor binding.  This was further confirmed via mouse intramuscular injections with AAV2 
RGD 662.   Briefly, bioluminescence imaging revealed similar in vivo transduction profiles 
for AAV2 RGD 662 and wt AAV2 one-week post administration (data not shown).   
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In the case of AAV4 and AAV5 HI loops, significant phenotypic variations were seen 
possibly due to lower sequence homology with AAV2.  For instance, the AAV4 HI loop is 
comprised of a higher number of hydrophobic residues than the loop from AAV2 based on 
the amino acid sequence and crystal structure (38).  The 3-dimensional structure of the 
AAV2 VP3 monomer (Figure 4C) shows that the side chains of residues 659 and 660 point 
away from the capsid and do not interact with the residues in the underlying subunit.  On the 
other hand, the conserved phenylalanine at position 661 interacts with proline 373 in the EF 
loop of the underlying subunit as mentioned in the results.  The alanine-to-serine change at 
position 663 of the AAV2 HI4 mutant might contribute a hydrogen bond interaction due to a 
potentially accessible hydroxyl group that is not present in the AAV2 HI loop.  The K665P 
change in AAV2 HI4 suggests a possible contribution to increased hydrophobic interactions 
with proline, valine, phenylalanine and methionine residues found in the underlying subunit 
of AAV2.   However, this assessment is based on a structure model of AAV2 HI4 and a more 
accurate analysis of the AAV4 HI loop amino acid contributions to AAV2 capsid stability is 
dependent upon knowing the crystal structure of the AAV2 HI4 mutant. 
Collectively, the aforementioned amino acid changes in AAV2 HI4 could enhance HI 
loop-EF loop interactions and thereby could well account for increased capsid stability as 
demonstrated through increased resistance to heat treatment in comparison to AAV2.  In 
addition, such increases in capsid stability and possible gross conformational changes to the 
five-fold pore might account for lower packaging efficiency and titers seen with the AAV2 
HI4 mutant.  It is possible that the AAV capsid “breathes” or expands in volume during viral 
genome packaging, and if the capsid is too stable or held too tightly together, it may be more 
difficult for the Rep protein to package the viral genome.  The idea of capsid expansion has 
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been studied in bacteriophage, and it has been shown that during the DNA packaging process 
a conformational change occurs which causes an increase in capsid volume (56).   
Additionally, previous data suggest that the Rep protein is bound in higher quantities 
to the capsids of packaging deficient mutants (9) possibly due to “jamming” of the genome 
threading machinery.  Such has also been noted in the case of AAV2 HI4, wherein the 
particle bound increased amounts of Rep protein in comparison with AAV2 (data not 
shown).  For the AAV2 HI4 mutant, it is possible that there is increased stability of the 
particle based on the presence of another protein or proteins on the capsid surface.  
In the case of AAV2 HI5, despite normal expression of capsid subunit proteins, no 
intact capsid assembly is observed.   This was further confirmed via EM analysis on cesium 
chloride gradient fractions of the AAV2 HI5 transfected cell lysate.  It was determined that 
the AAV2 HI5 mutant may form pentamers, but does not form proper intact particles (data 
not shown).  This phenotype is likely attributable to the fact that the AAV5 HI loop is one 
amino acid shorter, based on the crystal structure (140) than the wt AAV2 HI loop.  In 
corollary, insertion of the missing threonine at position 659, minimally rescues capsid 
assembly.  Therefore, the length of the HI loop in relation to the underlying subunit appears 
to be crucial for proper capsid assembly, while the loop amino acid interactions with the 
underlying subunit dictate genome packaging efficiency.  This was further corroborated by 
the fact the AAV2 HI loop glycine extensions formed intact virus particles, but were unable 
to package the viral genome based on dot blot and western dot blot analyses (data not 
shown).    
Following the domain swaps we decided to use peptide substitutions in order to 
mutate multiple residues of the HI loop.  Many groups have successfully inserted peptides, 
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specifically at the three-fold loops, on the capsid surface as a means to retarget the virus for 
specific tissue types (35, 120, 121, 154).   In this study we used peptides, not as insertions, 
but substitutions in a novel region of the capsid.  Peptide substitution within the AAV2 HI 
loop showed that certain amino acid changes do not affect virus titer and transduction, as 
seen with the AAV2 RGD 658, AAV2 RGD 662 and AAV2 QPEHSST mutants.  However, 
some peptide substitutions resulted in marked changes in phenotype that were dependent on 
the amino acid position substituted.  For instance, substitution with peptide RGD at position 
660 (AAV2 RGD 660), SGRGDS starting at position 658 (AAV2 SGRGDS), VNTANST 
starting at position 658 (AAV2 VNTANST) and SIGYPLP also starting at position 658 
(AAV2 SIGYPLP) resulted in decreased titer and infectivity.  All of these mutants replace 
the conserved F661 residue observed in all serotypes. 
Interestingly, a number of these mutants, such as AAV2 VNTANST, SIGYPLP, 
RGD 660 and SGRGDS, also revealed differential banding patterns seen with B1 antibody 
staining of a western blot (Figure 6C).  Specifically, there appears to be a decreased 
incorporation of VP1 capsid subunits in these mutant capsids.  It is likely that such 
phenotype, which would reduce the effectiveness of the PLA2 domain (located in the VP1 N-
terminal domain) required for endosomal escape and nuclear entry of the viral capsid, could 
explain the decrease in transduction seen with these mutants (36, 40, 71, 125).  The lower 
titers of the aforementioned mutants can possibly be attributed to improper capsid assembly 
(9, 132) and defective packaging (9).  In the AAV2 VNTANST mutant there is an additional 
protein band seen between VP2 and VP3 with B1 staining that is yet to be identified.  The 
observed protein product is most likely due to proteolytic processing of VP1, which could 
also account for the decreased amount of VP1 present in this capsid mutant.  The 77kDa 
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protein band in the case of AAV2 RGD 660 and AAV2 SGRGDS seen with A1 staining 
further corroborates these speculations (Figure 6C).  
As mentioned above one commonality shared by these defective peptide substitution 
mutants is that they span the conserved phenylalanine at amino acid position 661.  F661 
interacts with P373 in the EF loop in the underlying subunit of all serotypes through 
interactions (Figure 7B).  This interaction appears critical for stability (18) of assembled 
capsid subunits since the HI loop is the only region at the five-fold axis of symmetry that 
extends from one subunit and overlaps the underlying subunit.  Mutation of F661 results in a 
phenotype similar to that seen with peptide substitutions spanning this region.  Based on data 
shown in Figure 9, we hypothesize that the interaction between F661 and P373 is necessary 
to stabilize the capsid around the five-fold axis of symmetry, being of great importance due 
the five-fold pores’ contribution to viral genome packaging and infectivity (10, 156).  
Disruption of this interaction appears in particular, to reduce the amount of VP1 incorporated 
into these mutant capsids (Figure 9B).  
Additionally, such mutagenesis could result in improper incorporation of VP1 
subunits at the five-fold axis of symmetry, which would expose the critical PLA2 domain to 
cellular proteases during virus production.  If unassembled VP1 monomers or loosely 
assembled particles exposing the VP1 unique N-terminus are present, it is possible that they 
may be susceptible to cellular proteases.  This may not occur as readily in wildtype or other 
mutant viruses that are able to assemble the VP monomers efficiently in a stable 
configuration.  
 In conjunction with this observation, a similar phenomenon may be occurring in the 
AAV baculovirus production system (124, 135).  There appears to be inefficient 
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incorporation of VP1 into the AAV2 capsid during production in insect cells, and this may be 
due to the susceptibility of VP1 to cellular protease in the non mammalian cell environment 
(69).  The notion that VP1 is susceptible to cellular proteases is further substantiated by the 
fact that when mammalian cells are transfected with VP1 constructs, specifically 
VP1NLSFKN and VP1FKN, a second molecular weight band is detected between VP1 and 
VP2 in the cell lysates (40) similar to the result obtained in this study.  Upon mutation of 
F661 this molecular weight species was not only generated but also incorporated into the 
intact capsid.  
 In addition, it is not surprising that a single amino acid on the AAV capsid such as 
F661 could significantly impact the biology of the virus.  A recent study from our lab has 
shown that a single amino acid mutation, specifically K531E in AAV6 and E531K in AAV1, 
suppress and enhance heparin binding, respectively (157).  Taken together, our data supports 
the role of the HI loop as an important AAV capsid structural element, necessary for proper 
incorporation of VP1 into an assembled infectious particle and a functional five-fold pore 
that allows efficient packaging of viral genomes.  
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Table 1: Primers utilized for AAV2 HI loop mutant capsid generation 
Primer name Forward Reverse 
AAV2 HI-/- 5’ TCC TTC ATC ACA CAG TAC TCC 
ACG GGA CAG G 3’ 
5’ AGG ATT CGC AGG TAC CGG 
GGT GTT CTT GAT GAG 3’ 
AAV2 poly-glycine 5’ GGA GGA GGA GGA GGA GGA GGA 
GGA GGA GGA TCC TTC ATC ACA 
CAG TAC TCC ACG GGA CAG G 3’ 
TCC TCC TCC TCC TCC TCC TCC 
TCC TCC TCC AGG ATT CGC AGG 
TAC CGG GGT GTT CTT GAT GAG 
3’ 
AAV2 poly-glycine F661 5’ GCG AAT CCT GGA GGA GGA TTC 
GGA GGA GGA GGA GGA 3’ 
N/A 
AAV2 poly-glycine K665 5’ GGA GGA GGA GGA GGA AAG GGA 
GGA TCC TTC ATC 3’ 
N/A 
AAV2 poly-glycine F666 5’ GGA GGA GGA GGA GGA TTT GGA 
TCC TTC ATC ACA CAG 3’ 
N/A 
pXSA for HI loop 
serotype swaps 
(Sbf1) 5’ AGA GAT GTG TAC CTG CAG 
GGG CCC ATC TGG 3’ 
(Afe1) 5; AAG GAA AAC AGC AAG 
CGC TGG AAT CCC GAA 3’ 
N/A 
AAV5 HI loop 5’ GAT CCT GCA GGG ACC CAT CTG 
GGC CAA GAT C 3’ 
5’ GCT TGG AGT TTT CCT TCT 
TGA GCT CCC AC 3’ 
AAV4 HI loop 5’ GAT CCT GCA GGG TCC CAT TTG 
GGC CAA GAT T 3’ 
5’ GTT TGG ACC GCT CCT TCT 
GGA TCT CCC 3’ 
AAV2 HI5 TTSF  5’ CCC GGA AAT ATC ACC ACC AGC 
TTC TCG GAC GTG 3’ 
N/A 
pAge1 Nhel (Age1)) 5’ CTC ATC AAG AAC ACA 
CCG GTA CCT GCG 3’  
(Nhe1) 5’ GCG GCA AAG TTT GCT 
AGC TTC ATC ACA CAG TAC TCC 3’ 
 
N/A 
AAV2 SIGYPLP 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT AGC ATT GGT TAT CCT CTT 
CCT AAG TTT GCT AGC TTC ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
AGG AAG AGG ATA ACC AAT GCT 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 VNTANST 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT GTT AAT ACT GCT AAT 
AGC ACT AAG TTT GCT AGC TTC 
ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
AGT GCT ATT AGC AGT ATT AAC 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 QPEHSST 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT CAA CCT GAA CAT AGC 
AGC ACT AAG TTT GCT AGC TTC 
5’ GAT GAA GCT AGC AAA CTT 
AGT GCT GCT ATG TTC AGG TTG 
AGG ATT CGC AGG TAC CGG TGT 
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ATC 3’ GTT CTT 3’ 
AAV2 RGD 658 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT CGA GGA GAC TTC AGT 
GCG GCA AAG TTT GCT AGC TTC 
ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
TGC CGC ACT GAA GTC TCC TCG 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 RGD 660 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT TCG ACC CGA GGA GAC 
GCG GCA AAG TTT GCT AGC TTC 
ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
TGC CGC GTC TCC TCG GGT CGA 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 RGD 662 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT TCG ACC ACC TTC CGA 
GGA GAC AAG TTT GCT AGC TTC 
ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
GTC TCC TCG GAA GGT GGT CGA 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 RGD 663 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT TCG ACC ACC TTC AGT 
CGA GGA GAC TTT GCT AGC TTC 
ATC 3’  
5’ GAT GAA GCT AGC AAA GTC 
TCC TCG ACT GAA GGT GGT CGA 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 SGRGDS 5’ AAG AAC ACA CCG GTA CCT GCG 
AAT CCT TCG GGA CGA GGA GAC 
TCG GCG AAG TTT GCT AGC TTC 
ATC 3’ 
5’ GAT GAA GCT AGC AAA CTT 
CGC CGA GTC TCC TCG TCC CGA 
AGG ATT CGC AGG TAC CGG TGT 
GTT CTT 3’ 
AAV2 F661G 5’ GCG AAT CCT TCG ACC ACC GGC 
AGT GCG GCA AAG TTT GCT TCC 3’ 
N/A 
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Table 2.  Phenotype comparison between AAV2 HI loop capsid mutants 
Mutant Sequence Assembly 
(western 
dot blot) 
Packaging 
(DNA dot 
blot) 
Heparin 
Binding 
aInfectivity 
(luciferase 
assay) 
Alternative 
VP1 
(western 
blot)  
AAV2 HI -/- (655) ANP----------SFI - - N/A N/A N/A 
AAV2 poly-
glycine 
(655) ANP GGGGGGGGGG SFI + - + N/A - 
AAV2 G661F (655) ANP GGGFGGGGGG SFI + - N/D N/A N/D 
AAV2 G665K (655) ANP GGGGGGGKGG SFI + - N/D N/A N/D 
AAV2 G666F (655) ANP GGGGGGGGFG SFI + - N/D N/A N/D 
AAV2 HI1 (655) ANP PAEFSATKFA SFI + + + No change - 
AAV2 HI8 (655) ANP PTTFNSQKLN SFI + + + No change - 
AAV2 HI4 (655) ANP ATTFSSTPVN SFI + - + No change - 
AAV2 HI5 (655) GNI T- SFSDVPVS SFI - - N/A N/A N/A 
AAV2 RGD 658 (655) ANP RGDFSAAKFA SFI + + N/D No change - 
AAV2 RGD 660 (655) ANP STRGDAAKFA SFI + +/- N/D 4.7 + 
AAV2 RGD 662 (655) ANP STTFRGDKFA SFI + + N/D No change - 
AAV2 RGD 663 (655) ANP STTFSRGDFA SFI + +/- N/D bNo change - 
AAV2 
VNTANST 
(655) ANP VNTANSTKFA SFI + +/- + 27 + 
AAV2 
QPEHSST 
(655) ANP QPEHSSTKFA SFI + + + 2 + 
AAV2 SIGYPLP (655) ANP SIGYPLPKFA SFI + +/- N/D 10.4 + 
AAV2 SGRGDS (655) ANP SGRGDSAKFA SFI + +/- N/D 4.5 + 
AAV2 F661G (655) ANP STTGSAAKFA SFI + +/- + 13.55 + 
a      = Fold decrease in infectivity 
b        = In SK-OV3 cells 
+     =  Similar to wt 
+/-   = Packaging:  Approximately 5-fold lower in titer than wt 
-      = Packaging:  One log lower in titer than wt or unable to package the viral genome 
N/A = Not applicable 
N/D = Not determined 
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Figure 1. HI loop comparison between various AAV serotypes and                       
autonomous parvoviruses 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  HI loop comparison between various AAV serotypes and autonomous 
parvoviruses. (A) Comparison of amino acid sequence homologies between representative 
AAV serotypes. The HI loop amino acid sequence alignment is shown on the right.  Boxed 
are the ten most variable amino acids. (B) An arrow indicates the HI loop on an AAV2 
pentamer, which extends from one VP subunit and overlaps the neighboring VP. (C) Circled 
in black are the HI loops on a structural superimposition of the VP monomer subunits of 
multiple AAV serotypes, AAV2 (blue), AAV4 (red), AAV5 (gray), AAV1 (purple) and 
AAV8 (green) and autonomous parvoviruses CPV (orange), FPV (salmon), B19 (wheat), 
MVM (lime) and PPV (slate).
Homology 
  AAV2 (649) IKNTPVP ANP  STTFSAAKFA  SFITQYSTGQV 
   83% AAV1 (648) IKNTPVP ANP  PAEFSATKFA  SFITQYSTGQV 
   61%  AAV4 (647) IKNTPVP ANP  ATTFSSTPVN  SFITQYSTGQV 
   59% AAV5 (638) IKNTPVP GNI  T-SFSDVPVS  SFITQYSTGQV 
   83%  AAV8 (651) IKNTPVP ADP  PTTFNQSKLN  SFITQYSTGQV 
 
B.     C. 
 
AAV2   CPV  
AAV1   MVM 
AAV8   PPV 
AAV5   B19 
   FPV 
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Figure 2. AAV2 HI loop deletion and glycine substitution characterizations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 2.  AAV2 HI loop deletion and glycine substitution characterizations.  (A) AAV2 HI 
loop sequence alignment showing amino acids 658-667 that were removed  (AAV2 HI-/-) or 
substituted with glycine residues (AAV2 poly-glycine). (B) Western dot blot analysis of 
CsCl gradient fractions from AAV2, AAV2 HI-/- and AAV2 poly-glycine preparations with 
A20 antibody. Gradient fractions were collected, and blotted onto a nitrocellulose membrane.  
The membrane was incubated with primary antibody A20 (1:20) and incubated with 
A.   
 
AAV2       (648)  IKNTPVPANP STTFSAAKFA SFITQYSTGQV 
AAV2 HI-/-     (648)  IKNTPVPANP ---------- SFITQYSTGQV  
AAV2 poly-glycine (648)  IKNTPVPANP GGGGGGGGGG SFITQYSTGQV 
 
B. 
      1      2      3      4       5       6      7      8      9     10     11    12 
    
 
C. 
 
  AAV2 empty             AAV2 poly-glycine 
                                                             
               
 
AAV2 
 
AAV2 HI-/- 
 
AAV2  
poly-glycine 
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horseradish peroxidase conjugated secondary goat anti-mouse (1:5000). (C) Electron 
micrograph images of empty AAV2 and AAV2 poly-glycine particles. Gradient purified, 1X 
PBS Ca++/Mg++ dialyzed AAV2 (left panel) and AAV2 poly-glycine (right panel) empties 
were incubated on glow discharged copper grids negatively stained with 2% uranyl acetate. 
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Figure 3. AAV2 HI1 and AAV2 HI8 substitution mutant characterization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
AAV2     (648) IKNTPVPANP  STTFSAAKFA  SFITQYSTGQV 
AAV2 HI1 (648) IKNTPVPANP  PAEFSATKFA  SFITQYSTGQV 
AAV2 HI8 (648) IKNTPVPADP  PTTFNQSKLN  SFITQYSTGQV 
 
B.   C.    
                 
 
 
 
 
 
 
D. 
 
E. 
 
     L         W1        W2        W3       0.2M      0.3M     0.4M     0.5M      0.6M 
 
 
AAV2            AAV2 HI1         AAV2 HI8 
AAV2 
AAV2 HI1 
AAV2 HI8 
50nm 50nm 50nm 
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Figure 3.  AAV2 HI1 and AAV2 HI8 substitution mutant characterization.  (A) Sequence 
alignment of AAV2, AAV1 and AAV8 HI loop amino acids.  (B) Structural alignment of 
AAV2, AAV1 and AAV8 HI loops (yellow, pink and blue). (C) Electron micrograph images 
of AAV2, AAV2 HI1 and AAV2 HI8 1XPBS Ca++/Mg++ dialyzed CsCl purified (previously 
mentioned) DNA containing particles. (D) Radioactive DNA dot blot shown as fold change 
in titer (left panel) and luciferase assay on infected 293 cells with 3000 vg/cell (right panel 
n=3 SD=black bars).  (E) Heparin binding profiles of AAV2, AAV2 HI1 and AAV2 HI8.  
500ul of heparin type IIIS conjugated agarose beads (Sigma) were incubated with 1E10 
vector genome containing particles (L = load) for 10mins at room temperature.  The washes 
(1X PBS) and elutions (0.2M-0.6M PBS) were collected and capsids were detected via 
western dot blot analysis with A20 monoclonal antibody (1:20). 
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Figure 4.  AAV2 HI4 subsitution mutant characterization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  AAV2 HI4 substitution mutant characterization. (A) AAV2 HI4 titer and 
transduction.  AAV2 and AAV2 HI4 titers were quantified via radioactive DNA dot blot 
against the luciferase transgene, shown as fold change in titer (left panel).  AAV2 HI4 
transduction was quantified via luciferase assay of 293 cells infected with 3000 vg/cell (right 
panel n=3 SD=black bars). (B) Heat treatment of 6E8 AAV2 and AAV2 HI4 viral DNA 
containing particles, with temperatures tested on the left hand side were transferred to a 
nitrocellulose membrane and blotted with the antibodies listed across the bottom at a ratio of 
1:20. (C) Structural alignment of the AAV2 (yellow) and AAV4 (pink) HI loops from VP 
subunits. 
A. 
 
B.            C. 
 
        
         
 
A20      B1               A1 
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Figure 5. AAV2 HI5 substitution mutant characterization 
A. 
 
                                                                
 
 
AAV2  (655) ANPSTTFSAAKFA 
AAV2 HI5  (655) GNIT-SFSDVPVS 
 
 
 
B. 
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Figure 5. AAV2 HI5 substitution mutant characterization. (A) A sequence alignment of 
AAV2 and AAV5 HI loop residues (left hand side) and a structural alignment of AAV2 
(yellow) and AAV5 (cyan) HI loops (right hand side).  The amino acid position deleted in 
AAV5 relative to AAV2 in this region is depicted as a dash in the alignment and the 
threonine residue “inserted” at this position in AAV2 is indicated with a red arrow on the 
structural superimposition. (B) Western dot blot analysis of AAV2, AAV2 HI5, and AAV2 
HI5 TTSF (threonine inserted at amino acid position 659) CsCl gradient fractions blotted 
with A20 antibody (1:20). 
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Figure 6. AAV2 HI loop peptide substitution mutant characterizations 
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AAV2 (658)     STTFSAAKFA 
AAV2 VNTANST   VNTANSTKFA 
AAV2 QPEHSST   QPEHSSTKFA 
AAV2 SIGYPLP   SIGYPLPKFA 
 
AAV2 RGD 658    RGDFSAAKFA 
AAV2 RGD 660    STRGDAAKFA 
AAV2 RGD 662    STTFRGDKFA 
AAV2 SGRGDS     SGRGDSAKFA 
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VP2 
VP3 
 
VP1 
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Figure 6.  AAV2 HI loop peptide substitution mutant characterizations. (A) A sequence 
alignment shows residues in the AAV2 HI loop that were substituted with specific peptides 
indicated in orange.  (B) HI loop peptide substitution titer and transduction.  Fold change in 
titer as compared to AAV2 determined by radioactive DNA dot blot analysis (left panel). 
Fold change in transduction of infected 293 cells (3000 vg/cell) determined by luciferase 
assay (right panel n=3 SD=black bars). (C) Western blot analysis of peptide substitution 
mutants incubated overnight at 4°C with A1 (1:20) and B1 (1:20) monoclonal antibodies.  A 
red arrow indicates an additional protein band detected with A1 antibody (bottom panel). 
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Figure 7. Residue F661 structure model and sequence alignment and AAV2 F661G 
substitution mutant characterization 
 
A. 
                             661 
 
AAV2 (658) STTFSAAKFA 
AAV1 (657) PAEFSATKFA 
AAV4 (656) ATTFSSTPVN 
AAV5 (647) T-SFSDVPVS 
AAV8 (660) STTFNSQKLN 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
C.    D.  
            
  
Figure 7.  Residue F661 structure model and sequence alignment and AAV2 F661G 
substitution mutant characterization. (A) Sequence alignment of representative serotypes 
shows that F661 is conserved (cyan).  (B) The HI loop located on a pentamer at the five-fold 
face (bottom left) is magnified (bottom right) showing the HI loop from one VP (white) 
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extends over the underlying VP (pink).   F661 side chain (cyan) near the center of the HI 
loop forms a hydrophobic interaction with a conserved proline residue (yellow) of the 
underlying adjacent VP (top right). (C) Fold change in AAV2 F661G viral titer determined 
by radioactive DNA dot blot against the luciferase transgene. (D) Transduction quantified 
post 293 cell infection with AAV2 and AAV2 F661G (3000 vg/cell) and evaluated via 
luciferase assay (n=3 SD=black bars).  
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Figure 8. AAV2 F661G VP1 externalization and virus infectivity 
 
A. 
  AAV2                                              AAV2 F661G 
  
No HT  37°C    60°C   65°C   75°C          No HT   37°C   60°C   65°C   75°C 
 
 
B. 
 AAV2                           AAV2 F661G 
             
12hrs post infection                                   12hrs post infection  
Figure 8.  AAV2 F661G VP1 externalization and virus infectivity.  (A) Heat treatment of 
6E8 AAV2 and AAV2 F661G viral DNA containing particles (temperatures across the 
bottom).  Treated capsids were blotted on a nitrocellulose membrane and intact capsids, 
dissociated VPs and externalized VP1 unique N-termini were detected with A20, B1 and A1 
antibodies (1:20) as indicated on the right hand side. (B) Hela cells were infected with 50000 
vg containing particles of AAV2 or AAV2 F661G.  Cells were fixed and permeabilized, and 
intact capsids were detected with primary A20 antibody (1:10) and 488nm fluorophore-
A20 
 
B1 
 
A1 
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conjugated secondary antibody (1:1250).  The nucleus was stained blue with DAPI. Red 
arrows indicate AAV2 (left panel) and AAV2 F661G (right panel) intact capsids. 
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Figure 9. AAV2 F661G viral protein incorporation 
A. 
 
 
 
 
 
               Y aa15-29               Y aa60-74                     YA1 aa123-131 
 
 
B. 
 
 
 
 
 
 
 
     
             B1         A1               aa60-74            aa15-29 
 
Figure 9.  AAV2 F661G viral protein incorporation.  (A) The schematic represents AAV2 
VP3 with an enlargement of the VP1 unique region (orange).  The yellow and purple regions 
represent VP1/VP2 and the VP1/VP2/VP3 common regions, respectively.  Antibodies 
generated (Pacific Immunology) recognize specific amino acid stretches in the VP1 unique 
region as indicated at the bottom of the schematic (1:1000).  (B) Western blot analysis of 
AAV2 and AAV2 F661G capsids with B1 and A1 antibodies (1:20), listed below the blot, 
detected an additional protein band at ~77kDa (red arrows). 
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Abstract 
 
The ability to manipulate the adeno-associated virus capsid allows researchers to 
understand capsid domains and develop efficient vectors for gene delivery. In this report we 
have focused on the HI loop, a previously characterized capsid domain. We substituted 
specific amino acids, AAV2 aa662-667, located within this region of AAV2 and AAV9 
capsids with a hexa-histidine tag without disrupting key amino acid contacts shown to be 
important for viral assembly.  The resulting AAV2 HI6xHis and AAV9 HI6xHis could be 
purified via nickel affinity chromatography as a potential universal purification scheme for 
AAV vectors.  Further we were able to conjugate Ni-NTA gold nanoparticles to these 
capsids, thereby demonstrating their potential as novel reagents for EM applications, such as 
the determination of VP location in the intact capsid and histological analysis of patient 
samples.  While the presence of hexa-histidine tags on the surface did not affect capsid 
infectivity in vitro, significantly reduced transduction was observed following intramuscular 
administration in mice.  Interestingly, his-tagged AAV capsids were detargeted from the liver 
following intravenous administration. However upon generation of chimeras with fewer 
hexa-histidines tags on the surface, transduction is rescued in vivo.  In summary, we have 
introduced a multifunctional domain into a novel site on the capsid surface that can be 
utilized for universal AAV vector purification, capsid labeling with gold nanoparticles and 
generating vectors detargeted from the liver.  
 
 
 Introduction 
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As gene therapists we are constantly manipulating the AAV capsid in order to 
generate vectors for gene delivery.  Understanding the domains and individual amino acids 
on the surface of each AAV serotype allows for the creation of tailored vectors with specific 
tissue tropisms and subsequently disease targets. Not only do we need to understand the 
capsid function of specific serotypes as they relate to vector design but also need to produce 
and purify the vectors for such usage.  Currently there is no universal method for purification 
of all AAV serotypes, however, there are many techniques that are being utilized for multiple 
serotypes and are necessary for progress in the field and the development of clinical vectors. 
 For AAV2 the preferred purification method is separating empty particles from 
genome containing particles via iodixanol gradient and then purification on a heparin column 
to remove cellular protein post gradient centrifugation.  AAV2 can be purified on a heparin 
column since it binds heparan sulfate as a primary receptor however, other AAV serotypes 
do not bind heparan sulfate as a primary receptor, or their primary receptors are not yet 
known.  
Recently Smith et al. 2007 described a technique involving polyethylene-glycol 
purification, anion-exchange chromatography and gel filtration.  This method has been 
shown to be a technique with the capabilities of separating empty from genome containing 
capsids.  First the authors report using a POROS 50HS for cation-exchange followed by 
anion exchange resin Q-sepharose XL (106).  All techniques have their advantages and 
disadvantages but have yet to be expanded and applied to all serotypes and their variants.  
These advances in purification are vital for production of clinical grade vectors. 
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There have been many other advances in AAV purification post-production in recent 
years.  A few researchers have inserted tags on the virus surface, specifically a hexa-histidine 
tag at the VP3 N-terminus (165) and also at the 3-fold loops at amino acid position 585 (68). 
These techniques may become useful with further development and in vivo tissue tropism 
characterization. 
Previous studies focused on the five-fold axis of symmetry (10, 24, 40, 96) have 
allowed for further understanding of capsid structure and function. The five-fold axis of 
symmetry has been implicated in multiple roles such as vector genome packaging, viral 
capsid assembly, and VP1 externalization. Recent data has described this region of the capsid 
as being crucial for proper VP1 incorporation into the intact particle (24) and additionally, 
during primary receptor attachment has been shown to change conformation upon heparan 
binding using cryo-EM and image reconstruction (75).  
 In the current study based on the need for a universal purification scheme, we have 
expanded on our previous work with the HI loop as a novel site on the AAV capsid for 
peptide substitution without disrupting primary receptor recognition (24).  We substituted 
amino acids at the five-fold of AAV2 and AAV9 that were not crucial for capsid integrity 
with a hexa-histidine domain, utilized for affinity column purification. Additionally, we 
demonstrated the ability to use the hexa-histidine vector as a tool for nanogold labeling for 
EM application.  Another interesting feature observed was the detargeting ability of the 
histidine tagged AAV capsids from the liver as a function of the ratio of hexa-histidines on 
the capsid surface. In this manuscript, we have illustrated the use of a novel site on the AAV 
capsid for a single peptide substitution, generating a multifunctional tool for applications in 
basic virology and vectorology. 
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Materials and Methods 
 
Generation of mutants 
AAV2 HI6xHis mutants were generated using PCR with the Expand Long Template 
PCR kit (Roche) or site directed mutagenesis (Stratagene QuikChange). Primers 
complementary to the pXR2 backbone were generated by Integrated DNA Technologies 
(www.idtdna.com) with nucleotide extensions coding for the histidine tag.  The primers used 
for AAV2 HI6xHis were 5’-
CACCATCACCATCACCATTCCTTCATCACACAGTACTCCACGGGACAG-3’ and 5’-
ATGGTGATGGTGATGGTGGAAGGTGGTCGAAGGATTCGCAGGTAC-3’ (PCR 
Expand Long Template) Amino acids 662-667 in VP3 were replaced with the histidine 
residues.  For the mutants containing fewer histidine residues within the HI loop primers 
were designed as follows for use in site-directed mutagenesis: AAV2 HI1His:  
5’- GAATCCTTCGACCACCTTCAGTCACGCAAAGTTTGCTTCCTTC-3’, AAV2 
HI2His: 5’-CCTGCGAATCCTTCGACCACCTTCAGTCACCACAAGTTTGCTTCC-3’, 
AAV2 HI3His:  
5’-CCTTCGACCACCTTCCACCACCACAAGTTTGCTTCCTTCATCACACAG-3’, 
AAV2 HI4His:  
5’-CCTGCGAATCCTTCGACCACCTTCCATCACCACCACTTTGCTTCCTTC-3’, AAV2 
HI5His:  
5’-GCGAATCCTTCGACCACCTTCCATCACCACCACCACGCTTCCTTCATCAC-
3’.AAV9 HI6xHis was generated by GeneArt. 
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Virus production 
Virus was produced using the triple transfection method described in Xiao et. al. 
1998 (159).  Cells were transfected with pXR (pXR2 or pXR9) containing the capsid 
mutations, pXX6-80 helper plasmid, and pTR-CMV- or CBA-Luciferase.  In the case of 
chimeric mutants, pXR2 and pXR2 HI6xHis was transfected at a ratio of 1:1 or 5:1, 
respectively, totaling 10ug plasmid DNA (107).  Cells were harvested 60hrs post transfection 
and purified using cesium chloride gradient density centrifugation for 5hrs at 65,000 rpm or 
overnight at 55,000rpm for iodixanol gradient centrifugation.  CsCl gradients were 
fractionated and virus dialyzed against 1X PBS with calcium and magnesium, or the layer 
between 40 and 60% iodixanol was pulled from the gradient and further purified on the 
FPLC 1ml His-Trap HP nickel column (Amersham). Viral titers were determined by dot blot 
analysis or q-PCR using primers specific to the TR-Luciferase transgene. 
 
Fast protein liquid chromatography 
Various volume and vector genome quantities of iodixanol gradient purified virus 
was further purified through a nickel column (HisTrap HP 1ml column, Amersham) at a flow 
rate of 0.2ml/min.  Load volumes were mixed with binding buffer (5mM imidazole, 20mM 
sodium phosphate and 0.5M NaCl pH 7.4)) prior to loading. The column was washed with 5 
column volumes water, equilibrated with 5 column volumes binding buffer, 5ml of sample 
mixed with binding buffer was injected into the column, washed with 5 column volumes 
binding buffer, and eluted with 5 volumes elution buffer (500mM imidazole, 20mM sodium 
phosphate and 0.5M NaCl pH7.4). Peak fractions were detected based on UV absorbance at 
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280nm and verified by vector genome quantification using q-PCR with primers specific to 
the luciferase transgene.  Peak fractions were dialyzed against 1X PBS Ca++ Mg++.   
 
In vitro transduction assays 
293 cells were infected with 1000 to 3000 vector genome containing particles of 
AAV2 HI6xHis per cell pre and post FPLC column elution.  Cells were lysed with 100ul 1X 
passive lysis buffer (Promega) and the lysates were mixed with 100ul luciferin (Promega). 
Relative light units were detected with a Victor2 Luminometer. 
 
Gold particle conjugation  
Approximately 1E9 virus particles (AAV2 or AAV2HI6xHis eluted from the nickel 
column) were blocked with 0.05%Tween, 20mM NaCl and 50mM Tris pH7.5 for 30mins at 
room temperature.  The gold particles (www.nanoprobes.com) were added to the blocked 
virus particles and incubated anywhere from 5 to 30mins at room temperature at a 
concentration 60 times the nanomolar amount of His tags present in the sample.  
 
Electron microscopy 
Glow discharged carbon coated copper grids were incubated with 15ul virus or virus 
pre-incubated with gold particles for 2minutes.  For virus not conjugated to gold particles, the 
grids were washed twice with ddH2O and then negatively stained with 2% uranyl acetate 
stain for 30 seconds.  For virus conjugated to gold particles, grids were washed 2x with wash 
buffer containing 200mM NaCl and 20mM imidazole to remove nonspecific binding.  They 
were then washed with ddH2O and stained with Nanovan (Nanoprobes- 
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www.nanoprobes.com). Grids were visualized using the Leo 910 TEM in the Microscopy 
Laboratory Services at the University of North Carolina at Chapel Hill.   
 
In vivo experiments 
Balb/C female mice were injected via tail vein with 1E10 or 1E11 or intramuscular 
injection into the gastrocnemus with 1E10 vector genome containing particles (AAV2, 
AAV2 HI—His mutants, AAV9, AAV9 HI6xHis).  Mice were imaged at weekly intervals 
post injection following intraperitoneal injection with D-Luciferin (NanoLight) using the 
IVIS Xenogen imaging system.  Mice were imaged for 1 minute or 5 minutes at 5 minutes 
post administration of D-luciferin substrate. 
 
Tissue harvesting and genome quantification 
Animals were sacrificed two weeks post IV injection.  The liver was harvested and a 
section of the liver was homogenized and incubated with 180ul ATL buffer and 20ul 
proteinase K solution (Qiagen DNeasy Blood and Tissue Isolation Kit).  The tissue was 
incubated at 50 degrees overnight and genomes in the tissue were quantified via q-PCR 
(Roche) with primers specific to the luciferase transgene. The primers used were 5’-AAV 
AGC ACT CTG ATT GAC AAA TAC-3’ and 5’-CCT TCG CTT CAA AAA ATG GAA C-
3’. The mouse lamin B2 gene was also quantified and vector genome copies were normalized 
to the number of diploid genomes present in the sample.  Additionally, total vector genomes 
were quantified in the blood stream at various timepoints post injection as indicated in the 
figures.   Blood was collected in EDTA coated capillaries and total viral genome DNA was 
isolated via DNeasy Blood and Tissue Kit (Qiagen). 
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Blood incubation studies 
1E10 vector genome containing particles were incubated with blood for determination 
of particle stability and hepatocyte binding.  For particle stability in mouse blood AAV2 and 
AAV2 HI6xHis were incubated with 10ul of blood from an uninfected mouse at room 
temperature for 30minutes and then treated with DNase at 37°C (plus calcium and 
magnesium) for 1hour or not incubated with blood and solely incubated with DNase.  DNase 
was inactivated upon addition of 4ul of 0.5M EDTA.  Total vector genomes were isolated via 
DNeasy Blood and Tissue Kit (Qiagen) and quantified via q-PCR with primers specific to the 
luciferase transgene.  For hepatocyte binding studies, hepatocytes were isolated from an 
uninfected mouse liver post liver perfusion with 20ml collagenase at a concentration of 
2.5mg/ml in 1XPBS.  The liver was spun in 40ml 1X PBS for 2hours at 4°C until cells were 
in suspension.  Cells were pelleted at 2500rpm for 5min and 20ml of supernatant was 
disposed.  Cells were resuspended in remaining 20ml and aliquots were pipetted into 1.5ml 
eppendorf tubes.  Samples were spun at 50g for 4min to pellet the PCs (parenchymal cells). 
The PCs were resuspended in 1X PBS and spun at 50g for 4min.  This was repeated 3 times 
with 1X PBS.  Finally the PCs were spun at 250g for 4min and the PC supernatant was 
removed and pelleted. 1E10 vector genome containing particles alone or preincubated with 
mouse blood were incubated with PCs at 4°C for 1hour in rotating suspension.  Post 
incubation cells were maintained on ice and unbound virus was removed via multiple wash 
steps with 1X PBS post centrifugation at 50g for 4mins.  The pelleted cells were lysed and 
total DNA was isolated (viral and mouse genomic) with the DNeasy Blood and Tissue Kit 
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(Qiagen).  The genomes were quantified via q-PCR against the luciferase transgene and the 
mouse lamin gene as a control. 
 
Results  
 
As a gene therapy vector, AAV is under constant characterization and modification in 
hopes of developing a more efficient vector for gene therapy.  To generate enhanced vectors, 
we focus on capsid structure-function relationships.  Over the years research has shown that 
specific regions of the virus capsid are crucial for specific virus functions.  For instance, the 
VP1 N-terminus for phospholipase activity necessary for virus trafficking (125), basic 
regions for capsid assembly and nuclear localization (42), and the five-fold pore for viral 
genome packaging and potentially Rep protein interactions and VP1 unique N-terminal 
externalization (10).  Recently, it has been shown that the HI loop on the capsid surface is 
necessary for proper VP incorporation into the intact particle.  Additionally, it was 
determined that the HI loop is highly plastic, meaning that certain residues can be substituted 
while retaining wildtype properties as long as specific amino acid interactions are maintained 
between the HI loop and the underlying subunit.  Based on these structure-function studies, 
we demonstrated the plasticity of this novel capsid region, and its ability to tolerate amino 
acid substitutions.   
Specifically, we substituted amino acids 662-667 with six histidines for tagged 
universal metal affinity purification of all AAV serotypes.  There are multiple proposed 
purification techniques such as antibody purification and column chromatography (68), both 
of which are waiting expansion to other serotypes.  Additionally there are reports of tagged 
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purification methods involving insertion peptides at the VP2 N terminus or the heparin 
binding sited within VP3, both of which provide potential reagents for various applications.  
This study aids in the development of a universal purification method for all AAV serotypes, 
demonstrates the utilization of this domain as a site for gold particle conjugation, and 
displays a novel method for vector tropism alteration. 
 
AAV hexa-histidine production and in vitro characterization 
The HI loop, surrounding the five-fold pore, was chosen as the site of peptide 
substitution due to the previously established plasticity of this region of the capsid.  Without 
affecting the conserved capsid stabilizing phenylalanine-proline interaction at amino acid 
position 661, residues 662-667 (VP1 numbering) of the AAV2 capsid were substituted with 
six histidine residues via PCR.  The histidine residues were chosen due to the necessity for 
the development of a universal purification method of all AAV serotypes.  Virus particles 
generated contained 60 copies of the tag due to its presence in each VP3 monomer.   
Incorporation of the hexa-histidine motif into the virus capsid did not affect virus titer and 
transduction based on luciferase assay post infection of 3000 vector genome containing 
particles per 293 cell (Figure 1). The hexa-histidine tag was also incorporated into the AAV9 
capsid at the same location (GeneArt) for further purification characterization. 
 
Affinity column purification of AAV hexa-histidine vectors 
 The hexa-histidine tag was tolerated by the AAV2 and AAV9 capsid, therefore, it 
was necessary to determine if these particles could bind a nickel column and be eluted from 
that column in a pure peak fraction.  We first validated virus particle nickel-binding affinities 
81 
 
with Micro Bio-Spin Chromatography Columns (BioRad) packed with nickel-agarose beads 
(Ni-NTA Qiagen).  Beads were incubated with 1E10 vector genome containing particles 
(cesium chloride gradient purified).  Flow through, wash and elution fractions (buffers from 
Qiagen Ni-NTA kit) were collected and blotted on a nitrocellulose membrane.  AAV2 
HI6xHis bound the nickel beads and were eluted from the packed column, whereas AAV2 
wildtype particles were unable to bind the column based A20 primary antibody staining 
detecting intact capsids on a nitrocellulose membrane (data not shown).  
In order to further assess the nickel binding capabilities of the tagged virus, iodixanol 
gradient purified virus was loaded onto an FPLC nickel His-Trap HP column (Amersham).  
Following equilibration, approximately, 1E13 vector genome containing particles of AAV2 
HI6xHis were injected onto the column. AAV2 HI6xHis bound to the column and eluted 
primarily in a peak elution fraction based on FPLC protein detection at 280nm (Figure 2A). 
In order to confirm the elution of vector genome containing particles q-PCR of the luciferase 
transgene was performed on each FPLC fraction (Figure 2B).  The protein detection in the 
peak elution fraction directly corresponded with the vector genomes recovered from that 
fraction.  Therefore, viral particles remained intact during the elution from the nickel column.  
On the other hand, AAV2 wildtype particles did not bind to the column efficiently and 
primarily eluted in the column wash fractions based on the protein chromatogram and vector 
genome quantification (Figure 2A and B).  To further substantiate the capability of the AAV 
particle containing the hexa-histidine tag to bind nickel, AAV9 HI6xHis was passed through 
the nickel column.  In corroboration with previous data, AAV9 HI6xHis bound the nickel 
column and eluted off with 500mM imidazole with a similar chromatographic and vector 
genome quantification profile as to AAV2 HI6xHis (Figure 2A and B).  Collectively, 
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aforementioned results suggest potential development of a universal purification scheme for 
AAV vectors. 
 
AAV hexa-histidine particles purity 
Additional biochemical analyses were performed in order to further characterize the 
purity and infectivity of the virus particles eluted from the FPLC nickel column. AAV2 
HI6xHis and AAV9 HI6xHis FPLC column fractions (30ul), including the load, were run on 
a 10% Bis-Tris acrylamide gel (NuPage, Invitrogen).  Gels were silver stained with 
Invitrogen Silver Express and fraction 14, the peak elution fraction from the FPLC column 
runs involving AAV2 HI6xHis and AAV9 HI6xHis showed pure, concentrated viral protein 
bands of VP1, VP2 and VP3 as compared to the load control (Figure 3A).   
Using a Leo 910 TEM, electron micrographs were taken of the load and peak 
fractions of AAV2 HI6xHis and AAV9 HI6xHis FPLC column runs.  EM images revealed 
the purity of peak column fractions, potentially slightly increased from the load, and the 
maintenance of particle gross conformation post column elution (Figure 3B).  Not only did 
virus sample purity increase post nickel column purification (Figure 3A), but also virus 
infectivity was maintained (data not shown). This data demonstrates that replacing amino 
acids 662-667 with a hexa-histidine tag is a valid method for AAV universal purification.  
The hexa-histidine peptide allows for recovery of a pure virus fraction post metal affinity 
purification (Figure 3A and B).  Based on these data, we chose to characterize the virus in 
vivo. 
 
Hexa-histidine nanogold labeling 
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 In addition to the aforementioned studies, we evaluated the potential for exploiting 
the hexa-histidine tag on the AAV capsid for nanogold labeling in EM application.  From 
Nanoprobes, Ni-NTA-nanogold of 1.8nm in diameter was obtained and incubated in excess 
with AAV2 and AAV2 HI6xHis virus particles.  Post incubation the virus particles were 
incubated and stained on a copper grid. As expected the Ni-NTA-nanogold particles bound to 
AAV2 HI6xHis containing the hexa-histidine tag but did not bind the wildtype AAV2 
particles that are lacking the tag as detected by electron microscopy (Figure 3C).  Therefore, 
this domain is a novel site to use for gold particle conjugation, and in this case potentially for 
the purpose of labeling a viral particle as a means to characterize its properties in vitro, such 
as subunit detection, viral particle tracking, or detection in tissue samples for histological 
analysis. 
 
AAV hexa-histidine vectors are detargeted from the liver 
The utilization of the vector as a tool for universal purification is extremely promising 
but would be further validated by its ability to maintain wildtype properties in vivo.  
Therefore we injected our histidine tag intramuscularly (IM) and intravenously (IV) in order 
to monitor tropism and transduction levels as compared to wildtype AAV2 particles carrying 
the luciferase transgene.  First, we injected AAV2 and AAV2 HI6xHis IM.  Contrary to the 
in vitro data where AAV2 HI6xHis and AAV2 were similar in heparin binding (data not 
shown) and 293 cell transduction (Figure 1), AAV2 HI6xHis was ten fold lower in muscle 
transduction than AAV2 as determined by photon quantification (Figure 4A) post animal 
imaging. Strikingly, AAV2 HI6xHis was unable to transduce the liver post IV injection 
based on luciferase imaging (Figure 4B).  
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To further substantiate this data AAV9 and AAV9 HI6xHis was injected via tail vein 
to analyze transduction capabilities.  AAV9 was able to transduce tissue systemically, as 
defined in the literature (54).  However, like AAV2 HI6xHis, AAV9 HI6xHis displayed 
reduced muscle transduction and was unable to transduce the liver based on photon 
quantification post live animal imaging (Figure 4C). Based on these data, it is believed that 
the hexa-histidine tag, is disrupting the ability of the virus to transduce cells in vivo.  In order 
to determine if the hexa-histidine tag was altering vector tropism, we generated chimeric 
vectors containing fewer hexa-histidine peptides on the capsid surface. 
With regards to AAV2 H6xHis, we wanted to determine if this mutant was retargeted 
to another organ or circulating in the blood for a longer period of time than AAV2 due to it 
being detargeted from the liver.  However, what we found was that AAV2 HI6xHis virus has 
similar vector genome distribution to AAV2 in the lung, heart, spleen and kidney, but not in 
the liver. AAV2 on average presented five-fold more vector genome copies in the liver than 
AAV2 HI6xHis (Figure 4D). In addition, AAV2 HI6xHis based on vector genome 
distribution in the blood at 1, 3, 6, 24, and 48 hours post IV injection, displayed a similar 
circulation pattern as AAV2.  Therefore this mutant is not retargeted to another organ, nor is 
it circulating in the bloodstream for an extended period of time. 
 
Hexa-histidine chimeras rescue vector tropism 
AAV2 HI6xHis contains 60 copies of the hexa-histidine tag, therefore we generated 
chimeras containing fewer copies.  We transfected cells with multiple ratios of pXR2 
wildtype to pXR2 HI6xHis, with 1:1 or 4:1, respectively.  The ratios are indicators of the 
amount of VP incorporated containing the tag based on work previously done by Joe 
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Rabinowitz (107). Therefore capsids will contain approximately 30 wildtype AAV2 VPs and 
30 AAV2 HI6xHis VPs or 48 wildtype AAV2 VPs and 12 AAV2 HI6xHis VPs.  These 
chimeras were generated to determine if fewer copies of the hexa-histidine tag on the capsid 
surface would allow for rescued transduction in the muscle and liver. 
Prior to in vivo characterization of the chimeras AAV2 1: AAV2 HI6xHis 1 and 
AAV2 4: AAV2 HI6xHis were passed through the FPLC nickel column to eliminate 
wildtype particles that may have been generated during virus production.  Interestingly, 
AAV2 1: AAV2 HI6xHis 1 bound and eluted from the column with a similar profile to 
AAV2 HI6xHis and AAV2 4: AAV2 HI6xHis 1 bound and eluted from the column with an 
elution profile similar to AAV2 and AAV2 HI6xHis (Figure 5A and 2B).  Based on q-PCR 
of eluted vector genomes, AAV2 4: AAV2 HI6xHis 1 eluted from the column similar to 
AAV2 HI6xHis in the flowthrough, and then progressively eluted in the wash fractions 
similar to AAV2, where increased vector genomes were detected (Figure 5A). AAV2 4: 
AAV2 HI6xHis 1 particles and AAV2 1: AAV2 HI6xHis 1 particles eluted primarily in 
elution 2 (Figure 5A) as seen with AAV2 HI6xHis and AAV9 HI6xHis (Figure 2B). 
 Post purification, we injected our chimeric mutants containing fewer copies of the 
hexa-histidine tags on the capsid surface IM and IV along with AAV2 for comparison.   
AAV2 1: AAV2 HI6xHis 1, which based on plasmid ratios during transfection of virus 
production should have 30 monomer copies of AAV2 and AAV2 HI6xHis, behaved similarly 
to AAV2 HI6xHis intramuscularly (Figure 4B and 5B), demonstrating a ten fold lower 
transduction as compared to wildtype AAV2 particles post photon quantification (Figure 
5D).   However, AAV2 4: AAV2 HI6xHis 1 shows similar transduction to AAV2 wildtype 
particles, with a complete rescue of virus infectivity in skeletal muscle (Figure 5B and D).  
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Therefore, the reduced number of hexa-histidine peptides on the surface of the capsid 
allowed for complete rescue of vector transduction in the muscle.   
Interestingly, a different phenotype was observed post IV injection via the tail vein. 
When comparing the 1:1 ratio of AAV2: AAV2 HI6xHis viral particles to the 4:1 ratio there 
is an increase in liver transduction (Figure 5C), however not to wildtype levels seen with 
AAV2.  Muscle transduction with the 4:1 particles averaged five-fold higher than the 1:1 
ratio when 1E10 vector genome containing particles were injected (Figure 5D).  
Interestingly, AAV2 1: AAV2 HI6xHis 1 liver transduction resembled that of AAV2 
HI6xHis (Figure 4B), and there is a slight rescue of liver transduction with the 4:1 chimeric 
as seen in Figure 5C.  The transduction observed with the 4:1 chimeric is not a full rescue as 
determined by luminescence and vector genome quantification in the liver (Figure 5B and C).  
 
Liver detargeting due to hexa-histidine motif 
 In addition to the molecular manipulation via the generation of chimeric particles 
containing fewer hexa-histidine motifs, genetic manipulation was also performed in order to 
determine if mutation of the HI loop or the number of histidines on the surface was 
responsible for the observed liver detargeting phenotype.  The HI loop was mutated in order 
to contain fewer histidine residues; 1, 3, and 4, generating AAV2 HI1xHis, AAV2 HI3xHis, 
and AAV2 HI4xHis, respectively. 
 These vectors containing the luciferase transgene were injected intramuscularly and 
intravenously to examine muscle and liver transduction. Post IM injection of 1E10 vector 
genome containing particles of AAV HI1, HI3, HI4, and HI6xHis in comparison to AAV2 
control, it was determined that all vectors containing fewer than six histidines in the HI loop 
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were able to transduce muscle similarly to AAV2 control (Figure 6A), whereas AAV2 
HI6xHis transduced five- to tenfold less efficiently than AAV2 based on photon 
quantification from animal imaging (data not shown). 
 Post systemic injection of 1E11 vector genome containing particles of the histidine HI 
loop mutants, a more remarkable phenotype was observed.  AAV2 HI1, HI3 and HI4xHis 
were able to transduce the liver to the same efficiency as that of AAV2 control, and did not 
display an ablation of transduction as observed with the AAV2 HI6xHis vector (Figure 6B).  
These data strongly suggest that the detargeting phenotype is solely due to the presence of 
the hexa-histidine domain and not mutation of the HI loop or the number of histidines on the 
capsid surface.   
 
Discussion  
 
Most proteins purified via a hexa-histidine peptide are tagged at the N or C terminus 
(116, 136) for efficient nickel binding.  However, the AAV VP monomer assembles leaving 
the N and C – termini of the viral protein monomers hidden.  The N termini of the VPs are 
internal to the capsid until triggered by a stage in the virus life cycle to extrude (71) and the 
C termini are folded within the two-fold axis of symmetry, but are surface accessible.  
Despite this fact the C-terminus of VP3 was utilized as a site for a poly-histidine insertion in 
the AAV capsids for universal purification (165). This was an advancement in the field 
towards the development of a purification method, requiring the need for multiple construct 
transfection in order to produce VP1 and VP2 without the presence of the tag.  It would be 
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beneficial to carry the research further and determine if insertion into this location affects 
natural virus tropism and structure. 
In efforts to characterize specific regions on the AAV capsid, many researchers have 
identified locations on the capsid surface that could tolerate peptide insertions in order to 
redirect vector tissue tropism.  For instance, in 2000 one of the first studies executed, 
determined key spots on the capsid surface, including loop regions and the N-terminus of 
VP1 and VP2 as sites that can accept insertions, specifically the HA epitope (156).  Since this 
finding was prior to the determination of the AAV2 crystal structure (163), it was believed 
that if regions could tolerate these peptides, by retaining AAV wildtype phenotype and 
gaining HA binding capabilities, they were most likely surface loops, giving the AAV 
community insight as to what regions of the capsid were surface exposed.  Also, in doing so, 
the potential sites for heparin binding were determined, due to the generation of insertion 
mutants with decreased infectivity and heparin binding capabilities.  Therefore, this study 
alone, was a gateway for determining sites that could tolerate insertions and key functions of 
various locations on the capsid surface.  
After these studies, there was a surge in studies involving AAV2 retargeting.  An 
early study involved tumor-targeting peptides and their incorporation into two putative loops 
on the AAV surface at amino acid positions 449 and 588.  Loop replacements or substitutions 
were also generated, but the loop insertions outperformed the replacements based on 
biochemical assays. However, it was determined that altering these two sites on the capsid 
surface ablated heparin binding and allowed for virus retargeting (43).  In a similar study 
(119), altered AAV2 vectors with insertion peptides on the capsid surface, again eluding to 
regions on the capsid that might be responsible for heparin binding.  Not only were capsid 
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insertions used to determine sites of receptor interaction but also sites of capsid 
immunogenicity, which based on studies converges with the heparin binding site (53, 137).  
After the resolution of the AAV2 crystal structure (160) it was confirmed that the three-fold 
is on the surface and combined with data from above can tolerate peptide insertions (88, 101, 
148, 149, 154).  
The three-fold was an obvious choice for peptide insertion for virus retargeting based 
on the toleration of insertions and ablation of heparin binding.  However, in our study it was 
important to maintain heparin binding properties due to the necessity of AAV2 phenotypic 
retention.  Therefore, based on work performed at the five-fold axis (24) it grew apparent that 
this site, specifically the HI loop, could tolerate change. The positions in which to place the 
tag were chosen based on previous work performed in our laboratory.  The six variable 
residues after the conserved F661 were substituted with six histidines prior to the start of the 
conserved portion of the loop as it enters the beta sheet within VPs.  Therefore, all subunits 
contained the hexa histidine peptide, being present 60 times on the capsid surface.   
Instead of inserting a peptide, this is the first published account of the capsid 
tolerating a peptide substitution at a prominent surface loop and its utilization for multiple 
applications. The HI loop was an obvious choice based on its apparent inability to affect 
virus tropism and the potential to tolerate amino acid changes (24).  The substitution of this 
region with histidines did not affect AAV2 wildtype properties such as titer, infectivity 
(Figure 1), and overall gross conformation based on EM analysis.  Therefore, we decided to 
characterize this mutant with regards to vector purification. 
 The viral vectors were purified on a nickel column via FPLC.  AAV2 was unable to 
bind the column efficiently as expected, and mostly eluted in the sample 
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injection/flowthrough fractions, whereas AAV2 HI6xHis and AAV9 HI6xHis eluted primary 
in peak elution fraction 2. Interestingly, capsids containing the histidine tags eluted from the 
column in elution fraction 2, being the optimal location for peak virus elution based on vector 
genome quantification and protein detection (Figure 2).  When calculated, AAV2 HI6xHis 
vector recovery in the peak elution fraction was approximately 39% of the total preparation 
loaded, but further optimization might be required in order to determine the optimal flow rate 
and column size for vector recovery.   
 It is clear that AAV2 and AAV9 vectors containing the hexa-histidine tag can be 
purified via nickel column.  To check vector purity we analyzed the FPLC fractions via silver 
stain.  AAV2 and AAV9 HI6xHis both displayed vector purity in the peak elution fraction 
(elution 2), corresponding to the peak fraction vector genome containing fraction (Figure 2A 
and 3B). To further characterize vector purity, electron microscopy was performed on the 
load and peak elution fractions.  Based on EM it is apparent that iodixanol purification is 
clean, as seen in Figure 2, but FPLC nickel column purification post iodixanol gradient 
slightly improves vector purity due to the presence of fewer cellular contaminants (Figure 
3B).  In addition to this data, AAV2 HI6xHis peak elution fraction is similar in infectivity to 
its load fraction (data not shown).  Additionally, the hexa-histidine tag on the virus particle 
allows for conjugation of a Ni-NTA nanogold particle for capsid labeling.  This reagent may 
prove useful for the ability to follow the viral particle through the cell and understand capsid 
trafficking via electron microscopy.   
 Post in vitro characterization and validation we injected these vectors in vivo for 
further assessment.  Earlier Koerber et al. (68) demonstrated the ability of the AAV2 capsid 
to tolerate a hexa-histidine insertion at the three-fold heparin binding site. This insertion 
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decreased heparin binding capabilities due to its location, but when tested in the brain, 
proved to be functional (68).  Indeed, it has been shown that vectors that do not bind heparin, 
display increased vector spread in the CNS (19). However, it is unclear how the vector would 
behave in other organs and/or the bloodstream, and if placement of the histidine tag in 
another location on the capsid would alter the in vivo tropism profile. 
 In the current study, we first injected AAV2 and AAV2 HI6xHis IM.  Based on 
luciferase imaging AAV2 HI6xHis transduced the muscle ten-fold lower than AAV2 (Figure 
4A). Knowing that AAV2 transduces the liver, we wanted to examine the behavior of AAV2 
HI6xHis post systemic injection (31).  Along with the reduced transduction of the muscle 
tissue seen with AAV2 HI6xHis there appeared to be no liver transduction of AAV2 
HI6xHis. From this data it was apparent that the presence of sixty hexa-histidine tags on the 
capsid surface was altering the ability to enter tissues.  In congruence, AAV9 HI6xHis 
produced similar results.  AAV9 HI6xHis was unable to transduce the liver and displayed 
decreased muscle transduction as compared to AAV9, which transduces systemically post IV 
injection (Figure 4C).  
 In order to determine if the hexa-histidines were altering vector transduction and 
tropism, chimeric vectors were generated (40, 107) containing fewer tags than 60 on the 
surface, approximately 30 and 12 based on transfection ratios. As expected AAV2 1: AAV 
HI6xHis 1 displayed a similar elution profile to AAV2 HI6xHis from the nickel column, 
presumably due to the number of hexa-histidine peptides on the capsid surface.  Whereas, 
AAV2 4: AAV2 HI6xHis 1 displayed a similar elution profile to AAV2 in the wash 
fractions, due to the prevalence of more wildtype VPs and less hexa-histidine tags on the 
capsid surface based on transfection ratios during virus production. 
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 Post purification we injected mice IM and IV with the chimeras. Strikingly, post IM 
injection of the AAV2 4: AAV2 HI6xHis 1 chimera, there was a complete rescue of virus 
infectivity, based on animal imaging.  However, in the liver there was only a partial rescue of 
transduction with the AAV2 4: AAV2 HI6xHis 1 chimera based on imaging and vector 
genome quantification (Figure 5B and C). 
 There may be multiple reasons for this disparity.   It was considered possible that the 
presence of the histidine residues in the HI loop could be altering receptor interactions that 
may be occurring with this region of the capsid.  Based on the ability of AAV2 HI6xHis to 
bind heparin with a similar affinity as AAV2 (data not shown) and earlier studies (24) we did 
not believe this to be the case.  However, to further prove that the HI loop is not involved in 
receptor binding, we substituted the HI loop with a decreasing number of histidine residues, 
4, 3, and 1, and all mutants were able to transduce the muscle similarly to AAV2.  
Additionally all mutants were able to transduce the liver as well as AAV2, unlike AAV2 
HI6xHis (Figure 6A and B).  Therefore, the HI loop does not seem to be playing a role in 
receptor binding in the context of AAV2 in the muscle and liver.  In addition, from these 
experiments, it was determined that it is not the number of histidines on the capsid surface 
that is causing the liver detargeting phenotype, but solely the hexa-histidine motif.  This was 
concluded from the in vivo data involving AAV2 HI4xHis and AAV2 4: AAV2 HI6xHis 1 
vectors.  AAV2 HI4xHis contains a total of 240 histidines on the capsid surface and is able to 
transduce the muscle and liver similarly to AAV2 (Figure 6), whereas AAV2 4: AAV2 
HI6xHis 1 contains approximately 72 histidines on the capsid surface and is unable to 
transduce the liver to the same efficiency as wildtype (Figure 5C). 
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 In order to further assess the observed phenotypes we performed capsid stability 
assessments in mouse blood and also hepatocyte binding studies ex vivo (Figure 7A and B).  
Interestingly, we were unable to demonstrate the inability to bind hepatocytes as potentially 
seen in vivo with genome quantification post liver harvestation (Figure 5D).  When capsids 
were incubated with blood, and then parenchymal cells for cell surface binding, there was no 
difference between control AAV2 and AAV2 HI6xHis and AAV2+blood and AAV2 
HI6xHis+blood (Figure 7B). Therefore, mouse blood, in an ex vivo setting was not affecting 
viral particle binding, however, this may be due to the fact that the ratio of virus particles to 
blood ex vivo was much greater than it would be in vivo.  Knowing that binding to 
hepatocytes in this system was unaffected, particle stability in blood was assessed.  AAV2 
and AAV2 HI6xHis vector genome containing particles were incubated with blood for 
30mins at room temperature and then treated with DNase. Compared to control particles 
incubated with DNase, there appeared to be a slight drop in quantified vector genomes post 
DNase treatment of AAV2 and a more remarkable decrease in vector genome copies of 
AAV2 HI6xHis (Figure 7B).  Therefore it stands to reason that the AAV2 HI6xHis virus 
particles may have an altered conformation in the blood leading to a less stable particle, 
ablating its ability to efficiently infect certain tissues in vivo. 
It is known that histidine residues chelate ions such as copper, cobalt, nickel, 
cadmium, and calcium (15464) in the context of histidine rich calcium binding protein 
(HRC) (65, 113) in mice.  Interestingly, bis-histidine stimulates the uptake of cobalt, 
cadmium and zinc into erythrocytes (50), all ions being present in the blood plasma.  
Therefore, it is quite possible that post intravenous administration, the capsids, which are 
covered in histidine residues are chelating ions in the bloodstream, preventing the capsids 
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from successfully entering the liver.  The capsid binding to ions may induce a conformational 
change at the three-fold, inhibiting primary receptor recognition for cellular entry.  For 
example, ions induce a conformational change in the HIV virion infectivity factor affecting 
protein aggregation (100) and hepatitis B virus capsid protein affecting capsid assembly 
(127). 
 In addition to HRC, HRG (histidine rich glycoprotein), whose exact function is 
unknown, binds heme, divalent metal ions (86), heparan sulfate (11), plasminogen (12), 
thrombospondin (74), insoluble IgGs (37) and may be involved in blood coagulation (134).  
Therefore, it is possible that when the his tagged AAV capsids are in contact with blood, they 
may be participating in interactions with any of the aforementioned molecules. These 
interactions may be affecting particle stability in the bloodstream and/or generating large 
complexes unable to enter the hepatocytes, and are rather being degraded following uptake 
by Kupffer cells.  This may explain why AAV2 HI6xHis and the AAV2/AAV2 HI6xHis 
chimeras are able to transduce the muscle and not the liver as efficiently.  
This unique phenotype may allow for vector development, specifically for diseases 
where the liver is not a target organ. Therefore the AAV9 HI6xHis virus might be a potential 
candidate for further development as a vector since it retains the ability to transduce multiple 
organs with the exception of the liver.   
 We have located a novel site on the virus capsid that can be utilized for substitution 
with a hexa-histidine motif.  This motif can be used for viral protein purification. 
Additionally, the hexa-histidine motif present on the capsid surface can be used for gold 
particle conjugation for EM applications.  Finally, by altering the ratio of hexa-histidines on 
the capsid surface, it is possible to modulate tissue tropism, where we can control liver 
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targeting. In summary, HI loop substitution with a hexa-histidine motif generates 
multifunctional AAV capsids important for the advancement of tools in gene therapy 
applications 
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Figure 1. Substitution of the AAV2 HI loop with a hexa-histidine motif 
A. 
 
AAV2  (658)  STTFSAAKFA 
     AAV2 HI6xHis  (658)  STTFHHHHHH 
    B.         C. 
 
Figure 1. Substitution of the AAV2 HI loop with a hexa-histidine motif. (A) Model of the 
AAV2 capsid pentamer using MacPymol (http://pymol.sourceforge.net/).  The HI loop, 
amino acids 662-667, is substituted with six histidine residues as depicted by the model of 
the five-fold axis (left) and the sequence alignment (right). (B) AAV2 HI6xHis titer was 
determined via q-PCR of the luciferase transgene and compared to AAV2 wildtype titer. (C) 
AAV2 and AAV2 HI6xHis transduction was quantified via luciferase assay of 293 cells 
infected with 3000 vector genomes per cell (N=3 SD=black bars). 
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Figure 2. Affinity chromatography purification of AAV capsids  
A. 
AAV2 HI6xHis     AAV9 HI6xHis 
 
 
 
 
 
 
 
 
 
B. 
 
 
Figure 2.  Affinity chromatography purification of AAV capsids containing the hexa-
histidine motif.  (A) AAV2 HI6xHis (left) and AAV9 HI6xHis (right) was purified via metal 
affinity chromatography through a 1ml His-Trap HP nickel column (Amersham).  At a 
wavelength of 280nm the FPLC detector determined the peak protein elution fraction.  An 
arrow indicates the peak elution fraction of virus protein from the column.  (B)  Vector 
genome quantification of AAV2 HI6xHis and AAV9 HI6xHis nickel column fractions as 
compared to AAV2.  Approximately 1E13 vector genome containing particles were loaded in 
the injection loop and injected across the nickel column.  Total vector genomes in each 
column fractions were quantified via q-PCR against the luciferase transgene. 
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Figure 3. Vector purity and gold particle labeling 
A. 
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C. 
AAV2           AAV2 HI6xHis   AAV2 HI6xHis 
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Figure 3.  Vector purity and nanogold particle labeling.  (A) Silver stain analysis of AAV2 
HI6xHis and AAV9 HI6xHis nickel column fractions.  30ul of the load (L), flowthrough 
(FT), wash (W) and elution (E) fractions were loaded onto a NuPage gel (Invitrogen).  
Protein was detected via Silver Express (Invitrogen).  (B).  EM analysis of viral particle 
purity post nickel column purification.  15ul of AAV2 HI6xHis (left) and AAV9 HI6xHis 
(right) load and peak elution fractions were incubated on glow discharged carbon coated 
copper grids.  (C) EM analysis of Ni-NTA gold particle labeled AAV2 HI6xHis capsids.  
AAV2 (left) and AAV2 HI6xHis (right) were incubated with Ni-NTA nanogold particles 
(Nanoprobes).   
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Figure 4.  Hexa-histidine vectors detarget the liver 
A. 
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Figure 4. Hexa-histidine vectors detarget the liver. (A) 1E10 vector genome containing 
AAV2 and AAV2 HI6xHis were injected intramuscularly and (B) intravenously. Two weeks 
post vector administration mice were injected IP with D-luciferin firefly luciferase substrate 
(Nanolight) and imaged for 1minute or 5minutes, respectively via an IVIS Xenogen imaging 
system 5minutes post substrate administration.  (C) 1E11 vector genome containing particles 
of AAV9 and AAV9 HI6xHis were injected intravenously and imaged as mentioned above. 
(D) AAV2 and AAV2 HI6xHis vector genomes were quantified in multiple organs via q-
PCR of the luciferase transgene 48hrs post systemic injection (left panel) and in the blood 
post systemic injection at 1, 3, 6, 24 and 48hrs post systemic injection (right panel).  
SD=black bars N=3. 
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Figure 5.  Chimeric hexa-histidine vectors rescue tissue transduction in vivo  
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Figure 5.  Chimeric hexa-histidine vectors rescue tissue transduction in vivo.  (A) 1E12 
vector genome containing AAV2 1: AAV2 HI6xHis 1 and AAV2 4: AAV2 HI6xHis 1 
chimeras were passed through the FPLC nickel column.  Flowthrough (FT), wash (W), and 
elution (E) column fractions were collected and vector genomes in each fraction were 
quantified via q-PCR of the luciferase transgene.  (B)  1E10 vector genome containing 
AAV2 1: AAV2 HI6xHis 1 (middle) and AAV2 4: AAV2 HI6xHis 1 (right) were injected 
intramuscularly into the right and left gastrocnemus. Animals were imaged as described 
previously and photons were quantified via Living Imaging 2.5 Software.  (C) 1E10 AAV2, 
AAV2 1: AAV2 HI6xHis 1, and AAV2 4: AAV2 HI6xHis 1 vector genome containing 
particles were injected intravenously.  Two weeks post IV injection the mice were imaged as 
described above. (D) Photons emitted post IM and IV injection were quantified and graphed 
(left panel).  Liver tissue was harvested 2 weeks post IV injection and vector genomes 
present in the liver post IV injection were quantified via q-PCR with primers against the 
luciferase transgene (right panel).  The m-lam gene present in the sample was quantified as a 
control. N=3 or 4 and SD=black bars. 
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Figure 6. HI loop replacement with fewer histidines does not alter virus transduction 
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Figure 6.  HI loop replacement with fewer histidines does not alter virus transduction.  (A) 
1E10 vector genome containing particles of AAV2, AAV2 HI6xHis, AAV2 HI1xHis, AAV2 
HI3xHis and AAV2 HI4xHis were injected intramuscularly and mice were imaged three 
weeks post injection as described previously. (B) 1E11 vector genome containing particles of 
AAV2, AAV2 HI6xHis, AAV2 HI1xHis, AAV2 HI3xHis and AAV2 HI4xHis were injected 
systemically and also imaged three weeks post injection as previously mentioned. 
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Figure 7.  AAV2 HI6xHis displays an altered phenotype in the presence of blood 
A.          B. 
 
Figure 7.  AAV2 HI6xHis displays an altered phenotype in the presence of blood. (A) 1E10 
vector genome containing particles of AAV2 and AAV2 HI6xHis were incubated with serum 
for 30minutes at room temperature and were then incubated with isolated mouse hepatocytes 
for 1hour at 4°C.  Hepatocytes were pelleted and washed with 1X PBS and vector genomes 
bound to the cells were quantified via q-PCR with primers specific to the luciferase 
transgene.  (B) 1E10 vector genome containing particles of AAV2 and AAV2 HI6xHis were 
incubated with mouse blood for thirty minutes at room temperature and then with DNase for 
1hour at 37°C.  Total vector genomes were quantified via q-PCR as mentioned previously 
post DNase treatment and DNA isolation.  
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Redefining the dead zone 
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Abstract 
  
By characterizing surface domains on the AAV capsid, we are able to gain insight on 
capsid regions required for specific stages in the life cycle.  In order to utilize AAV to its full 
potential as a viral vector, more has to be learnt about the vector as a virus.  In previous 
research, I uncovered a domain on the capsid crucial for maintaining primary contacts at the 
five-fold axis necessary for proper viral assembly (24).  Determining this not only shed light 
on AAV biology but also regions of the capsid that are or are not amenable to manipulation 
for uses in gene therapy.  Therefore, it was necessary to further characterize other surface 
loops in order to uncover more about the AAV life cycle and advance developments in 
vectorology.  Based on the literature and previous research in the lab (Bowles unpublished), 
the surface loop I between the five-fold and two-fold axis a region in the dead zone became 
an obvious choice due to its potential roll in virus infectivity (79, 156).  A series of AAV2 
insertion and AAV1 substitution and deletion mutants in surface loop I amino acid 265 were 
generated. It was determined that alteration of this position lead to a series of mutants with 
enhanced tissue transduction in muscle and liver tissues.  This observation was further 
substantiated by the insertion of an amino acid into position 265 of a vector unable to 
transduce the liver (AAV2i8), which completely rescued its detargeted phenotype.  Via 
further analyses, it was determined that the mutations led to a gain of function at the cellular 
entry level, aiding in the development of vectors with enhanced transduction capabilities for 
efficient gene delivery. 
 
Introduction 
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As determined by the AAV2 crystal structure (163) the two-fold axis of symmetry is 
the weakest region of the AAV capsid based on amino acid contact energies. Additionally, it 
is not a region of topological variance between serotypes, unlike the three-fold axis, which is 
necessary for host cell receptor recognitions due to the variability of the three-fold peaks.  
Furthermore, the region between the two-fold and five-fold axes has been deemed the dead 
zone, for it has been involved in multiple mutagenesis studies determining that mutation to 
this region is detrimental to virus transduction even though the capsid does not utilize this 
region to interact with heparan sulfate primary receptor (79, 156).  Recent cryo-EM analysis 
has further substantiated this fact via capsid-heparin footprint analysis (94), however, this 
observation does not rule out the possibility of this region interacting with co-receptors on 
the cell surface or being involved in other stages in the AAV life cycle. 
 During the realization that this region was not involved in receptor recognition, it was 
uncovered that this area was playing a role in a specific stage of the virus life cycle, 
infectivity.  One mutagenesis study by Lochrie et. al. (79), demonstrated that mutation of the 
dead zone loop led to increased viral transduction.  Specifically, mutation of S267 to A or T 
increased transduction four-fold to nine-fold respectively.  Other mutations to the dead zone 
decreased virus transduction without affecting heparan binding.   Additionally, in another 
mutagenesis study (156), involving this surface loop generated non-infectious particles, or 
particles that were partially defective in infectivity and lacking A20 antibody recognition. 
 Recently, a study also confirmed this general region as a hot spot on the capsid 
surface (168).  The authors mutated all surface tyrosine residues to phenylalanines, due to the 
possibility of capsid tyrosine phosphorylation, and the necessity to determine the role of 
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capsid phosphorylation in the virus life cycle.  Specifically tyrosine 730 at the two-fold axis 
of symmetry, in close proximity to the 265 surface loop, participates in virus transduction 
upon mutagenesis.  Alteration of this single tyrosine increased virus transduction in specific 
tissue types and further research is being performed to determine the mechanism. 
Additionally, research from our lab by Dawn Bowles (unpublished) determined that 5 
residues in the AAV1 capsid were necessary for the increased muscle transduction as 
compared to AAV2.  Amino acids in AAV2 were mutated to those present in the two-fold 
and between the two and five-fold of the AAV1 capsid, increasing AAV2 muscle 
transduction in vivo and decreasing AAV2 neutralizing antibody recognition.  This mutant 
was deemed AAV2.5 and is currently in clinical trial for muscular dystrophy.  However, the 
mechanisms leading to the observed phenotypes from the aforementioned mutations remain 
unknown.  Therefore, in this study we characterized the loop between the two- and five-fold 
(surface loop I) in hopes to further understand the mechanism of increased transduction.  
Specifically, we characterized position 265 on the AAV2 capsid, obtaining striking results 
with regards to transduction in specific tissues. Due to the studies mentioned above and the 
research that will be presented in Chapter 4 of this dissertation, this region of the capsid is no 
longer the “dead zone,” but a hot zone that upon mutagenesis results in remarkable levels of 
increased virus transduction in multiple AAV backgrounds. 
 
Materials and methods 
 
Generation of mutants 
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All constructs were generated in the pXR2, pXR2 2i8 or pXR1 backbone.  Site 
directed mutagenesis (Stratagene QuikChange Site-Directed Mutagenesis kit) was used in 
order to insert or substitute point mutations or delete existing nucleotides.  
 
Virus production 
Virus was produced using the triple transfection method developed in our lab as 
described in Xiao et. al. 1998 (159).  Cells were transfected with pXR2, pXR2i8 or pXR1 
containing the capsid mutations, pXX6-80 helper plasmid, and pTR-CBA-Luciferase 
containing the luciferase reporter transgene flanked by terminal repeats.  Cells were 
harvested 60hrs post transfection and purified using cesium chloride gradient density 
centrifugation for 5hrs at 65,000 rpm or overnight at 55,000rpm.  Gradients were fractionated 
and virus dialyzed against 1X PBS supplemented with calcium and magnesium.  Viral titers 
were determined by q-PCR with primers specific to the luciferase transgene.   
 
Western dot blot, heat treatment, and western blot  
 
Production of empty and full capsids was determined post transfection by loading 2ul 
of the virus fractions onto a nitrocellulose membrane in a dot blot apparatus.  Membranes 
were blocked in 10% milk in PBS for 30mins at RT and incubated with A20 primary 
antibody (dilution 1:20) (153) in 2% milk for 1 hour at RT.  Membranes were washed 5 times 
with 1X PBS and incubated with goat anti-mouse horseradish peroxidase-conjugated 
secondary antibody (Pierce dilution 1:5000) for 30mins.  The membranes were washed as 
described above, and capsid production was visualized using the SuperSignal West Femto 
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Maximum Sensitivity Substrate chemiluminescence kit from Pierce.  To examine VP1 
exposure, capsids were heat treated at a range of temperatures (Results) and blotted onto a 
nitrocellulose membrane through a dot blot apparatus.  The membrane was incubated as 
described above except A1 (1:20) and B1 (1:20) (153) primary antibodies were used to detect 
VP1 exposure and capsid viral protein dissociation upon heat treatment, respectively.  For 
western blotting approximately 1E10 dialyzed vg containing particles were mixed with 
NuPAGE LDS sample buffer  (Invitrogen), run on a NuPAGE gel (Invitrogen), transferred to 
a nitrocellulose membrane (Invitrogen) and blotted as described above.  
 
Cell culture 
C2C12 muscle cells were cultured with DMEM 10%FBS. Cells were plated in 12 
well plates and differentiated with DMEM 10%Horse serum.  HUVEC (human umbilical 
vein endothelial cells), C166 yolk sac/vascular endothelial cells, and MEC (mouse 
myocardial endothelial cells) were obtained from Cam Patterson’s laboratory at the 
University of North Carolina at Chapel Hill.  The C166 and MEC lines were cultured with 
High Glucose DMEM and 10%FBS (Gibco).  The HUVEC line was cultured in EBM-2 
(Lonza). 
 
In vitro transduction assays 
Viral transduction was characterized in multiple cell lines.  Cells were infected with 
dialyzed virus.  293 and C2C12 cells plated at a density of 4E5cells/well were infected with 
3000 vector genome containing particles.  HUVEC, C166 and MEC cells lines were infected 
with 1000 vector genome containing particles per cell.  24hours post infection media was 
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removed from the wells and cells were lysed with 1X passive lysis buffer (Promega).  
Luciferin substrate was added to the cells (Promega Luciferase Assay Kit) and relative light 
units were collected using a Victor 2 luminometer.  
 
In vivo infectivity  
AAV2 and AAV1 variants carrying the CBA-luciferase transgene were injected into 
mice at varying viral genome amounts.  Female Balb/C mice were injected with AAV2, 
AAV1 265 and AAV2i8 265 mutants. AAV2 and AAV1 265 mutants were injected 
intramuscularly at 1E10vector genome particles unless indicated otherwise.  AAV2 2i8 was 
injected tail vein for systemic transduction at a titer of 1E11 vector genome containing 
particles. Mice were injected with D-luciferin substrate (Nanolight) and 5mins post injection 
were imaged in the Xenogen IVIS system.  Images were quantified using the Igor Pro 3.0 
software.  Animals were imaged for multiple exposure time durations and timepoints post 
viral injection as indicated in the Results. 
 
In vitro uncoating Assay 
Female Balb/C mice were injected with 1E10 vector genome containing particles of 
AAV2 and AAV2 265D carrying the GFP transgene in the gastrocnemus muscle.  Mice were 
perfused with 4% paraformaldehyde and muscle tissue was harvested at 24hrs, 48hrs, 72hrs 
and 1week post injection.  Muscle tissue was fixed in 4% paraformaldehyde for 48hrs and 
then maintained in 30% sucrose.  Muscle tissue was homogenized via three freeze/thaws and 
mortar and pestle grinding.  Half of the tissue was sonicated and treated with DNase at 37C 
for 1hour.  All preparations were incubated with Proteinase K and ATL lysis buffer from the 
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Qiagen DNeasy Blood and Tissue Kit.  Total vector genomes per mg tissue was determined 
via q-PCR with primers specific to the GFP transgene.   
 
PC and NPC separation  
Mice were injected with 1E10 vector genomes of AAV 265 insertion mutants.  Two 
weeks post IV injection, hepatocytes were isolated from mouse liver post liver perfusion with 
20ml collagenase at a concentration of 2.5mg/ml in 1XPBS.  The liver was spun in 1X PBS 
for 2hours at 4°C until cells were in suspension.  Cells were pelleted at 2500rpm for 5min 
and 20ml of supernatant was disposed.  Cells were resuspended in remaining 20ml and 
aliquots were pipetted into 1.5ml eppendorf tubes.  They were spun at 50g for 4min to pellet 
the PCs (parenchymal cells) and the supernatant was transferred to a new tube for NPC 
harvesting.  The PCs were resuspended in 1X PBS and both PC and NPC tubes were spun at 
50g for 4min.  The PC supernatant was removed and cells were again resuspended in 1X 
PBS and the NPC supernatant was transferred to a new collection tube.  Both PCs and NPCs 
were spun at 250g for 4min and the PC supernatant was removed and pellet frozen and the 
NPC supernatant was further spun intensely on a desktop microfuge in order to pellet the 
NPCs.  The genomes were quantified via q-PCR against the luciferase transgene and the 
mouse lamin gene as a control. 
 
Results 
 
In this study we characterized the dead zone loop (surface loop I) on the capsid 
surface (Figure 1), as it pertains to virus transduction in vitro and in vivo.  As mentioned 
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previously, this region of the capsid in the past, did not warrant much attention due to its lack 
of participation in receptor recognition like the three-fold loops, and viral genome packaging, 
viral assembly, and potential Rep binding like the five-fold axis.  Mutagenesis studies in the 
distant and recent past have described this surface loop as being important in viral 
transduction, altering virus infectivity upon mutation.  Strikingly, multiple studies describe 
specific positions within this region, that upon mutation to alternate amino acids increase 
transduction significantly. In this study we further characterize this region of the capsid for a 
greater understanding of the contribution of this region of the capsid to AAV biology and 
vectorology.   
 
In vitro characterization of AAV2 265 mutants 
 All amino acids were inserted into amino acid position 265 of the AAV2 capsid in 
order to determine the phenotype described by AAV2 265T transduction. It was unclear as to 
if the increase in transduction was due to the specific threonine amino acid inserted into the 
position or if it was a phenotypic product of mutating the 265 position within the surface 
loop.  Therefore, all twenty amino acids were inserted into this position and mutants were 
characterized biochemically via titer, western dot blot, western blot and cell infectivity 
analyses.  Titer was quantified via q-PCR of the produced mutants.  Viral titers between 
mutant capsids were equivalent to each other.  However, all titers were slightly lower than 
AAV2 wildtype. Post titer evaluation, the mutant capsids were western blotted in comparison 
to AAV2 in order to determine if the viral proteins were incorporated into the capsid at the 
expected 1:1:10 ratio.  All AAV2 265 insertion mutants contained the appropriate ratios of 
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viral proteins when compared to AAV2 on a western blot, as detected by primary B1 
antibody against dissociated capsid proteins.   
 Post titer and western blot characterization, AAV2 265 insertion mutants were blotted 
on a nitrocellulose membrane to determine the ratio of empty to full capsids with primary 
A20 antibody detection against the intact particle.  A20 was unable to detect the AAV2 265 
mutants, except for AAV2 265G, eluding to the importance of this site on the antibody-
capsid recognition footprint (Table 2).  Post biochemical analysis we determined cell 
infectivity of these mutants in two different cell lines, 293, in which AAV2 transduces well 
and C2C12. C2C12 cells may mimic observed phenotypes in vivo since we are injecting 
mouse muscle tissue with our AAV2 variants.  AAV2 265 insertion mutants were able to 
transduce 293 and differentiated C2C12 cells similarly based on luciferase assay.  
Interestingly, the mutant with the most variant cell infectivity in 293 cells was AAV2 265C 
with reasons to be touched on in the Discussion. Post analysis in vitro we injected our 
mutants in vivo to determine in vivo transduction levels based on animal imaging (Figure 2). 
 
AAV2 265 insertion mutants display increased transduction in muscle and liver 
 All AAV2 265 mutants at a vector genome copy number of 1E10 were injected 
intramusculary into the right and left gastrocnemus.  Animals were imaged at 1wk, 2wks, 
4wks and 8wks.  From this first round of animal injections, we decided to further 
characterize a subset of these mutants that displayed an increased transduction pattern in vivo 
(data not shown).  AAV2, AAV2 265 D, E, F, K, L, P, T, and V were examined further in 
vivo (Figure 2). 
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 These viruses were reinjected at 1E10 vector genome containing particles.  Mice were 
imaged at one-week intervals to track the gene expression pattern between variants.  
Interestingly, most variants displayed increased transduction as compared to AAV2 over a 
five week period, however, there were a few 265 insertion mutants that displayed increased 
transduction, anywhere from five to ten fold over AAV2 wildtype particles.  These mutants 
were AAV2 265D, E, and F.  Amino acids D (aspartic acid) and E (glutamic acid) are 
negatively charged while, F is a bulky hydrophobic residue.  Strikingly, AAV2 265T, the 
original mutation derived from AAV1, did not display as large of an increase in muscle 
transduction as AAV2 265D and F.  Therefore, other mutations to this region of the capsid 
can increase infectivity more so than the parent amino acid sequences (Figure 2). 
 Similar to the observed phenotype in muscle, displayed was an increase in 
transduction post intravenous injection. 1E10 vector genome containing particles of AAV2, 
AAV2 265D, AAV2 265T and AAV2 265P were injected via tail vein and mice were imaged 
two weeks post injection.  Post photon quantification, all AAV2 265 insertion mutants 
transduced the liver tissue anywhere from 10 to 100 fold greater than AAV2.  Therefore, the 
insertion mutation can increase AAV2 transduction in multiple tissue types (Figure 3A and 
B). 
 
AAV1 265 substitution biochemical analysis 
 AAV1 was chosen as the next candidate to receive the transduction increasing 
mutations.  As mentioned previously, the AAV2 265 mutants were generated based on a 
sequence alignment between AAV2 and AAV1 (Figure 4A), describing this site as a 
potential site for the increased transduction observed post AAV1 intramuscular transduction 
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as compared to AAV2.  In the amino acid alignment, AAV1 is one amino acid longer, the 
threonine at position 265 is an insertion as compared to the AAV2 capsid surface loop I. 
Therefore, we chose to mutate the AAV1 threonine amino acid to D, E, or F or delete the 
threonine to make the loop similar to AAV2 in amino acid length.  The hypotheses being that 
mutation of the threonine will either cause AAV1 to behave more like AAV2, or it will cause 
an increase in transduction if the disruption of the 265 loop is a universal gain of function 
effect. 
 AAV1 T265D, E, F and del were generated and characterized first in vitro.  These 
mutants were able to generate titers similar to wildtype AAV1. Additionally, when western 
blotted, these mutants contained the appropriate ratio of VP1, VP2 and VP3 as expected.  
When assayed for infectivity in tissue culture, similar to AAV2 and the 265 insertion 
mutants, all AAV1 mutants infected 293 cells anywhere from five to tenfold less than AAV1 
when infected with 3000 vector genome containing particles per cell.  Virus infectivity in 
C2C12 cells was similar to 293 cells, with an infectivity of five to tenfold lower than the 
parent AAV1 with the exception of AAV1 T265F, being about five-fold higher in infectivity 
when compared to AAV1 (Figure 4A). However, due to the inconsistency in infectivity 
between in vitro and in vivo results as seen with the AAV2 265 insertion mutants, the AAV1 
mutants were further characterized in vivo. 
 
AAV1 265 substitution mutants in vivo 
 The AAV1 T265 substitution mutants were injected intramuscularly in two different 
vector genome doses, 1E9 and 1E10.  Interestingly, at a dose of 1E9 vector genome 
containing particles, there was a significant increase in vector transduction between the T265 
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mutants and AAV1 wildtype particles.  AAV1 265 mutants ranged from ten to one hundred 
fold higher in infectivity as compared to AAV1 based on photon quantification post animal 
imaging (Figure 4B).  These mutants were higher transducers at a dose of 1E9 vector genome 
containing particles than the AAV2 265 substitution mutants at a 1E10 dose. Once the dose 
of the AAV1 T265 mutants was increased to 1E10 vector genome containing particles a 
different phenotype is observed. At a higher dose, the AAV1 T265 substitution and deletion 
mutants do not display a striking increase in vector transduction as compared to wildtype 
AAV1 particles (Figure 4C). 
 Of all mutants, the one with the largest increase in transduction was AAV1 T265 
deletion (Figure 4B), with an increase of five-fold greater than AAV1 at 1week post and 
sustained at 6 weeks post IM injection.  Therefore, the observed increase in transduction 
upon mutation of this region of the capsid was not serotype or capsid background specific, as 
seen with the increases in both AAV1 and AAV2 muscle and liver transduction, respectively.  
 
AAV2 2i8 insertion mutants in vivo 
Due to the dramatic increases in transduction observed with the AAV1 and AAV2 
265 mutants, it was decided to generate the in another backbone.  AAV2i8, a vector 
generated by Asokan et al. 2009 (unpublished), detargets the liver, but transduces 
systemically similar to AAV8 based on photon quantification post animal imaging and vector 
genome distribution analysis.  The observed phenotype is due to the presence of the AAV8 
three-fold loop on the AAV2 capsid, ablating the ability of AAV2 to bind heparin sulfate.  
AAV2i8 was of interest for this study due to its liver detargeting capabilities, and the 
potential of the 265 insertion mutant to increase or rescue transduction in the liver.  
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 Therefore, 265D, E, and F were inserted into AAV2i8, along with Q as an arbitrary 
mutation to this region of the capsid. Interestingly, when 293 cells were infected with 
AAV2i8, there was decreased transduction as compared to AAV2 as expected due to the lack 
of heparin binding capabilities, however AAV2i8 265D, E, F and Q increased AAV2i8 
transduction ten fold (Figure 5B).  Based on these data, it was apparent, that these vectors 
should be injected in vivo for complete transduction characterization.  1E10 vector genome 
containing particles of AAV2i8 265E were injected via tail vein into mice in order to monitor 
systemic transduction.  As mentioned previously AAV2i8 cannot efficiently transduce the 
liver, however, AAV2i8 265E (Figure 5C), D, F and Q (data not shown) were able to rescue 
liver transduction based on photon quantification post animal imaging and vector genome 
quantification (Figure 5).  
Therefore, it is apparent that the 265 position on the AAV capsid plays an important 
role in virus infectivity, shown with an increase in tissue transduction when insertions are 
generated in AAV2, AAV1 is mutated, and an insertion is generated in a mutant unable to 
transduce a certain tissue type efficiently in the case of AAV2i8.  Due to this observed effect 
it was imperative to determine the mechanism behind observed phenotype, whether it be due 
to pre or post entry mechanisms. 
 
AAV2 265 insertion mutant mechanism  
Uncoating 
Due to the observed increase in transduction upon mutation of the 265 region of the 
capsid, multiple possibilities were explored.  Our first hypothesis was that mutation of this 
region affected vector uncoating.  First, vector stability was examined via heat treatment 
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analysis.  1E10 viral particles of AAV2 and AAV2 265D were incubated at a range of 
temperatures as indicated in the results and blotted onto a nitrocellulose membrane.  Capsid 
viral proteins at the various temperatures were detected via B1 antibody against dissociated 
viral proteins and A1 antibody against the VP1 unique N-terminus.  A20 antibody to detect 
intact particles could not be used since the 265 mutants were undetectable by this antibody.  
In doing so it was determined that based on heat treatment of the capsid particles, there was 
no difference in stability of AAV2 and AAV2 265D at varying temperatures (Figure 6A). 
Not only did we look at particle stability, but also the ability of the viral capsid to 
protect genomes in vivo.  AAV2 and AAV2 265D were injected at a vector genome 
containing number of 1E10 into the left and right gastrocnemus.  The muscle was harvested 
at 24hrs, 48hrs, 72hrs and 1week post infection.  The muscle tissue was homogenized and 
left untreated or treated with DNase to degrade genomes that were unprotected by capsid 
particles.  Following treatment the muscle was treated with proteinase K and lysis buffer 
(Qiagen) in order to break down the tissue and open any capsid particles that remained intact.  
Therefore, we could compare protected viral genomes to unprotected.  Based on q-PCR 
quantification of vector genomes, on average, there appears to be a trend in the reduction of 
AAV2 265D genomes protected over time as compared to AAV2 on average. However, due 
to large error bars, the trend is not statistically significant, and based on data mentioned in 
this chapter, uncoating does not appear to be the mechanism behind the increase in 265 
mutant transduction  (Figure 6B). 
 
Endothelial cell infectivity 
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 An alternate mechanism for the ability of increased viral transduction observed in 
vivo, is the ability of the 265 mutants to enter a cell type that they were unable to transduce 
prior to mutation of this region.  Based on aforementioned data it is apparent that the AAV2 
265 insertion mutants transduced 293 cells similar to each other and less efficiently than 
AAV2, not being a reflection of what occurred in vivo. Additionally, when infectivity of 
these mutants was assayed on differentiated C2C12 cells a similar result was observed.  The 
AAV2 265 mutants transduced similarly to each other, some of which similar to AAV2 and 
some slightly less than (Figure 7A).   
 Since we observed the increased transduction in vivo, knowing that the mutants were 
able to infect muscle and liver well in vivo based on animal imaging post 265 mutant 
infection, it was hypothesized that the 265 insertion mutants might be infecting a common 
cell type found in multiple tissues, such as endothelial cells.  Therefore, we obtained multiple 
endothelial cell lines for in vitro transduction assays.  Three cell lines were utilized, HUVEC 
(human embryonic stem cells), C166 (yolk sac/vascular endothelial cells), and MEC (mouse 
myocardial endothelial cells.  With regard to the HUVECS, the AAV2 265 mutants 
transduced less efficiently than AAV2, however, the AAV2 265 mutants were able to 
transduce the C166 and MECs more efficiently than AAV2.  Of the AAV2 265 mutants 
tested, all were able to transduce C166 cells approximately 50 fold higher than AAV2.  
Additionally, AAV2 265D and E were able to transduce MECs approximately 3 and 2 fold 
better than AAV2, respectively whereas AAV2 265T and P were able to transduce 34 and 15 
fold better than AAV2, respectively (Figure 7B).  Based on the aforementioned in vitro data 
the possibility remains that the AAV2 265 insertion mutants gain the ability to transduce 
endothelial cells in vivo. 
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Liver PC and NPC infectivity 
 Based on the increase in endothelial cell transduction in vitro, relating this to in vivo 
infectivity was warranted.  Post vector uncoating analyses it was determined that the increase 
in transduction was most likely not associated with this aspect of the virus life cycle but 
potentially had to do with pre-entry mechanisms.  The AAV2 265 insertion mutants and 
AAV2i8 and AAV2i8 265E vectors were an optimal choice due to the observed increase in 
transduction and ability of 265E to rescue the lack of liver infectivity seen with the parent 
AAV2i8 vector, respectively.  
In order to determine the mechanism behind the increase in liver transduction with 
the AAV2 265 and AAV2i8 265E vectors, the liver was harvested two weeks post 
intravenous injection and separated into its individual cellular components being 
parenchymal cells (hepatocytes) and nonparenchymal cells (endothelial, Kupffer and stromal 
cells).  PCs and NPCs were separated via centrifugation and vector genomes and mouse 
lamin genes in each cell population were quantified via q-PCR.   Based on the quantification 
AAV2 265 insertion mutants displayed an appreciable increase in vector genome copies in 
both PC and NPC fractions as compared to wildtype AAV2 injected animals (Figure 8A) 
with no cell type preference.  Not only did the AAV2 265 insertion mutants display an 
increase in liver tropism, but also AAV2i8 265E.  When AAV2i8 livers were harvested and 
separated, AAV2i8 265E displayed an increase in vector genome copies on average in both 
PC and NPC fractions but more a remarkable increase in the NPC fraction over parent 
AAV2i8 (Figure 8B).  From the liver data, it is apparent that it does not take nearly as many 
genome copies of AAV2i8 265E to display a drastic increase in transduction in the liver 
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based on luminescence (Figure 6B) as it does the AAV2 control and AAV2 265 insertion 
mutants (Figure 4). 
 
Discussion 
 
 Studies on this region in our laboratory initiated with Dawn Bowles, with the desire 
to determine the amino acids responsible for AAV1 muscle tropism.  Post intramuscular 
injection, it became clear that AAV1 transduces muscle tissue more efficiently than AAV2 
and the mechanism behind that was unknown.  Post sequence alignment with the AAV1 and 
AAV2 capsids, multiple amino acid differences between the two became potential candidates 
for AAV1’s enhanced transduction capabilities. After narrowing down the pool of varying 
amino acids between AAV1 and AAV2, five were chosen for further analysis.  Identified 
were AAV2 Q263, 265, N709, V712 and T720, and they were mutated to A, T insertion, A, 
A, and N to the corresponding amino acid in AAV1.  From this it was determined that the 
265 positional insertion may play an important role in viral infectivity, and warranted further 
analyses.  This was also based on previous work in the literature, since mutations of amino 
acids in this general region greatly affected virus infectivity, eluding to the fact that the dead 
zone may be playing an important role yet to be identified.   
 Triaging amino acid sequences in order to identify those that are important for viral 
phenotypic properties is commonly performed. In our lab alone, regions identified have been 
shown to play a role in receptor binding, such as the heparin binding and integrin binding 
motifs (5, 46, 157).  Additionally, recent data has suggested that removal of the heparin 
binding motif and replacement it with the corresponding amino acids from the other 
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serotypes, generates viruses with unique tropisms (Asokan unpublished).  Therefore, 
previous research warranted further characterization of disparate regions between serotypes, 
including the 265 surface loop region within the dead zone.   
It is apparent that this region plays a very important role in virus infectivity and 
potentially antibody recognition.  Post biochemical characterization it became clear that 
mutation of this region did affect A20 primary antibody binding as seen in the literature, but 
did not affect 293 and C2C12 cell infectivity or other biochemical properties as shown in 
Figure 2.  However, AAV2 265C displayed a decrease in infectivity but this may be due to 
the abundance of particle aggregates including empty particles visualized via EM analysis 
(data not shown).  The cysteines present on the capsid surface may be creating inter-virion 
disulfide bonding, leading to the generation of aggregates during viral production and 
purification.  The aggregation, a combination of empty and full particles could be the source 
of the AAV2 265C inefficient in vitro transduction.  However, of the insertion mutants tested 
in vivo, AAV2 265 insertion mutants displayed an increase in transduction of muscle and 
liver tissue based on imaging and vector genome analysis, and infected endothelial cells in 
tissue culture where AAV2 could not.  Due to these results, it was apparent that the mutants 
gain an ability to infect cells, whether it is specific to a certain type, or a more universal 
effect.   An interesting observation was made during the in vivo analyses, was that AAV2i8 
265E displayed a drastic increase in liver transduction based on photons, however, not a large 
increase in vector genomes in the liver, as compared to the AAV2 and AAV2 265 disparity 
(Figures 6 and 8).  This may have to do with the presence of the AAV8 capsid on AAV2i8 
265E, as previous research shows that the AAV8 capsid can uncoat more efficiently, leading 
to an increase in transduction (131).   The disparity between the in vitro and in vivo 
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transduction results may be due to the variance in receptors expressed on the cell types in 
vitro versus in vivo. 
 However, the overall increase observed with the vectors in vivo, may have to do with 
the 265 mutants’ ability to bind a cell surface receptor that it was unable to prior to 
mutagenesis.  Based on modeling, it became apparent that mutagenesis of these region 
potentially led to an increase in negative charge around the 265 positions specifically at 
amino acids D470, D473, and E500 (circled in black in Figure 9).  Due to the fact that one 
can make multiple amino acid changes to this region such as 265D, E or F to AAV2, 265Q, 
D, E or F to AAV2i8, and delete or substitute 265 in AAV1, the observed phenotypes are 
most likely a result of a local or gross conformational change to the capsid.  Therefore the 
amino acid insertions may cause local conformational changes making the virus amenable for 
cellular entry via a specific mechanism.  
 Additionally, it is possible that mutation of surface loop I is greatly affecting the 
gross conformation of the capsid. For instance, regardless of what mutation is generated in 
AAV1, whether it is a substitution or deletion of T265, there is an observed increase in vector 
transduction in the mouse gastrocnemus muscle.  Furthermore, substitution of AAV2 265 and 
AAV2i8 265 with various amino acids generated a pool of vectors with enhanced muscle and 
liver transduction and rescued liver transduction, respectively.  Therefore, mutation of 
surface loop I in this position may cause a gross conformational change ablating coreceptor 
or primary receptor interactions at this region or nearby regions of the capsid.   
In the case of AAV2 it is well substantiated that these virus particles utilize the three-
fold peaks as regions for receptor recognition (5, 79, 96, 157), utilization of other regions of 
the capsid for coreceptor interactions is not out of the question.  Many viruses use the valleys 
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on the surface as regions for receptor binding, and in this instance, the 265 loop being studied 
is exposed on the surface between the two-fold and five-fold axes, but does not protrude as 
much as the three-fold peaks.  Rhinovirus, a picornavirus, utilizes a deep crevice, known as 
the canyon, on the capsid surface for ICAM-1 receptor attachment on host cells (17).  
Similarly to rhinovirus, poliovirus, another picornavirus binds the primary CD155 (47, 166) 
in its capsid canyon, and upon entry, the interaction movies deeper into the canyon.  This is 
not unique to these two viruses, coxsackievirus displays the same canyon-receptor 
recognition (102) further substantiating the idea that AAV could be binding a coreceptor via 
interactions with the canyons of the capsid. 
 However, as previously mentioned in this thesis (Chapter II) it is apparent that single 
amino acid mutations can greatly affect AAV life cycle properties such as receptor 
recognition. Studies involving gross mutagenesis of the AAV2 capsid have generated an 
abundance of capsid mutants with multiple phenotypes such as loss of titer, infectivity and 
heparin binding (9, 10, 79, 96, 156).  Due to their abundance, most of these many are yet to 
be characterized with regards to the mechanism behind their observed phenotypes.  However, 
a few studies have extensively investigated the mechanisms behind the phenotypic changes.  
Previous research demonstrated that a single mutation E531K in the AAV1 capsid can 
generate heparan sulfate binding particles, and the converse mutation in AAV6 can remove 
them (157).  Additionally, mutation of surface tyrosines, specifically amino acid 730 (168) 
can generate particles with enhanced transduction capabilities, due to the apparent ablation of 
ubiquitinated capsids targeted for degradation.  Therefore it is not unlikely that a single 
amino acid change within some other region of the capsid may lead to alteration of capsid 
properties. 
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 Additionally, the AAV2 265 mutants may allow for the development of vectors that 
maintain the ability to escape antibody recognition in the serum post injection (53, 76, 164).  
Since the AAV2 265 mutants lose the ability to be recognized by primary antibody A20 in 
vitro as described in this chapter and in the literature (79), these mutants may be further 
investigated for their potential as vectors with the ability to escape the immune response.  For 
preliminary evidence, these mutants were injected intramuscularly along with AAV2 in 
separate mice, serum was collected, and serum was incubated with the corresponding AAV2 
265 mutant or AAV2 for infectivity studies.  From this, it was determined that a subset of 
mutants, display a decrease in antibody titer production or affinity for a neutralizing antibody 
which will allow for further investigation as a means to develop vectors for multiple 
injections (data not shown). 
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Table 1. Primers used for generation of 265 Mutants 
AAV2 265 substitutions 5’- CCAGCCAATCANNKGGAGCCTCGAACG -3’ 
AAV1 T265deletion 5’- CTCCAGTGCTTCAGGGGCCAGCAACG-3’ 
AAV1 T265D 5’-GCAAATCTCCAGTGCTTCAGACGGGGCCAGCAACGAC-3’ 
AAV1 T265E 5’-GCAATCTCCAGTGCTTCAGAGGGGGCCAGCAACG-3’ 
AAV1 T265F 5’-GCAATCTCCAGTGCTTCATTCGGGGCCAGCAACGAC-3’ 
AAV2i8 265D 5’-ATTTCCAGCCAATCAGACGGAGCCTCGAACGAC-3’ 
AAV2i8 265E 5’-ATTTCCAGCCAATCAGAGGGAGCCTCGAACGAC-3’ 
AAV2i8 265F 5’-ATTTCCAGCCAATCATTCGGAGCCTCGAACGAC-3’ 
AAV2i8 265Q 5’-ATTTCCAGCCAATCACAGGGAGCCTCGAACGAC-3’ 
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Figure 1.  Sequence alignment of AAV 265 position  
A. 
AAV1 (258)KQISSTST-GASND 
AAV2      KQISSGS--GASND 
AAV3      KQISSQS--GASND 
AAV4      KRLGESL-----QS 
AAV5      REIKSGS-VDGSNA  
AAV6      KQISSAST-GASND  
AAV7      KQISSETAG-STND 
AAV8      KQISNGTSGGATND 
AAV9      KQISNSTSGGSSND 
AAV10     KQISNGTSGGSTND  
AAV11     LRLGTTS-----SS 
 
 
 
Figure 1.  Sequence alignment of AAV 265 position.  Aligned is the surface loop I within 
the dead zone of a variety of AAV serotypes displaying the variability within this region (left 
panel).  To the right is a model of the five-fold axis of symmetry of AAV2 (blue) with the 
AAV2 265 loop present between the five-fold and two-fold axes highlighted in pink. 
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Table 2. Phenotypic comparison between AAV2 265 insertion mutants 
Insertion mut 
 
Western blot 
 
A20 recognition 
 
Titer 
 
293 infectivity 
 
C2C12 Infectivity 
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AAV2 S 
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AAV2 T 
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AAV2 V 
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AAV2 W 
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++++ 
 
++ 
 
 
ND 
AAV2 Y 
 
++++ 
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++++ 
 
++ 
 
 
ND 
Table 2.  Phenotypic comparison between AAV2 265 insertion mutants. Listed are all AAV2 
265 insertion mutants generated and their phenotypes post biochemical analyses.  
Specifically, all mutants were western blotted and stained with B1 primary antibody (1:20), 
western dot blotted with A20 primary antibody (1:20), and titered via q-PCR with primers 
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specific to the luciferase transgene, Viral infectivity was analyzed in 293 (HEK) and 
differentiated C2C12 cells via luciferase assay as mentioned previously.  In the A20 
recognition column (-) refers to the lack of A20 recognition.  In all columns (++++) denotes 
similar to wildtype AAV2 capsids, (+++) within 10fold similarity, (++) = 10fold less similar 
than, (+) more than 10fold lower in similarity. ND= not determined. 
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Figure 2. AAV2 265 insertions display increase in muscle transduction over time 
Figure 2.  AAV2 265 insertions display increase in muscle transduction over time.  Mice 
were injected intramuscularly (right and left gastrocnemus) with 1E10 vector genome 
containing particles.  Mice were imaged at 1week increments until 5 weeks and then imaged 
again on week ten via the IVIS Xenogen imaging system.  Shown in six panels are multiple 
AAV2 265 insertion mutant expression compared to AAV2 over time (upper left chart) and 
select mutants from that chart as compared to AAV2 (AAV2 265D, E, F, T and P).  
SD=Black bars N=4. 
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Figure 3. AAV2 265 mutants display an increase in liver transduction  
A. 
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Figure 3.  AAV2 265 mutants display an increase in liver transduction.  (A) 1E11 vector 
genome containing particles were injected into mice via tail vein for liver transduction 
analysis.  AAV2 265D, P and T were compared to AAV2 wildtype capsid transduction levels 
via animal imaging two weeks post intravenous injection.  (B) Using the Living Image 
software 2.5, luciferase gene expression was quantified. 
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Figure 4. Mutation of aa265 within the AAV1 capsid generates mutants with increased 
muscular transduction capabilities 
A. 
AAV1 (258)   KQISSTSTGASND 
AAV2         KQISSGS—GASND 
B.  
C. 
  
Figure 4.  Mutation of aa265 within the AAV1 capsid generates mutants with increased 
muscular transduction capabilities.  (A) AAV1 and AAV2 amino acid sequences of the 
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region of interest within the surface loop I were aligned via sequence analysis, with AAV1 
being one amino acid longer than AAV2 within this region. 293 and C2C12 cells were 
infected with AAV1 T265D, E, F and deletion  (Δ)  at 3000 vector genome containing 
particles per cell. (B) AAV1 T265D, E, F and deletion (Δ) and 1E9 or (C) 1E10 vector 
genome containing particles were injected intramuscularly.  Animals were imaged one week 
post injection via IVIS Xenogen imaging system and photons emitted quantified via Living 
Image software 2.5. (SD=black bars, N= 3 or 4) 
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Figure 5. Double mutant AAV2i8 265E generates vectors with enhanced transduction 
capabilities 
A. 
 
 
 
 
 
B. 
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Figure 5.  Double mutant AAV2i8 265E generates vectors with enhanced transduction 
capabilities.  (A) Displayed is a model of the three-fold (left) and five-fold (right) of AAV2.  
Circled in yellow on each model are the locations of mutagenesis, the AAV8 substitution on 
AAV2 (AAV2i8 left) and the AAV2 265 insertion (right).  The resulting virus contained both 
the 2i8 substitution mutation and the 265E insertion. (B) 293 cells were infected with 3000 
vector genome containing particle per cell of AAV2i8 265 mutants and infectivity was 
quantified via luciferase assay as mentioned previously. (C) 1E10 vector genome containing 
particles of AAV2i8 and AAV2i8 265E were injected into mice via tail vein for systemic 
distribution.  Mice were imaged 2 weeks post injection via the IVIS Xenogen imaging 
system as previously mentioned. 
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Figure 6. Uncoating of AAV2 265 mutant 
A. 
            AAV2    AAV2 265D            AAV2   AAV2 265D 
          
              A1     B1 
B.  
   
Figure 6. Uncoating of AAV2 265 mutant.  (A)  1E10 vector genome containing particles of 
AAV2 and AAV2 265D were heat treated at increasing temperatures and blotted on a 
nitrocellulose membrane.  Dissociated capsids were detected with A1 (1:20 against the VP1 
unique N-terminus) and B1 (1:20 against the VP C-termini). (B) Female Balb/C mice were 
injected with 1E10 vector genome containing particles of AAV2 or AAV2 265D in the 
gastrocnemus.  Muscle was harvested at 24hrs, 48hrs, 72hrs, and 1week post injection.  Half 
of the homogenized muscle tissue was sonicated and incubated with DNase.  Vector genomes 
RT 
37°C 
55°C 
59°C 
65°C 
75°C 
140 
 
were quantified via q-PCR using primers specific to the luciferase transgene and normalized 
per milligram weight of the tissue sample.  
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Figure 7. AAV2 265 mutants gain endothelial cell transduction capabilities in vitro 
A. 
B. 
 
 
Figure 7.  AAV2 265 mutants gain endothelial cell transduction capabilities in vitro.  (A) 
293 cells (top) and differentiated C2C12 cells (bottom) were infected with 3000 vector 
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genomes per cell of all AAV2 265 insertion mutants carrying the luciferase transgene.  
Infectivity was quantified via luciferase assay as mentioned previously (Promega).  (B) 
Endothelial cells (HUVEC, C166 and MEC) were infected with 1000 vector genomes per 
cell with a collection of AAV2 265 insertion mutants, AAV2 265D, E, T and P and 
infectivity was quantified via luciferase assay 24hrs post infection. 
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Figure 8. AAV 265 insertion mutants infect PC and NPCs efficiently. 
A. 
 
B. 
 
Figure 8.  AAV 265 insertion mutants infect PCs and NPC efficiently.  (A and B) Mice were 
injected with AAV 265 mutants at a dose of 1E10 vector genome containing particles.   Two 
weeks post injection the livers were harvested and separated into PC and NPC fractions via 
differential centrifugation.  DNA was isolated via DNeasy purification (Qiagen) and genome 
copies were quantified in each fraction via q-PCR with primers specific to the luciferase 
transgene and mouse lamin gene. 
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Figure 9. Surface roadmaps of AAV2 265 insertion mutants. 
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Figure 9. Surface roadmaps of AAV2 265 insertion mutants. Surface roadmaps were 
generated with RIVEM to determine the local and global effects of the AAV2 265 insertion 
mutants.  Circled in black are amino acids D470, D473 and E500. The color representations 
are green-hydrophobic, yellow-hydrophilic/neutral, red-acidic, blue-basic. The black lined 
triangle connects the axes of symmetry with the pentagon being the five-fold, the triangles 
being the three-folds, and the oval the two-fold. 
 
CHAPTER V 
Synopsis and Future Directions 
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In this dissertation multiple surface loops on the AAV capsid surface were 
characterized using a battery of assays, ranging from basic biochemical to in vivo 
characterization.  Each study performed displays important implications for future 
application in gene therapy, however, there are still many questions to be answered and more 
research to be performed.   
Surface loop dynamics in AAV capsid assembly 
 In this study, via capsid domain swapping and further mutagenesis we identified a 
domain that is necessary for viral capsid assembly.  The HI loop was studied in order to 
determine its role in the virus life cycle due to it being a prominent region on the five-fold 
that surrounds the pore, determined to be necessary for viral genome packaging, potentially 
Rep protein binding and VP1 externalization.  In this thesis, viral genome packaging was 
discussed. For instance, via AAV2 HI loop removal and glycine loop substitution it was 
determined that the HI loop is necessary for viral protein assembly and viral genome 
packaging, respectively.  However, the ablation of viral genome packaging may be due to an 
inability of the Rep protein to interact with the capsid properly upon mutagenesis of the HI 
loop.  Similarly, upon replacement of the AAV2 HI loop with AAV4, there is a tenfold 
decrease in titer (Figure 4A), and based on previous work, AAV2/4 chimeras display a 
decrease in packaging capabilities (107).  Based on preliminary data from 
immunoprecipitations, there does not appear to be a reduction in Rep protein binding to the 
particles that cannot package the viral genome efficiently, such as with AAV2 poly-glycine 
and AAV2 HI4 (data not shown). If anything, there appears to be an increase in Rep protein 
binding as seen with AAV2 432 packaging mutant examined by Bleker et al. (9).  However, 
more experiments would have to be performed to determine if the HI loop is a potential site 
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for Rep protein binding, such as immunoprecipitations with HI loop packaging defect 
mutants, and transfections where the Rep protein is supplied in trans.  For instance, when 
producing AAV2 HI4, the AAV4 Rep protein should be supplied to see if that would rescue 
the defect in packaging capabilities.  Furthermore, viral genome packaging was not the only 
capsid phenotype affected by mutagenesis of the HI loop.  Additionally, upon swapping the 
AAV2 HI loop with multiple serotypes specifically with the HI loop of AAV4, it was 
apparent that the HI loop plays a role in viral capsid stability, with the HI loop of AAV4 
increasing AAV2 capsid resistance to heat treatment (Figure 4B).   
 Along these lines, the decrease in packaging capability may be related to the increase 
in particle stability observed with AAV2 HI4, possibly alluding to the fact that the capsid has 
to be amenable to conformational change during packaging, such as capsid expansion.  This 
is a phenomenon that bacteriophage use to increase capsid capacity prior to genome 
packaging (56).  The ability of the AAV capsid to expand during this stage in the viral life 
cycle should be explored via cryo-EM analysis and image reconstruction. 
 Not only was the HI loop swapped with other serotypes, but also substituted with 
targeting ligands, specifically peptides directed towards vascular endothelial cells (149) and 
RGD domains towards integrins on cancer cells (120). Our mutants with targeting ligands do 
not show an increase in transduction capabilities in vitro, however, these mutants should be 
tested in vivo to determine if they can retarget transduction.  Based on work in Chapter III 
and the ability of a hexa-histidine motif within the HI loop to interact with nickel, it stands to 
reason that another targeting ligand in this position may allow for the redirection of viral 
tropism.  
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However, from these substitutions, more was learnt about the viral life cycle. From 
the targeting ligands that spanned a conserved F661 within the HI loop, further site 
mutagenesis and molecular modeling studies, it was determined that F661 interacts 
specifically with a proline in the neighboring underlying subunit crucial for maintaining 
proper viral protein assembly.  Disruption of this hydrophobic amino acid interaction 
generates virus particles with a cleaved form of VP1 incorporated during capsid assembly 
into the intact particle, affecting viral infectivity.  Further work may be performed in order to 
determine the exact site of VP1 cleavage, including mutagenesis to potentially inhibit this 
from occurring, along with potentially inhibiting proteases during viral production in order to 
prevent their actions on the viral protein. 
 This study was the first published work elucidating key functions of surface domains 
in virus assembly.  Based on this work, there is a greater understanding of AAV capsid 
assembly and the importance of surface domains in this key stage of the virus life cycle.   
 From this research we have gained great insight as to locations amenable to 
manipulations for other purposes.  We uncovered key amino acid contacts necessary for VP 
assembly and therefore located others that were malleable.  Due to the plasticity of this 
region we were able to further utilize it as discussed in the second aim as a novel site for 
peptide insertion, specifically a hexa-histidine motif.  Additionally, determining the amino 
acids that are necessary for viral protein assembly, allowed for further utilization by another 
researcher, Chengwen Li.  He has substituted the HI loop with an immunodomain as a means 
to study the immunogenic pathway of AAV. 
Apart from this, knowing the AAV2-heparan sulfate complex cryo-EM analysis and 
image reconstruction has added some insight as to potential biological functions of the HI 
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loop besides being necessary for proper assembly.  For instance, it was demonstrated that this 
region might change conformation upon primary receptor recognition, and be important for 
priming the capsid for downstream stages such as VP1 extrusion and viral capsid uncoating.  
More research has to be performed in order to determine if the HI loop is participating in this 
aspect of the viral life cycle.  If this is the case, the HI loop has the potential to play a role in 
multiple stages of the virus life cycle. 
 
Multifunctional capsids: Site-specific incorporation of a hexa-histidine motif 
 Due to the characterization of the HI loop, it was clear which amino acids could be 
altered in this region of the capsid for application purposes.  Therefore a portion of the HI 
loop was substituted with a hexa-histidine motif in order to use the nickel affinity properties 
of hexa-histidine peptides.  In this case, we hoped to develop a universal purification method 
for the multiple AAV serotypes and many various isolates.   
 Upon substitution of the HI loop with the hexa-histidine motif we are able to utilize 
the vector for multiple functions.  AAV2 and AAV9 with the hexa-histidine motif present on 
all sixty subunits gain the ability to be purified via a nickel column, resulting in pure peak 
fractions as determined through further biochemical analysis. The reagents developed and 
characterization performed opened many possibilities for future work.  With the utilization of 
the hexa-histidine motif as a tag for universal purification, it allows for purification of the 
viral capsid via a uniform method that can be applied to multiple or all serotypes.   In order to 
advance this technology, it will be beneficial to substitute the HI loop of all serotypes with 
the hexa-histidine motif, produce tagged virus in large quantities, and purify via the nickel 
column.  Additionally, enlarging the His-Trap column size may increase the amount of virus 
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that can be purified and recovered.  Altering the flow rate and the imidazole concentration in 
the elution buffers could uncover preferred conditions for purification via this method.  
However, this technique is powerful and shows potential for further development.  
Additionally this reagent is being further expanded to study capsid-protein interactions 
whether they are on the cell surface, cytosol or serum via pull-down with nickel conjugated 
NTA beads.  Therefore, this reagent may become beneficial in elucidating key stages in the 
virus life cycle through protein-protein interactions. 
Additionally, the hexa-histidine motif can be utilized as a site for nanogold 
conjugation for potential future EM applications. There may be many applications for this 
reagent.  For instance, there have been minimal studies uncovering the pathway of virus 
trafficking.  Being able to nanogold label the virus particle may prove to be a powerful tool 
in the understanding of virus trafficking.  Additionally, these particles may be utilized for 
histological purposes post infection, which may be ideal for analyzing patient samples and 
locating virus capsids post infection.  One other aspect that may prove beneficial is 
generating virus with the hexa-histidine tag present solely in VP1.  Little is known about VP1 
with regards to its position in the virus capsid post viral assembly since the crystal structure 
is based on VP3 subunits.  Therefore, the presence of the hexa-histidine motif in the VP1 
subunit may allow for further understanding on the role of the individual viral protein 
subunits.  
Post in vitro validation, the vectors were injected in vivo for further characterization.  
Even though the vectors maintain the ability to infect cells in vitro similar to wildtype, they 
display a decrease in muscle transduction and an ablation of liver transduction in vivo. 
Interestingly, substituting the HI loop with the hexa-histidine peptide does not disrupt the 
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heparin-binding site, the location of primary receptor recognition.   Therefore ablation of 
primary receptor interactions is not the reason for the decrease in liver transduction 
capabilities.  It appears as if only sixty copies of the tag completely diminish transduction 
capabilities.  Based on studies involving hepatocyte binding and capsid stability in the 
presence of mouse blood (Figure 7), it was determined that these particles may be less stable 
in the bloodstream, leading to the less efficient liver targeting, however, more experiments 
need to be performed in order to confirm that, such as determining the number of protected 
and unprotected genomes in the bloodstream over time post intravenous injection with AAV2 
HI6xHis in addition to determining if fewer copies of the hexa-histidine motif on the capsid 
surface increases stability. 
However, due to the liver detargeting phenotype, and depending on the mechanism 
behind it, another location such as the three-fold loop remains available for peptide insertions 
for retargeting of the virus capsid to specific tissues. Therefore, experiments should be 
performed where the AAV2 HI6xHis mutant contains a targeting ligand at position 585 to 
determine if tropism can be redirected post systemic injection, assuming the particle is not 
completely destabilized in the bloodstream. 
Nonetheless, by altering the number of hexa-histidines on the capsid surface, we can 
modulate muscle and liver transduction. For instance, in the case of muscular dystrophy, it 
may be beneficial to have a vector with decreased liver transduction, while maintaining the 
ability to transduce other organs in the body including the skeletal muscle, as seen with 
AAV9 HI6xHis. Additionally, in the case of AAV2 HI6xHis, we may be able to generate a 
vector containing the hexa-histidine motif, but also carrying a targeting peptide that may 
direct it to another tissue of interest, specifically in the three-fold loop, the site of primary 
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receptor recognition.  Therefore, this reagent may develop into a more powerful tool with 
multiple capabilities and functions for future uses in virology and vectorology.  However, as 
mentioned previously, by altering the ratio of hexa-histidines on the capsid surface, we were 
able to maintain the ability to purify the AAV histidine mutants and fully and partially rescue 
muscle and liver transduction, respectively.  
 
Redefining the dead zone 
 Based on my previous research, characterizing another loop on the capsid surface was 
an obvious transition.  Surface loop I in the dead zone, a region thought to not be responsible 
in receptor binding, displayed a potential role in infectivity based on research in the 
literature.  Additionally, previous work in the lab alluded to this region as being important for 
viral infectivity.  Through further characterization of this domain some insight was gained on 
an alternative aspect of the virus life cycle, infectivity. 
Specifically, amino acid position 265 on the capsid surface was characterized, being a 
prominent region, exposed for potential interactions with proteins or cell surfaces.  Upon 
amino acid insertion at position 265 in the AAV2 capsid, an increase in muscle transduction 
was observed in vivo, specifically with aspartic acid, glutamic acid and phenylalanine 
insertions.  Additionally, when the corresponding mutation was generated in AAV1, the 
same increase in muscle transduction was observed post mouse intramuscular injection, 
whether an amino acid was substituted or deleted in this position.  It became apparent that 
mutating this loop greatly affected viral transduction in vivo.  Additionally, AAV2 265 
insertion mutants display an increase in liver transduction post intravenous administration, 
similar to the observed increase in muscle.  Post genome quantification, it was determined 
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that more vector genomes of the 265 insertion mutants enter the liver as compared to the 
wildtype AAV2 virus particles. 
 To further validate this observed phenotype we chose to utilize a previously 
characterized vector in Dr. Aravind Asokan’s laboratory as our next backbone.  This unique 
vector AAV2i8 transduces entire mouse skeletal muscle via loss of heparan sulfate binding 
capabilities.  Due to the loss in heparin binding, this mutant is also deficient in transducing 
the liver based on vector genomes and transgene expression.   As a result, this vector became 
an obvious candidate for the 265 positional insertional mutagenesis, hoping to increase 
transduction and/or regain transduction in the liver. 
 Upon mutation of the AAV2i8 265 position on the capsid surface, an interesting 
phenotype was observed.  Inserting a phenylalanine, aspartic acid, glutamic acid, or 
glutamine results in a remarkable increase in viral transduction in vivo.  All AAV2i8 265 
mutants regain liver transduction capabilities post systemic injection, being a gain of function 
or ability to infect a region that the mutant was unable to prior to mutagenesis based on 
animal imaging and vector genome quantification. 
 This observed mechanism may not be universal. For instance, the 265 insertion in the 
AAV2 backbone may be affecting the capsid in a completely different manner than in AAV1 
or AAV2i8.  This being said, based on further in vitro studies, it appears as if the AAV2 265 
mutants gain the ability to infect endothelial cells in tissue culture, whereas AAV2 could not.  
Presumably, these mutants gain a tropism for this cell type in a tissue culture setting. 
 Based on this further studies have to be performed in order to confirm such effects.  
For instance, the AAV 265 mutants may gain the ability to bind to specific cell surfaces via 
receptor mediated interactions that they were unable to before.  In order validate this 
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hypothesis, capsid pull-down studies would have to be performed to identify interacting 
partners.  This could be executed via capsid biotinylation or utilizing the hexa-histidine tag as 
a means to purify the AAV 265 mutants since the primary antibodies do not recognize these 
mutants. Curiously, based on modeling of the capsid surface via roadmap analysis using 
RIVEM (Agbandje-McKenna), it appears as if mutation of the 265 position may result in the 
exposure of more negatively charged residues on the capsid surface near the two-fold axis of 
symmetry as compared to AAV1 and AAV2.  This phenotypic alteration may be a 
consequence of a gross conformational change allowing for the interaction with variant 
receptors on cell surfaces.  This avenue has to be explored further but provides interest in the 
possibility of relating AAV capsid structure to function. 
Along these lines, it would be beneficial to determine if a change in this position in 
all serotypes results in this effect.  It is quite possible that this may be a universal phenotype 
that would aid in the development of more efficient vectors for gene therapy applications.  
Specifically, the AAV2 265 mutants could be developed for gene therapy studies including 
hemophilia with our vector carrying secretable Factor IX post intramuscular injection (13).  
AAV2i8 265 mutants, could also be utilized in the clinic due to the approval of AAV2 
vectors for trial and their ability to transduce systemically similar to AAV8 and AAV9.  
Additionally, studies with this loop may take a completely different path. Recently, 
the AAV2 265 substitution mutants were injected into the brain, and there is evidence that 
they outperform the parent serotype on number and type of neuronal cells transduced. This 
further substantiates the gain of tropism phenotype, however, more experiments are being 
performed in order to characterize this phenomenon. Additionally, there is preliminary 
evidence that these mutants may generate low antibody titers or have a weak affinity for 
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neutralizing antibody interactions thereby opening the possibility for the development of 
vectors that can escape the immune response. Also this site may be utilized as a location  for 
peptide insertion or substitution similar to what has been executed with the HI loop at the 
five-fold discussed in the first aim of this dissertation.  This location on the capsid surface 
appears to tolerate changes and therefore may be explored for that purpose down the road.  
Overall, this dissertation research has opened many possibilities for future development in 
understanding the virus and the vector.   
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APPENDIX I 
 
 
 In addition to interests involving the AAV2 capsid with regards to surface domains 
involved in the virus life cycle, AAV4 arose as an interesting candidate for studies on 
structure-function dynamics.  Stemming from the finding that the presence of the AAV4 HI 
loop on the AAV2 capsid increased capsid stability, the AAV4 axes warrant further in order 
to understand the structural domains on the capsid surface and their functional attributes.  
Therefore a collection of mutants was generated to aid in the study of AAV4 capsid 
structure-function. 
 
AAV4 three-fold 
  
 After noting that the HI loop may be involved in capsid stability based on heat 
treatment analysis (Chapter II).  We decided to study another region of the AAV4 capsid, the 
three-fold.  On the three-fold axis of symmetry resides the three-fold spikes, similar to AAV2 
but blunted topologically in comparison (97, 160, 163).  Therefore, we targeted the surface 
tyrosines for two reasons, one being that they can hydrogen bond and interact with partners 
and two specific surface tyrosines on the AAV2 capsid may be phosphorylated (168), 
potentially contributing to specific stages in the virus life cycle.   
 Therefore, the AAV4 YKIPA surface domain that is present in both AAV4 and 
AAV11 spanning amino acid positions 491-495 was mutated (Figure 1).  This domain was of 
interest based on its presence in two serotypes, it being on the surface of the three-fold 
containing a tyrosine residue, and matching potential receptor internalization domains. 
  Upon removal of this domain, AAV4-YKIPA was unable to infect cos-7 cells in 
vitro (Figure 2A).  This observation may have been due to a change in receptor binding or a 
158 
 
downstream stage in the virus life cycle.  Therefore we analyzed the cell surface binding 
capabilities of this mutant.  Interestingly, AAV4-YKIPA was able to bind the cos-7 cell 
surface similarly to AAV4 based on vector genome quantification via densitometry analysis.  
However, when vector genomes were quantified post virus internalization in the cytoplasmic, 
membrane and nuclear subcellular fractions, there were less genomes present inside of the 
cell as compared to wildtype AAV4 genomes (Figure 2B).  To determine if the inability to 
transduce cos-7 cells was due to a change in capsid stability we performed a heat treatment 
analysis, and observed the instability of AAV4-YKIPA initiating capsid dissociation at 59 
degrees, whereas the AAV4 capsid maintaining stability until 75 degrees Celsius as detected 
with A1 and ADK4 primary antibodies to detect dissociated and intact capsid particles, 
respectively (Figure 2C).   
 This region remained intriguing due to it being exposed on the capsid surface and 
deleting the entire domain altered capsid stability. Therefore YK (491) and KY(504) based 
on further structural analysis were mutated to AA (Figure 1).  Conformationally, these 
residues assemble in close proximity to possibly form a hypothesized nonlinear 
internalization motif.   AAV4 YK-AA and KY-AA were unable to infect Cos-7 cells similar 
to the AAV4-YKIPA profile (Figure 3A). However, these mutants were able to bind mucin, 
confirming the lack of participation in cell surface recognition (Figure 3B).  To determine if 
the observed decrease in transduction was due to capsid stability, we performed heat 
treatment analysis, which revealed the same phenotype as AAV4-YKIPA, with an ability to 
dissociate at 65C whereas AAV4 can withstand heat treatment up to 75C and potentially 
beyond (Figure 3C).  Therefore, it was apparent that this region of the capsid is playing a 
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crucial role in capsid stability even though the side chains appear vulnerable to potential 
interactions with partners based on the crystal structure.  
Therefore, to maintain capsid stability, instead of domain removal and alanine 
mutagenesis, we chose to solely mutate the tyrosines on the surface of the three-fold to 
phenylalanines to ensure unaltered hydrophobic interactions with the side chain ring structure 
(Figure 1).  Mutation of the phenylalanines alone did not affect capsid stability based on heat 
treatment analysis (Figure 4B), nor did they affect viral transduction in cos-7 cells (Figure 
4A), therefore the tyrosines on the surface of the three-fold are necessary for maintenance of 
viral capsid stability.  Additionally, these mutants were injected systemically into mice and 
determined that altering the surface tyrosine did not affect tropism and transduction unlike 
what is observed with mutation of specific surface tyrosines on the AAV2 capsid. 
 
AAV4 two-fold 
  Post analysis of what was thought to be a key domain on the three-fold axis, 
determining that it was necessary for AAV4 capsid stability, we decided to analyze the two-
fold axis with a collection of mutant constructs generated by Joe Rabinowitz.  The two-fold 
mutants were chimeras between AAV4 and AAV2, where small amino acid stretches of 
AAV4 were replaced with the corresponding AAV2 amino acids (Figure 5A).  Originally, 
these constructs were generated in order to determine if altering the two-fold of AAV4 would 
alter capsid uncoating since it is believed that AAV4 may uncoat more slowly than AAV2 
based on in vivo data (169). 
 Amino acids 253-267, 369-385, 694-705 in the AAV4 capsid were substituted with 
those from AAV2 in separate constructs and virus was produced.  More chimeras were 
generated by cotransfecting all three constructs, which would completely replace the two-
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fold, or just the AAV4/2 253-267 and AAV4/2 694-705 constructs to replace the surface and 
inner capsid regions of the two-fold axis.  All mutants generated virus except for AAV4/2 
369-385 based on dot blot analysis against the viral transgene (data not shown).   
 Additionally a western dot blot was performed on all viral preparations, and ADK4, 
the AAV4 primary antibody against intact particles was unable to recognize AAV4/2 253-
276 (data not shown).  Therefore, we may have determined one of the conformational 
epitopes necessary for primary antibody recognition. Next viral infectivity was examined on 
293 and cos-7 cells to determine if the presence of the AAV2 domains on the capsid surface 
would rescue the inability of AAV4 to transduce or ablate AAV4 transduction, respectively 
(Figure 5B).  The AAV4/2 chimeras were unable to transduce both cell types, therefore, the 
presence of AAV2 amino acids on the AAV4 capsid did not increase AAV4’s ability to 
infect 293 cells and actually rendered the AAV4 capsid noninfectious in cos-7 cells.  
 Contrary to what was determined with the removal of the AAV4 YKIPA domain, all 
of these two-fold mutants maintained stability during heat treatment analysis similar to 
AAV4 wildtype particles based on the ability to protect the viral transgene post DNase 
treatment (Figure 5C).   
 Even though these mutants were not playing a role in capsid stability they may be 
playing a role in other aspects of the AAV4 life cycle.  For instance, AAV4/2 253-267 was 
undetectable by primary antibody ADK4 against the intact particle, which potentially 
implicates this region as an epitope for antibody recognition or upon mutation 
conformationally changes the capsid elsewhere ablating antibody recognition.  Additionally, 
AAV4/2 694-705 was unable to bind a mucin column (Figure 5D), containing the sialic acid 
residues established to be necessary for AAV4 primary receptor binding.  Therefore the C-
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terminal portion of the AAV4 capsid may be partly responsible for primary receptor 
recognition. Additionally, this mutant was injected IV along with AAV4 wildtype capsids as 
a control (Figure 6A).  AAV4 transduces the lung and heart post systemic injection, however 
AAV4/2 694-705 was unable to transduce the heart and lung based on relative light units and 
vector genome quantification, and instead seemed to transduce the abdominal muscle more 
efficiently than other tissue types (Figure 6B).  To further validate the lack of ability to bind 
sialic acid AAV4 was injected IV post systemic injection of sialidase ablating the ability of 
AAV4 to transduce in vivo (Figure 6C).  Therefore, the AAV4/2 694-705 chimera may be a 
variant of AAV4 not affecting capsid stability, but potentially AAV4 tropism by ablation of 
sialic acid binding properties.   
 
Conclusions and future work 
 In this study a series of mutants were generated in order to uncover more about the 
AAV4 capsid structure-function relationship. In doing so, we stumbled across what may 
develop to be important findings about multiple regions of the capsid and their contributions 
to functionality. 
 The AAV4 capsid topologically is extremely different than the AAV2 capsid, 
specifically in the loop regions.  AAV4 has rounder more blunt three-fold spikes with 
narrower valleys and a deeper two-fold depression than observed with the AAV2 capsid 
structure.   
 There has not been much research performed on the AAV4 capsid with regards to 
understanding capsid domains.  However it has been well established with the AAV2 capsid 
that specific domains, for example the three-fold loops are responsible for primary and co-
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receptor binding as well as immune system stimulation (5, 64, 156).  The 265 loop in the 
dead zone also plays a role in primary antibody recognition, where upon mutation A20 is 
unable to recognize the intact particle (79) (Bowles/DiPrimio unpublished).  Interestingly, we 
chose to study multiple regions of the capsid, assuming these regions might be playing 
similar roles as in AAV2 but surprisingly observed varying results.   
 With regards to the three-fold axis, we characterized what was thought to be 
potentially a domain, YKIPA, for cell surface interactions based on the topology and amino 
acid sequence conservation with AAV11.  Upon removal it was apparent that this domain 
was not involved in receptor recognition based on the ability of AAV4-YKIPA to bind cell 
surfaces.  However, when vector genomes were quantified post internalization, AAV4-
YKIPA infected cells contained fewer vector genomes as compared to AAV4.  It was quite 
possible that this domain was necessary for virus internalization since multiple receptors 
utilize tyrosine driven internalization domains such as YXXhydrophobic (150), NPXY (26), 
YXRF (16), and YKYSKV (60).   Not only did we think that YKIPA could be a linear 
domain, but conformationally, the AAV4 capsid forms a potential Y(491)KKY(594) motif 
on the capsid surface that warranted further characterization. 
 In order to determine if this domain was truly a tyrosine driven internalization motif, 
the tyrosines were mutated to phenylalanines to retain structural integrity.  AAV4 Y491F and 
Y594F behaved similarly to AAV4, disproving the theory that the YKIPA domain was 
necessary for virus internalization.  What was determined was that this region of the three-
fold is necessary for capsid stability, since based on heat treatment analysis, AAV4-YKIPA 
was less stable than AAV4, being an extremely stable particle, maintaining integrity at 75°C.   
Therefore, we believe that between the binding and internalization stages of AAV4, the 
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capsid particle is destabilized and releases the genome externally, or prematurely internally 
allowing for DNA degradation.  The three-fold axis, originally based on the AAV2 capsid 
structure is the most interdigitated region with the highest amino acid contact energies (163). 
Therefore the AAV4 data further validates the necessity to maintain contacts at this region 
for proper capsid stability.  Additionally, these data eliminated the possibility that the surface 
tyrosines at the three-fold axis are playing a role in capsid phosphorylation dissimilar to what 
is observed with the AAV2 capsid in the literature (168). 
 In addition, the two-fold axis of symmetry was analyzed with a series of AAV4/2 
chimeras.  The reason behind the generation of these mutants by Joe Rabinowitz 
(unpublished) was based on the assumption that AAV4 is slower to uncoat and release the 
genome when compared to other serotypes, and the two-fold axis is the weakest part of the 
capsid so by altering it, may allow for an earlier onset of genome release.  However, in the 
literature there is little proof of the two-fold axis being the site of virus uncoating (71), and 
AAV2 does not necessarily have a faster onset of expression that AAV4.  Based on data in 
this appendix, AAV4 transduces the heart at least one week post injection which is similar to 
AAV2 transduction in the liver from previous research, so it may be more beneficial to 
replace this region with amino acids from another serotype (131).  However, for the purpose 
of this study, we found these mutants interesting due to the possibility of uncovering other 
unknown phenotypic properties of the AAV4 capsid.  
 As predicted, domains for faster uncoating were not detected based on in vitro and in 
vivo studies.  However, in generating these viruses, we have potentially located a domain for 
primary ADK4 (72) antibody recognition or a region that induces a gross conformational 
change ablating antibody recognition with AAV4/2 253-276.  Antibody recognition epitopes 
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with respect to AAV2 have been determined by epitope mapping via phage display (153) or 
mutagenesis of the capsid (79) so with further analysis, we may be able to concretely identify 
epitopes on the AAV4 capsid surface.  
Additionally, even though in the case of AAV2 and AAV5 (Agbandje-McKenna 
unpublished), the three-fold is the site of primary receptor and co-receptor binding it is 
possible that other serotypes utilize the two-fold as seen with the ablation of sialic acid 
binding based on mucin studies with AAV4/2 694-705 (61, 141).   Substitution of this region 
of AAV4 with AAV2 amino acids may be affecting capsid gross conformation ablating 
receptor interactions, or this could actually be the site of primary receptor attachment.  It has 
also been reported that MVM utilizes another region of the capsid, the two-fold depression 
for receptor recognition (91). With regards to sialic acid binding Dr. Agbandje-McKenna has 
determined the residues for AAV5 sialic acid recognition via co-crystallization as well as 
MVM (personal communication), so potentially further biochemical and structural analysis 
may allow for the determination of AAV4 sialic acid binding residues as well.   Additionally, 
our treatment of mice with sialidase may be expanded as a model to study virus targeting in 
vivo in order to determine if mutants can enter tissues without using sialic acid, or heparin 
post heparinase treatment.  Therefore these studies have opened possibilities for multiple 
projects involving AAV4 and mutant derivatives.  
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Figure 1. Mutagenesis of the AAV4 YKIPA three-fold domain 
 
 
 
 
 
 
 
 
 
 
 
AAV2 (492)    SADN-----NNSE 
AAV4 (487)    ANQNYKIPATGSD 
AAV4-YKIPA (487) ANQN-----TGSD 
 
AAV4 YK-AA (487) ANQNAAIPATGSD 
AAV4 Y491F (487) ANQNFKIPATGSD 
 
AAV4 (497)    GSDSLIKYETHS 
AAV4 KY-AA (497) GSDSLIAAETHS 
AAV4 Y504F (497) GSDSLIKFETHS 
 
Figure 1. Mutagenesis of the AAV4 YKIPA three-fold domain. A model of the AAV4 three-
fold axis in blue with the YKIPA domain highlighted in pink is shown on top.  Below the 
model are sequence alignments of the YKIPA region of the capsid and the deletion, 
phenylalanine and alanine mutants generated. 
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Figure 2. Removal of the AAV4 YKIPA region affects capsid stability. 
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Figure 2. Removal of the AAV4 YKIPA region affects capsid stability.  (A) Cos-7 cells 
were infected with 3000 vector genome containing particles/cell of AAV4 and AAV4-
YKIPA carrying the luciferase transgene.  Viral infectivity was quantified via luciferase 
assay of cos-7 cells as previously mentioned (Promega). (B) AAV4 cell surface binding and 
internalization was quantified. Cos-7 cells were incubated in suspension with AAV4 and 
AAV4-YKIPA (5000 vector genome containing particles/cell) at 4°C for 1 hour to facilitate 
binding.  Cells were kept on ice, pelleted and washed three times with 1XPBS.  Bound 
genomes (density units) were quantified via dot blot analysis (left panel).  Cells in suspension 
with AAV4 and AAV4-YKIPA were incubated at 4°C to facilitate binding and then at 37°C 
for internalization.  2hours post internalization the Cos-7 cells were fractionated into the 
cytoplasmic, membranous and nuclear fractions (BioVision FractioPREP Cell Fractionation 
System). For viral genome quantification via DNA dot blot analysis (right panel). SD=black 
bars N=3 (C) 1E9 AAV4 and AAV4-YKIPA vector genome containing particles were 
incubated at varying temperatures and blotted on nitrocellulose membrane.  The membrane 
was blotted with primary ADK4 antibody (undiluted) against intact particles, or A1 (1:20) to 
detect VP1 exposed particles.    
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Figure 3. Alanine mutagenesis of three-fold residues yields unstable particles. 
A. 
AAV4 (487) ANQNYKIPATGSDSLIKY 
AAV4 (487) ANQNAAIPATGSDSLIAA   
B.  
                                  L      FT      W1     W2     W3    0.2M     0.3M    0.4M   0.5M   0.6M 
 
 
 
 
 
 
 
 
 
C.     YK-AA KY-AA AAV4         YK-AA KY-AA AAV4  YK-AA KY-AA AAV4 
 
 
 
 
 
 
 
 
 
 
 ADK4  A1   +DNase 
 
Figure 3.  Alanine mutagenesis of three-fold residues yields unstable particles. (A) Cos-7 
cells were infected with 3000 vector genome containing particles/cell of AAV4 KY-AA, 
AAV4 YK-AA and AAV4 and infectivity was quantified via luciferase assay as previously 
mentioned.  (B) 2E9 AAV4, AAV4 YK-AA and AAV4 KY-AA were incubated with mucin 
AAV4 
YK - AA 
KY - AA 
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65°C 
75°C 
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beads and eluted with increasing concentrations of salt.  Fractions were blotted on a 
nitrocellulose membrane and stained with primary antibody ADK4 against intact capsids. (C) 
6E8 AAV4, AAV4 YK-AA and AAV4 KY-AA particles were incubated at increasing 
temperatures, blotted on a nitrocellulose membrane and stained as previously mentioned.  
Additionally these heat-treated capsids were treated with DNase, blotted on a Hybond XL 
membrane, and genomes were detected with a radioactively labeled probed against the 
transgene. 
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Figure 4. Mutagenesis of three-fold tyrosines to phenylalanines rescues capsid stability 
A. 
 
 
B. 
 
 AAV4  Y491F Y594F Y491/504F   AAV4  Y491F Y594F Y491/504F 
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Figure 4.  Mutagenesis of three-fold tyrosines to phenylalanines rescues capsid stability.  (A) 
3000 vector genome containing AAV4 Y491F, Y504F and Y491/504F particles/cell were 
incubated with Cos-7 cells, and infectivity was quantified via luciferase assay.  (B)  6E8 
vector genome containing particles of the aforementioned mutants were heat treated, blotted 
and stained as mentioned above. 
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Figure 5. AAV4/2 chimeras yield phenotypic alterations. 
A. 
 
AAV4 (247) NNHLYKRLG---ESLQSNTYNGFSTP 
AAV4/2 253-276 (247) NNHLYKQISSGSGASNDNHYFGFSTP 
 
AAV4(364) (364) PQYGYCGLVTGNTSQQQTDRNAFYCLEY 
AAV4/2 369-385 (364) PQYGYLTLNNG---SQAVGRSSFYCLEY 
 
AAV4(690) (690) TSNYGQQNSLLWAPDAAGKYTEPRA 
AAV4/2 694-705 (690) TSNYNKSVNVDFTVDTNGVYTEPRA 
 
B.  Cos-7 and 293 cell transduction 
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Figure 5.  AAV4/2 chimeras yield phenotypic alterations.  (A) Listed are sequence 
alignments of the AAV4 capsid regions replaced with AAV2.  (B) Cos-7 cells and 293 cells 
were infected with 3000 vg containing particles/cell and quantified via luciferase assay as 
described previously. (C) AAV4/2 chimeras (6E8 vector genome containing particles) were 
incubated at increasing temperatures and treated with DNase to digest any exposed viral 
DNA.  The treatments were blotted on a membrane and analyzed via DNA dot blot against 
the luciferase transgene. (D)  AAV4 and AAV4/2 694-705 were incubated with mucin beads 
in a MicroBioSpin column (BioRad) and eluted with increasing concentrations of salt.  
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Figure 6. AAV4/2 694-705 particles are unable to transduce tissue in vivo. 
A. 
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Figure 6. AAV4/2 694-705 particles are unable to transduce in vivo. (A) 1E11 vg containing 
particles of AAV4 and AAV4/2 694-705 were injected into mice via tail vein, and imaged 
1week post injection with the IVIS Xenogen Imaging system (5min exposure).   (B) Tissues 
were harvested 2weeks post injection and vector genomes were quantified via q-PCR of the 
luciferase transgene. (C) Mice were injected with 100mU sialidase and three hours post 
injection were injected with 1E11 vector genome containing particles of AAV4. Mice were 
imaged as previously mentioned. 
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